0001354488-15-005412.txt : 20151208 0001354488-15-005412.hdr.sgml : 20151208 20151207210258 ACCESSION NUMBER: 0001354488-15-005412 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20151207 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151208 DATE AS OF CHANGE: 20151207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tribute Pharmaceuticals Canada Inc. CENTRAL INDEX KEY: 0001159019 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31198 FILM NUMBER: 151273967 BUSINESS ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 BUSINESS PHONE: 519-434-1540 MAIL ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060412 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR INTERNATIONAL INC DATE OF NAME CHANGE: 20010910 8-K 1 tbuff_8k.htm CURRENT REPORT tbuff_8k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): December 7, 2015
 
 
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
 
Ontario, Canada
 
000-31198
 
Not Applicable
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip Code)
 
(905) 876-1118
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 

Item 1.01  Entry into a Material Definitive Agreement.

Amendment No. 2 to the Agreement and Plan of Merger and Arrangement

On December 7, 2015, Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (“Tribute”), POZEN Inc., a Delaware corporation (“Pozen”), Aralez Pharmaceuticals plc, a public limited company formed under the laws of Ireland (formerly known as Aguono Limited, a private limited company formed under the laws of Ireland, and subsequently renamed Aralez Pharmaceuticals Limited prior to its re-registration as a public limited company) (“Former Parent”), Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“Parent”), Aralez Pharmaceuticals Holdings Limited, a private limited company formed under the laws of Ireland (formerly known as Trafwell Limited) (“Holdings”), ARLZ US Acquisition II Corp., a corporation formed under the laws of the State of Delaware (“US Merger Sub”), and ARLZ CA Acquisition Corp., a corporation formed under the laws of the Province of Ontario, Canada (“Can Merger Sub”), entered into Amendment No. 2 to the Agreement and Plan of Merger and Arrangement (“Amendment No. 2”) which amends that certain Merger Agreement (as defined below).

Amendment No. 2 amends certain provisions of the Agreement and Plan of Merger and Arrangement dated as of June 8, 2015, by and among Tribute, Former Parent, Holdings, ARLZ US Acquisition Corp., a corporation formed under the laws of the State of Delaware (“Former US Merger Sub”), Can Merger Sub and Pozen (the “Agreement”), as amended by Amendment No. 1 dated as of August 19, 2015 by and among Tribute, Former Parent, Holdings, Former US Merger Sub, US Merger Sub, Can Merger Sub and Pozen (“Amendment No. 1” and, together with the Agreement, the “Merger Agreement”), to effect the following changes: (i) remove Former Parent and Holdings as parties to the Merger Agreement and delete all conditions relating to the Former Parent and Holdings from the Merger Agreement, (ii) add Parent in place of Former Parent as a party to the Merger Agreement, whereby, after giving effect to the Merger Transactions (as defined below), the ultimate parent company of the combined companies will be Parent, (iii) amend and restate the Plan of Arrangement attached as Schedule II to the Merger Agreement (the “Amended and Restated Plan of Arrangement”), and (iv) to make certain other changes in connection with the foregoing.

In accordance with the Merger Agreement, as amended by Amendment No. 2, US Merger Sub will be merged with and into Pozen (the “Merger”). As a result of the Merger, the separate corporate existence of US Merger Sub will cease and Pozen will continue as the surviving corporation.  On the date of the closing of the Merger, Pozen will become an indirect wholly-owned subsidiary of Parent. 

In accordance with the Merger Agreement, as amended by Amendment No. 2, Can Merger Sub and Tribute shall amalgamate by way of a court-approved plan of arrangement (the “Arrangement” and together with the Merger, the “Merger Transactions”).  Tribute will survive the Arrangement, the separate legal existence of Can Merger Sub will cease, and Tribute and Can Merger Sub will continue as one corporation (“Amalco”), with the property of Can Merger Sub becoming the property of Amalco.  Upon completion of the Arrangement, Tribute will also become a wholly-owned subsidiary of Parent.

As a result of Amendment No. 2, Former Parent is no longer a party to the Merger Agreement or any of the transactions contemplated by the Merger Agreement, as amended by Amendment No. 2.

Other than as expressly modified pursuant to Amendment No. 2, the Merger Agreement, which was previously filed by Tribute as Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on June 12, 2015, as amended by Amendment No. 1 dated as of August 19, 2015, remains in full force and effect. The foregoing description of Amendment No. 2 is only a summary, and does not purport to be complete and is qualified in its entirety by reference to Amendment No. 2, a copy of which is filed as Exhibit 2.2 hereto, and is incorporated herein by reference.

Second Amended and Restated Debt Facility Agreement

On December 7, 2015, Tribute entered into a Second Amended and Restated Debt Facility Agreement (the “Second Amended and Restated Facility Agreement”) by and among Parent, Pozen, Tribute, Deerfield Private Design Fund III, L.P. (“Deerfield Private Design”), Deerfield International Master Fund, L.P. (“Deerfield International”), and Deerfield Partners, L.P. (“Deerfield Partners” and, together with Deerfield Private Design, and Deerfield International, the “Lenders”).  The Second Amended and Restated Facility Agreement amends and restates the Amended and Restated Debt Facility Agreement (the “Amended and Restated Facility Agreement”) dated as of October 29, 2015 by and among Pozen, Stamridge Limited, a private limited liability company incorporated under the laws of the Republic of Ireland (the “Former Borrower”), Tribute, Former Parent, the Lenders and certain other lenders party thereto.

 
 

 
 
Pursuant to the Second Amended and Restated Facility Agreement, Tribute will borrow from the Lenders up to an aggregate principal amount of US$275 million (the “Aggregate Principal”).  Of the Aggregate Principal, US$75 million will be in the form of a 2.5% senior secured convertible promissory note due six years from issuance and convertible into common shares of Tribute (“Tribute Shares”) at a conversion price equal to a 32.5% premium to the Equity Price (as defined below) (the “Convertible Notes”) issued and sold by Tribute to the Lenders, upon the terms and conditions of the Second Amended and Restated Facility Agreement.  Following the consummation of the Merger Transactions, the obligations under the Convertible Notes will be assumed by Parent, and the Convertible Notes will be exchanged for convertible notes of Parent (“Parent Convertible Notes”).  The Parent Convertible Notes shall be secured by the assets of Parent and its Subsidiaries (as defined in the Second Amended and Restated Facility Agreement).  The Parent Convertible Notes may thereafter be convertible into common shares of the Parent, par value US$0.001 per share (“Parent Shares”).

The Convertible Notes will be issued by Tribute in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D under the Securities Act (“Regulation D”), solely to “accredited investors,” as such term is defined in Rule 501(a) of Regulation D.

Of the Aggregate Principal, up to an aggregate principal amount of US$200 million with an interest rate of 12.5%, which will be made available for Permitted Acquisitions (as defined in the Second Amended and Restated Facility Agreement), will be in the form of secured promissory notes due six years from issuance, issued and sold by Tribute to the Lenders (the “Acquisition Notes”), evidencing the Acquisition Loans (as defined in the Second Amended and Restated Facility Agreement), upon the terms and conditions and subject to the limitations set forth in the Acquisition Notes, all subject to the terms and conditions of the Second Amended and Restated Facility Agreement. In addition to the foregoing, the Second Amended and Restated Facility Agreement amends the Amended and Restated Facility Agreement by (i) substituting Parent for Former Parent, (ii) substituting Tribute for Former Borrower, (iii) substituting Tribute Shares for ordinary shares of the Former Parent, (iv) substituting Convertible Notes for Exchange Notes, (v) providing that the Obligations under the Second Amended and Restated Facility Agreement, as defined therein, shall be assigned to and assumed by Parent following consummation of the Merger Transactions, and (vi) making certain other changes to effect the foregoing.
 
A copy of the Second Amended and Restated Facility Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Second Amended and Restated Facility Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amended and Restated Facility Agreement. Capitalized terms used above without definition have the meanings given such terms in the Second Amended and Restated Facility Agreement.

Second Amended and Restated Registration Rights Agreement
 
In connection with the Second Amended and Restated Facility Agreement, on December 7, 2015, Parent and the Lenders entered into a Second Amended and Restated Registration Rights Agreement (the “Second Amended and Restated Registration Rights Agreement”). The Second Amended and Restated Registration Rights Agreement amends and restates the Amended and Restated Registration Rights Agreement entered into on October 29, 2015 by and among the Lenders and Former Parent (the “Amended and Restated Registration Rights Agreement”) in order to provide for certain changes required as a result of the Second Amended and Restated Facility Agreement, as discussed above.  Pursuant to the Second Amended and Restated Registration Rights Agreement, Parent agreed to prepare and file with the SEC a Registration Statement on Form S-3, or other such form as required to effect a registration of the Parent Shares issued or issuable upon conversion of or pursuant to the Convertible Notes (the “Registrable Securities”), covering the resale of the Registrable Securities and such indeterminate number of additional common shares as may become issuable upon conversion of or otherwise pursuant to the Convertible Notes to prevent dilution resulting from certain corporate actions. Such Registration Statement must be filed on or before January 15, 2016, and Parent shall use best efforts to get the Registration Statement declared effective no later than the Registration Deadline (as defined in the Second Amended and Restated Registration Rights Agreement). In the event the SEC does not permit all of the Registrable Securities to be included in the Registration Statement or if the Registrable Securities are not otherwise included in a Registration Statement filed under the Second Amended and Restated Registration Rights Agreement, the Parent has agreed to file an additional Registration Statement by no later than the Additional Filing Deadline (as defined in the Second Amended and Restated Registration Rights Agreement) covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act. The Second Amended and Restated Registration Rights Agreement also provides for piggy-back registration, subject to the terms and conditions of the Second Amended and Restated Registration Rights Agreement.
 
A copy of the Second Amended and Restated Registration Rights Agreement is attached hereto as Exhibit 10.2 and is incorporated herein by reference. The foregoing description of the Second Amended and Restated Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amended and Restated Registration Rights Agreement. Capitalized terms used above without definition have the meanings given such terms in the Second Amended and Restated Registration Rights Agreement.

 
 

 
 
Amended and Restated Share Subscription Agreement

On December 7, 2015, Tribute entered into an Amended and Restated Share Subscription Agreement (the “Amended and Restated Subscription Agreement”) by and among Parent, Former Parent, Tribute, Pozen, QLT Inc., a corporation existing under the laws of the Province of British Columbia, Canada (“Purchaser”), and the following investors thereto: Deerfield Private Design; Deerfield International; Deerfield Partners; Broadfin Healthcare Master Fund, Ltd.; JW Partners, LP; and JW Opportunities Master Fund, Ltd. (each, an “Investor” and together, the “Investors”).  The Amended and Restated Subscription Agreement amends and restates that certain share subscription agreement entered into on June 8, 2015 (the "Subscription Agreement") by and among Purchaser, Tribute, Pozen, Former Parent and certain investors. 

Pursuant to the Amended and Restated Subscription Agreement, immediately prior to the consummation of the Merger Transactions, Tribute will sell to Purchaser and the Investors up to US$75 million of the Tribute Shares in a private placement at a purchase price per share equal to  (a) the lesser of (i) US$7.20, and (ii) a five percent (5%) discount off the five day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, US$0.001 par value per share (the “Pozen Common Stock”), calculated over the five trading days immediately preceding the date of closing of the Merger Transactions, not to be less than US$6.25, multiplied by (b) 0.1455 (the “Equity Price”). In the event any of Pozen, Tribute or Parent announce a material event (other than results of any shareholder meeting) during the ten (10) day period immediately preceding closing of the Merger Transactions, then clause (ii) above shall be revised to read:  “(ii) a five percent (5%) discount off the two day VWAP per share of Pozen Common Stock, calculated over the two (2)  trading days immediately preceding the date of closing of the Merger Transactions, not to be less than US$6.25." Such Tribute Shares will be issued in reliance upon Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, solely to “accredited investors,” as such term is defined in Rule 501(a) of Regulation D.  Upon consummation of the Merger Transactions, Tribute Shares will be exchanged for Parent Shares.  The Amended and Restated Subscription Agreement provides that Parent shall prepare and cause to be filed with the SEC a registration statement to effect a registration of the Parent Shares to be issued under the Amended and Restated Subscription Agreement on or before January 15, 2016 and for certain other registration rights for each of Purchaser and the Investors under the Securities Act and the rules and regulations thereunder, or any similar successor statute, and applicable state securities laws.

The Amended and Restated Subscription Agreement amends and restates the Subscription Agreement by (i) removing Former Parent as a party to the Amended and Restated Subscription Agreement and substituting Parent for Former Parent, (ii) substituting Tribute Shares for ordinary shares of the Former Parent, (iii) updating the list of Investors that are parties to the Amended and Restated Subscription Agreement, and (iv) making certain other changes to effect the foregoing.

A copy of the Amended and Restated Subscription Agreement is attached hereto as Exhibit 10.3 and is incorporated herein by reference. The foregoing description of the Amended and Restated Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Subscription Agreement. Capitalized terms used above without definition have the meanings given such terms in the Amended and Restated Subscription Agreement.
 
Item 2.03  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above under “Item 1.01 Entry into a Material Definitive Agreement” in this Current Report is incorporated herein by reference.

Pursuant to the Second Amended and Restated Facility Agreement, repayment of the Convertible Notes and Acquisition Notes generally may be accelerated upon certain customary events of default, including, without limitation, the failure to pay principal or interest when due, failure to observe or perform certain covenants which remains uncured for a specified period after notice thereof, acceleration of certain other indebtedness, certain events of bankruptcy, and the Parent Shares ceasing to be listed on the Principal Trading Markets (as defined in the Second Amended and Restated Facility Agreement) or the Tribute Shares or Parent Shares ceasing to be registered under Section 12 of the Securities Exchange Act of 1934, as amended, in each case subject to the terms and conditions of the Second Amended and Restated Facility Agreement.

Item 3.02  Unregistered Sales of Equity Securities.

The information set forth above under “Item 1.01 Entry into a Material Definitive Agreement” in this Current Report is incorporated herein by reference.
 
 
 

 
 
Item 8.01  Other Events.

As a result of Amendment No. 2 discussed above, the special meeting of shareholders of Tribute, which was scheduled to be held on December 9, 2015 (the “Special Meeting”) and at which shareholders of Tribute were to vote on matters relating to transactions contemplated by the Agreement, has been cancelled. Shareholders should disregard the information circular mailed to shareholders on or about November 6, 2015.

On December 7, 2015, Tribute issued a press release announcing the execution of Amendment No. 2 and the cancellation of the Special Meeting.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Additional Information and Where to Find It

In connection with the proposed transaction, Parent, Pozen and Tribute will be filing documents with the SEC, including a Registration Statement on Form S-4 filed by Parent that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Pozen stockholders in connection with the proposed transaction.  It is expected that shares of Parent to be issued by Parent to Tribute shareholders, options of Parent to be issued by Parent to Tribute optionholders and Parent Convertible Notes to be issued to Tribute convertible noteholders will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Section 3(a)(10) thereof. Upon receipt of an interim court order in respect of the plan of arrangement, Tribute will be mailing an information circular to its shareholders in connection with the proposed transaction (the “Information Circular”).  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS AS WELL AS THE INFORMATION CIRCULAR WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PARENT, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s website at www.sec.gov. Investors and security holders will be able to obtain free copies of the Information Circular and other documents filed by Tribute on the System for Electronic Document Analysis and Retrieval website maintained by the Canadian Securities Administrators at www.sedar.com. Investors and security holders may obtain free copies of the documents filed by Pozen with the SEC on Pozen’s website at www.pozen.com under the heading “Investors” and then under the heading “SEC Filings” and free copies of the documents filed by Tribute with the SEC on Tribute’s website at www.tributepharma.com under the heading “Investors” and then under the heading “SEC Filings”.

Participants in the Solicitation

Pozen and Tribute and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Pozen and shareholders of Tribute in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus and Information Circular described above.  Additional information regarding the directors and executive officers of Pozen and Tribute is contained in their respective Annual Reports on Form 10-K for the year ended December 31, 2014 filed with the SEC.

No Offer or Solicitation

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 
 

 
 
Caution Regarding Forward-Looking Information and “Safe Harbor” Statement

This report contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Parent, Pozen and Tribute and the timing and benefits thereof, the anticipated equity and debt financings and the closings thereof, the combined company’s strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, competitive position, anticipated product portfolio, development programs and management structure, the proposed listing on the NASDAQ and TSX and other statements that are not historical facts. These forward-looking statements are based on Pozen’s and Tribute’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the parties’ ability to complete the combination and financings on the proposed terms and schedule; the parties’ ability to close the capital investment on the proposed terms and schedule; the combined company meeting the listing on the NASDAQ and TSX; risk that Parent may be taxed as a U.S. resident corporation; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company’s shares could decline, as well as other risks related to Pozen’s and Tribute’s business, including Pozen’s inability to build, acquire or contract with a sales force of sufficient scale for the commercialization of YOSPRALATM in a timely and cost-effective manner, the parties’ failure to successfully commercialize their product candidates; costs and delays in the development and/or FDA approval of the parties’ product candidates (including YOSPRALATM), including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of Pozen’s product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of its product candidates; the inability to maintain or enter into, and the risks resulting from Pozen’s dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including its dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, Pozen’s dependence on Patheon for the manufacture of YOSPRALATM 81/40 and YOSPRALATM 325/40 ; the ability of the parties to protect their intellectual property and defend their patents; regulatory obligations and oversight; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Pozen’s SEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent Quarterly Reports on Form 10-Q and in Tribute’s SEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent Quarterly Reports on Form 10-Q. Pozen and Tribute undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in their expectations.

Item 9.01.
Financial Statements and Exhibits.
d) Exhibits

Exhibit
No.
  
Description
2.1
 
Amendment No. 1 to the Agreement and Plan of Merger and Arrangement, dated August 19, 2015, by and among Pozen, Tribute, Former Parent, Holdings, Former US Merger Sub, US Merger Sub, and Can Merger Sub.
2.2*
 
Amendment No. 2 to the Agreement and Plan of Merger and Arrangement, dated as of December 7, 2015, by and among Pozen, Tribute, Former Parent, Holdings, US Merger Sub, Can Merger Sub, and Parent.
10.1*
 
Second Amended and Restated Debt Facility Agreement, dated as of December 7, 2015 by and among Parent, Pozen, Tribute, and the Lenders.
10.2
 
Second Amended and Restated Registration Rights Agreement, dated as of December 7, 2015 by and among Parent and the Lenders.
10.3
 
Amended and Restated Share Subscription Agreement, dated as of December 7, 2015 by and among Parent, Former Parent, Tribute, Pozen, Purchaser and the Investors.
99.1
 
Press release dated December 7, 2015.
______________________

*  Certain disclosure schedules have been omitted. Tribute hereby agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
 
TRIBUTE PHARMACEUTICALS CANADA INC.
 
       
Date: December 7, 2015
By:
/s/ Scott Langille  
    Scott Langille  
    Chief Financial Officer  
       
 





 
 

 

EXHIBIT INDEX

Exhibit
No.
  
Description
2.1
 
Amendment No. 1 to the Agreement and Plan of Merger and Arrangement, dated August 19, 2015, by and among Pozen, Tribute, Former Parent, Holdings, Former US Merger Sub, US Merger Sub, and Can Merger Sub.
2.2*
 
Amendment No. 2 to the Agreement and Plan of Merger and Arrangement, dated as of December 7, 2015, by and among Pozen, Tribute, Former Parent, Holdings, US Merger Sub, Can Merger Sub, and Parent.
10.1*
 
Second Amended and Restated Debt Facility Agreement, dated as of December 7, 2015 by and among Parent, Pozen, Tribute, and the Lenders.
10.2
 
Second Amended and Restated Registration Rights Agreement, dated as of December 7, 2015 by and among Parent and the Lenders.
10.3
 
Amended and Restated Share Subscription Agreement, dated as of December 7, 2015 by and among Parent, Former Parent, Tribute, Pozen, Purchaser and the Investors.
99.1
 
Press release dated December 7, 2015.
______________________

*  Certain disclosure schedules have been omitted. Tribute hereby agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

 
 
 

 
EX-2.1 2 tbuff_ex2.htm AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT, DATED AUGUST 19, 2015, BY AND AMONG POZEN, TRIBUTE, FORMER PARENT, HOLDINGS, FORMER US MERGER SUB, US MERGER SUB, AND CAN MERGER SUB. tbuff_ex2.htm
Exhibit 2.1
 
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF
MERGER AND ARRANGEMENT

AMENDMENT NO. 1, dated as of August 19, 2015 (this “Amendment”), to the Agreement and Plan of Merger and Arrangement, dated as of June 8, 2015 (the “Merger Agreement”), by and among Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario (“Tribute”), Aguono Limited, a private limited company incorporated in Ireland with registered number 561617 having its registered office at 56 Fitzwilliam Square, Dublin, 2, Ireland, and which has been renamed Aralez Pharmaceuticals Limited (“Parent”), Trafwell Limited, a private limited company incorporated in Ireland with registered number 561618 having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (and which has been renamed Aralez Pharmaceutical Holdings Limited) (“Ltd2”), ARLZ US Acquisition Corp., a corporation incorporated under the laws of the State of Delaware and a wholly-owned indirect subsidiary of Parent (“US Merger Sub”), ARLZ CA Acquisition Corp., a corporation incorporated under the laws of the Province of Ontario and a wholly-owned indirect subsidiary of Parent (“Can Merger Sub”) and POZEN Inc., a corporation incorporated under the laws of the State of Delaware (the “Company” and, together with Tribute, Parent, Ltd2, US Merger Sub and Can Merger Sub, the “Parties”).

W I T N E S S E T H :
 
WHEREAS, the Parties desire to amend the Merger Agreement to reflect the addition of ARLZ US Acquisition II Corp., a corporation incorporated under the laws of the State of Delaware, as a party to the Merger Agreement and to remove ARLZ US Acquisition Corp. as a party to the Merger Agreement;

WHEREAS, after giving effect to this Amendment all references to “US Merger Sub” shall mean ARLZ US Acquisition II Corp., a corporation incorporated under the laws of the State of Delaware, formed as a sister company to Parent; and

WHEREAS, Section 9.9 of the Merger Agreement provides that the Merger Agreement may, at any time and from time to time but not later than the Closing, as defined in the Merger Agreement, be amended by written agreement of the Parties without, subject to applicable Laws, further notice to or authorization on the part of the Pozen stockholders.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:
 
1.  Amendments.
 
(a)  
The initial recital to the Merger Agreement is hereby amended and restated in its entirety to read as follows:
 
“THIS AGREEMENT is made as of June 8, 2015 among Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario (“Tribute”), Aralez Pharmaceuticals Limited, a private limited company incorporated in Ireland with registered number 561617 having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Trafwell Limited, a private limited company incorporated in Ireland with registered number 561618 having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Ltd2”), ARLZ US Acquisition II Corp., a corporation incorporated under the laws of the State of Delaware, formed as a sister company to Parent (“US Merger Sub”), ARLZ CA Acquisition Corp., a corporation incorporated under the laws of the Province of Ontario and a wholly-owned indirect subsidiary of Parent (“Can Merger Sub”), and POZEN Inc., a corporation incorporated under the laws of the State of Delaware (“Pozen”).”
 
 
 

 
 
(b)  
The definition of US Merger Sub contained in Section 1.1 of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“"US Merger Sub" shall mean ARLZ US Acquisition II Corp., a corporation incorporated under the laws of the State of Delaware, formed as a sister company to Parent.”
 
(c)  
Subsection 3.3(h) is hereby amended and restated to read in its entirety as follows:
 
Parent Material Subsidiaries. Parent or a wholly owned Parent Subsidiary is, or will be prior to the Merger Effective Time, the sole registered and beneficial owner of all of the outstanding shares in the capital of or outstanding shares of capital stock or other ownership, equity or voting interests of the Parent Subsidiaries and US Merger Sub free and clear of any Liens (other than Permitted Liens), and no other Person other than Parent has any option, right, entitlement, understanding or commitment (contingent or otherwise) regarding the right to acquire any such share or interest in any of the Parent Subsidiaries or US Merger Sub and no outstanding option, warrant, conversion or exchange privilege or other right, agreement, arrangement or commitment obligating any such entity to issue or sell any share or ownership, equity or voting interest of such entity or security or obligation of any kind convertible into or exchangeable or exercisable for any shares or ownership, equity or voting interests of any such entity. Neither Parent nor any of the Parent Material Subsidiaries own any interest or investment (whether equity or debt) in any other Person, other than a Parent Material Subsidiary, which interest or investment is material to Parent and its Subsidiaries, taken as a whole.”
 
(d)  
A new Subsection 8.1(g) is hereby added as follows:
 
“the representation and warranty of Parent in Subsection 3.3(h) shall be true and correct.”
 
2.  
Miscellaneous.
 
(a)  
From and after the date hereof, all references in the Merger Agreement to “this Agreement” shall be deemed to mean the Merger Agreement as amended by this Amendment, but references to “the date of this Agreement,” or “the date hereof” in the Merger Agreement, as amended by this Amendment, shall be deemed to be August 19, 2015.
 
 
 

 
 
(b)  
Except as expressly amended hereby, the Agreement shall remain in full force and effect.
 
(c)  
Each party to this Amendment hereby represents that it has all requisite corporate power and authority to enter into and deliver this Amendment, to perform its obligations under the Amendment, and to consummate the transactions contemplated by this Amendment; that the execution and delivery of this Amendment and the consummation of the transactions contemplated by this Amendment by such party, as the case may be, have been duly authorized by all necessary corporate action on the part of such party and that this Amendment has been duly executed and delivered by such party and constitutes the legal, valid and binding obligation of such party enforceable against such party in accordance with its terms.
 
(d)  
The section headings in this Amendment are intended solely for convenience and shall be given no effect in the construction and interpretation hereof.
 
(e)  
This Amendment and all actions, proceedings or counterclaims (whether based on contract, tort or otherwise) arising out of or relating to this Amendment or the actions of Parent, Acquisition Sub or the Company in the negotiation, administration, performance and enforcement thereof, shall be governed by, and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of laws provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.
 
(f)  
This Amendment may be executed in counterparts, which together shall constitute one and the same Amendment.  The parties to this Amendment may execute more than one copy of this Amendment, each of which shall constitute an original.
 
* * * * *

[Signature Pages Follow]
 
 
 

 
 
IN WITNESS WHEREOF, Tribute, Parent, Ltd2, US Merger Sub and Can Merger Sub and the Company have caused this Amendment No. 1 to Agreement and Plan of Merger to be executed as of the date first written above by their respective officers thereunto duly authorized.


 
TRIBUTE PHARMACEUTICALS CANADA INC.
     
 
By:
/s/ Scott Langille
   
Name: Scott Langille
   
Title: Chief Financial Officer
     
 
ARALEZ PHARMACEUTICALS LIMITED
     
 
By:
/s/ William L. Hodges
   
Name: William L. Hodges
   
Title: Director
     
 
TRAFWELL LIMITED
     
 
By:
/s/ William L. Hodges
   
Name: William L. Hodges
   
Title: Director
     
 
ARLZ US ACQUISITION CORP.
     
 
By:
/s/ Adrian Adams
   
Name: Adrian Adams
   
Title: President
     
 
 
 

 
 
 
ARLZ CA ACQUISITION CORP.
     
 
By:
/s/ Andrew Koven
   
Name: Andrew Koven
   
Title: President
     
 
POZEN INC.
     
 
By:
/s/ Adrian Adams
   
Name: Adrian Adams
   
Title: Chief Executive Officer


 
ARLZ US ACQUISITION II CORP.
     
 
By:
/s/ Adrian Adams
   
Name: Adrian Adams
   
Title: President

 
 
 

 
EX-2.2 3 tbuff_ex21.htm AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF tbuff_ex21.htm
Exhibit 2.2
 
AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF
MERGER AND ARRANGEMENT

This AMENDMENT NO. 2 (this “Amendment”) to the Agreement and Plan of Merger and Arrangement is made as of December 7, 2015, by and among Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (“Tribute”), Aralez Pharmaceuticals plc, a public limited company formed under the laws of Ireland (formerly known as Aguono Limited, a private limited company formed under the laws of Ireland, and subsequently renamed Aralez Pharmaceuticals Limited prior to its re-registration as a public limited company) (“Former Parent”), Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“New Parent”), Aralez Pharmaceuticals Holdings Limited, a private limited company formed under the laws of Ireland (formerly known as Trafwell Limited, a private limited company formed under the laws of Ireland) (“Holdings”), ARLZ US Acquisition II Corp., a corporation formed under the laws of the State of Delaware (“US Merger Sub”), ARLZ CA Acquisition Corp., a corporation formed under the laws of the Province of Ontario, Canada (“Can Merger Sub”), and POZEN Inc., a corporation formed under the laws of the State of Delaware (“Pozen” and, together with Tribute, Former Parent, New Parent, Holdings, US Merger Sub and Can Merger Sub, the “Parties”).

W I T N E S S E T H :
 
WHEREAS, on June 8, 2015, Tribute, Former Parent, Holdings, ARLZ US Acquisition Corp., a corporation formed under the laws of the State of Delaware (“Former US Merger Sub”), Can Merger Sub and Pozen entered into the Agreement and Plan of Merger and Arrangement (the “Agreement”), pursuant to which (i) Tribute will combine with Can Merger Sub, (ii) Former US Merger Sub will merge with and into Pozen, with the separate corporate existence of Former US Merger Sub ceasing and Pozen continuing as the surviving corporation; and (iii) Former Parent would be the ultimate parent entity domiciled in Ireland;

WHEREAS, on August 19, 2015, Tribute, Former Parent, Holdings, Former US Merger Sub, US Merger Sub, Can Merger Sub and Pozen entered into that certain Amendment No. 1 to Agreement and Plan of Merger and Arrangement (“Amendment No. 1,” together with the Agreement, the “Merger Agreement”), whereby US Merger Sub was formed to replace Former US Merger Sub in order to optimize the corporate structure of Former Parent in the future;

WHEREAS, Tribute, Former Parent, Holdings, US Merger Sub, Can Merger Sub and Pozen desire to amend the Merger Agreement to add New Parent as a party to the Merger Agreement and to remove Former Parent as a party to the Merger Agreement, whereby, after giving effect to the transactions contemplated in the Merger Agreement, the ultimate parent company of the combined companies will be New Parent, a corporation formed under the laws of the Province of British Columbia, Canada; and

WHEREAS, Section 9.9 of the Merger Agreement provides that the Merger Agreement may, at any time and from time to time but not later than the Closing, as defined in the Merger Agreement, be amended by written agreement of the Parties without, subject to applicable Laws, further notice to or authorization on the part of the Pozen stockholders.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

 
 

 
 
1.  
Amendments.
 
(a)  
Preamble:
 
(i)  
The preamble which reads “WHEREAS, prior to the Merger Effective Time, as defined in Section 1.1, Parent shall re-register as a public limited company incorporated in Ireland and be renamed as Aralez Pharmaceuticals plc.” is hereby deleted in its entirety and all references thereto are hereby deleted in their entirety.
 
(b)  
General Definitions:
 
(i)  
All references to “Parent” in the Merger Agreement shall mean “Aralez Pharmaceuticals Inc.”, a corporation formed under the laws of the Province of British Columbia, Canada.
 
(ii)  
All references to “Ltd2” or “Trafwell Limited” in the Merger Agreement shall be deleted in their entirety.
 
(iii)  
All references to “ordinary shares” of Parent in the Merger Agreement shall be changed to “common shares” of Parent.
 
(iv)  
All references to “Schedule II – Plan of Arrangement” shall be changed to “Schedule II – Amended and Restated Plan of Arrangement”, attached as Schedule II to this Amendment.
 
(v)  
All references to “Parent Financing” in the Merger Agreement shall mean “Financing”, as defined in this Amendment.
 
(c)  
Section 1.1:
 
(i)  
The definition of “Holdco” contained in the Merger Agreement and all references thereto are hereby deleted in their entirety.
 
(ii)  
The definition of “Irish High Court Application” contained in the Merger Agreement and all references thereto are hereby deleted in their entirety.
 
(iii)  
The definition of “MFI Note” shall be added to the Merger Agreement immediately after the definition of “Merger Exchange Agent” and immediately prior to the definition of “NASDAQ” and shall read in its entirety as follows:
 
““MFI Note” means the unsecured convertible promissory note in the aggregate amount of C$5,000,000, dated June 16, 2015, issued by Tribute to Nidhi Nijhawan.”
 
(iv)  
The definition of “New Pozen Employees” contained in the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
““New Pozen Employees” means Adrian Adams, Jennifer Armstrong, Scott Charles, Andrew I. Koven, Mark Glickman, Eric L. Trachtenberg, James P.
 
 
2

 
 
Tursi, M.D., and any other Pozen employee to whom Pozen Options or Pozen restricted stock units are granted subsequent to June 8, 2015.”
 
(v)  
The definition of “Outside Date” contained in the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
““Outside Date” means April 30, 2016 or such later date as may be agreed to in writing by the Parties.”
 
(vi)  
The definition of “Parent Convertible Notes” shall be added to the Merger Agreement immediately after the definition of “Parent Board of Directors” and immediately prior to the definition of “Parent Financing” and shall read in its entirety as follows:
 
Parent Convertible Notes” means, following the Arrangement Effective Time, the “Convertible Notes” as defined in the Second Amended and Restated Facility Agreement, dated as of even date herewith, by and among Parent, Pozen, Tribute and the lenders party thereto.”
 
(vii)  
The definition of “Parent Distributable Reserves Proposals” contained in the Merger Agreement and all references thereto are hereby deleted in their entirety.
 
(viii)  
The definition of “Parent Distributable Reserves Resolution” contained in the Merger Agreement and all references thereto are hereby deleted in their entirety.
 
(ix)  
The definition of “Parent Financing” contained in the Merger Agreement shall be deleted and the definition of “Financing” shall be inserted immediately after the definition of “Final Order” and immediately prior to the definition of “Form S-4” and shall read in its entirety as follows:
 
““Financing” shall mean, collectively, (i) the senior secured credit facility of up to $200,000,000 of Tribute which, upon the Arrangement Effective Time, will be assumed by Parent and secured by the assets of Parent and each of its Subsidiaries; (ii) the $75,000,000 convertible notes of Tribute, which, upon the Arrangement Effective Time, will be assigned to Parent by the Lenders, and the convertible notes of Parent issued to the Lenders in exchange thereof, which shall be secured by the assets of Parent and its Subsidiaries; and (iii) the $75,000,000 equity financing of Tribute as contemplated by the Share Subscription Agreement between Parent, Pozen, Tribute and certain investors dated even date herewith.”
 
(x)  
The definition of “Parent Shares” contained in the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
““Parent Shares” means the common shares without par value in the capital of Parent.”
 
(xi)  
The definition of “Plan of Arrangement” contained in the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
 
3

 
 
““Plan of Arrangement” means the Amended and Restated Plan of Arrangement substantially in the form and content set out in Schedule II hereto, as the same may be amended, supplemented or varied from time to time in accordance with Article 7 of the Plan of Arrangement or at the direction of the Court in the Final Order with the prior written consent of Tribute and Pozen, each acting reasonably.”
 
(xii)  
The definition of “Tribute Convertible Notes” shall be added to the Merger Agreement immediately after the definition of “Tribute Compensation Optionholders” and immediately prior to the definition of “Tribute Disclosure Letter” and shall read in its entirety as follows:
 
““Tribute Convertible Notes” means, prior to the Arrangement Effective Time, the “Convertible Notes” as defined in the Second Amended and Restated Facility Agreement, dated as of even date herewith, by and among Parent, Pozen, Tribute and the lenders party thereto.”
 
(xiii)  
The definition of “Tribute Distributable Reserves Resolution” contained in the Merger Agreement and all references thereto are hereby deleted in their entirety.
 
(d)  
Section 2.1(g) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(g)           At the Merger Effective Time, by virtue of the Merger and without any action on the part of the Parties or any of their respective shareholders, all shares of common stock, par value $0.001 per share, of US Merger Sub issued and outstanding immediately prior to the Merger Effective Time, and all rights in respect thereof, shall be cancelled and US Surviving Company shall issue an equivalent number of fully paid shares of common stock, par value $0.001 per share, all of which shares shall be held by Holdings, and which shall constitute the only outstanding shares of capital stock of US Surviving Company.”
 
(e)  
A new Section 2.1(n) shall be added to the Merger Agreement and shall read in its entirety as follows:
 
“(n)           All events that are to occur at the Arrangement Effective Time shall occur immediately prior to all events that are to occur at the Merger Effective Time and immediately prior to US Merger Sub’s acquisition of Parent Shares. ”
 
The remainder of Section 2.1 shall be renumbered accordingly.
 
(f)  
Section 2.2:
 
(i)  
Section 2.2(b) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(b)           Registered Holders of Tribute Common Shares will be granted rights of dissent with respect to such shares in connection with the Arrangement pursuant to and in the manner set forth in Section 185 of the OBCA, as modified by the Plan of Arrangement (the “Tribute Dissent Rights”).  Beneficial Holders of
 
 
4

 
 
Tribute Common Shares and Holders of Tribute Convertible Notes, Tribute Options, Tribute Warrants, Tribute Compensation Options and the MFI Note will not have rights of dissent with respect to such securities in connection with the Arrangement. Tribute shall give Pozen (i) prompt notice of any written demands with respect to Tribute Dissent Rights, withdrawals of such demands, and any other instruments served pursuant to the OBCA and received by Tribute, and (ii) the opportunity to participate in all negotiations and proceedings with respect to such rights. Without the prior written consent of Pozen, except as required by applicable law, Tribute shall not make any payment with respect to any such rights or offer to settle or settle any such rights.”
 
(ii)  
Section 2.2(f) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(f)           Tribute shall advise the Canadian Court that the Parties intend to rely on the exemption from the registration requirements of the 1933 Securities Act provided by Section 3(a)(10) thereof to issue Parent Shares to Tribute Shareholders in exchange for their Tribute Common Shares, to exchange Tribute Convertible Notes for Parent Convertible Notes and to exchange Tribute Options for Parent Options, as applicable, all pursuant to the Arrangement, based on the Canadian Court’s approval of the Arrangement.”
 
(iii)  
Section 2.2(j) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(j)           The Tribute Convertible Notes, the MFI Note, the Tribute Options, the Tribute Warrants, the Tribute Compensation Options and the Tribute Stock Option Plan shall be treated as contemplated by, and in the manner set forth in, the Plan of Arrangement.”
 
(iv)  
Section 2.2(k) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(k)           The Arrangement shall be structured and executed such that the issuance of the Parent Shares to Tribute Shareholders in exchange for their Tribute Common Shares, the issuance of Parent Convertible Notes to holders of Tribute Convertible Notes in exchange for their Tribute Convertible Notes and the issuance of Parent Options to Tribute Optionholders in exchange for their Tribute Options, all pursuant to the Arrangement, will not require registration under the 1933 Securities Act in reliance upon Section 3(a)(10) thereof. Each of the Parties agrees to act in good faith, consistent with the intent of the Parties and the intended treatment of the Arrangement as set forth in this Section 2.2.”
 
(v)  
Section 2.2(m) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(m)           Each of Tribute, Pozen, Parent, Can Merger Sub and the Arrangement Exchange Agent (without duplication) shall be entitled to deduct and withhold from any consideration payable to any holder of Tribute Common Shares, Tribute Convertible Notes, the MFI Note, Tribute Options, Tribute Warrants or Tribute Compensation Optionholder, such amounts as Tribute, Pozen, Parent,
 
 
5

 
 
Can Merger Sub or the Arrangement Exchange Agent are required to deduct and withhold with respect to such payment under applicable Law. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes hereunder as having been paid to the holder of Tribute Common Shares, Tribute Convertible Notes, the MFI Note, Tribute Options, Tribute Warrants or Tribute Compensation Options in respect of which such deduction and withholding was made, provided that such withheld amounts are actually remitted to the appropriate taxing authority. To the extent that the amount so required or permitted to be deducted or withheld from any payment to a holder exceeds the cash component of the consideration payable to the holder, Tribute, Pozen, Parent, Can Merger Sub and the Arrangement Exchange Agent are hereby authorized to sell or otherwise dispose of such portion of the consideration payable to the holder as is necessary to provide sufficient funds to Tribute, Pozen, Parent, Can Merger Sub or the Arrangement Exchange Agent, as the case may be, to enable it to comply with such deduction or withholding requirement and Tribute, Pozen, Parent, Can Merger Sub or the Arrangement Exchange Agent shall notify the holder thereof and remit the applicable portion of the net proceeds of such sale to the appropriate taxing authority, and shall remit to such holder any unapplied balance of the proceeds of such sale.”
 
(g)  
Section 2.4(i) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(i)           Parent covenants and agrees that, promptly following Closing, it shall file with the SEC a Registration Statement on Form S-8 (the “Form S-8”) registering Parent Shares issuable pursuant to the 2016 Aralez Pharmaceuticals Inc. Omnibus Equity Plan.”
 
(h)  
The introduction to Section 3.1 of the Merger Agreement is hereby amended and restated in its entirety as follows:
 
3.1           Representations and Warranties of Pozen
 
Except as disclosed in the applicable section or subsection of the Pozen Disclosure Letter (it being agreed that disclosure of any item in any section or subsection of the Pozen Disclosure Letter shall be deemed disclosure with respect to any other section or subsection of the Pozen Disclosure Letter only to the extent the relevance of such item to such other section or subsection is reasonably apparent on its face), the Pozen Public Disclosure Record (other than any disclosure contained under the captions “Risk Factors” or “Forward Looking Statements” or similar captions and any other disclosure contained therein that is predictive, cautionary or forward-looking in nature), or as otherwise expressly disclosed to Tribute prior to the date of this Amendment in writing for the express purpose of qualifying the representations contained in this Section 3.1, Pozen represents and warrants to and in favor of Tribute and Parent as follows and acknowledges that Tribute and Parent are relying upon such representations and warranties in entering into this Agreement:”
 
(i)  
The introduction to Section 3.2 of the Merger Agreement is hereby amended and restated in its entirety as follows:
 
3.2           Representations and Warranties of Tribute
 
 
6

 
 
Except as disclosed in the applicable section or subsection of the Tribute Disclosure Letter (it being agreed that disclosure of any item in any section or subsection of the Tribute Disclosure Letter shall be deemed disclosure with respect to any other section or subsection of the Tribute Disclosure Letter only to the extent the relevance of such item to such other section or subsection is reasonably apparent on its face), the Tribute Public Disclosure Record (other than any disclosure contained under the captions “Risk Factors” or “Forward Looking Statements” or similar captions and any other disclosure contained therein that is predictive, cautionary or forward-looking in nature), or as otherwise expressly disclosed to Pozen prior to the date of this Amendment in writing for the express purpose of qualifying the representations contained in this Section 3.2, Tribute represents and warrants to and in favor of Parent and Pozen as follows and acknowledges that Parent and Pozen are relying upon such representations and warranties in entering into this Agreement:”
 
(j)  
Section 3.3(e) of the Merger Agreement is hereby amended and restated in its entirety as follows:
 
“(e)           Capitalization of Parent. As of the date of this Amendment, the authorized capital of Parent consists of an unlimited number of Parent Shares and an unlimited number of preferred shares, issuable in series, in the capital of Parent, of which there is one (1) Parent Share outstanding and nil preferred shares outstanding. All of the issued and outstanding common shares of Parent have been duly authorized and validly issued and are fully paid and non-assessable. Except as contemplated by the Merger, the Arrangement and this Agreement, as of the date of this Agreement, there are no outstanding agreements, subscriptions, warrants, options, rights or commitments (nor has Parent granted any other right or privilege capable of becoming an agreement, subscription, warrant, option, right or commitment) obligating Parent to issue or sell any common shares or other securities of Parent, including any security or obligation of any kind convertible into or exchangeable or exercisable for any common shares or other security of Parent.”
 
(k)  
Section 3.3(p) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(p)           Parent Shares Fully Paid and Non-assessable.  Upon their due issuance in accordance with the terms of this Agreement, the Parent Shares issued as Merger Consideration and Arrangement Consideration shall be fully paid and non-assessable common shares in the capital of Parent.”
 
(l)  
Section 5.1(b) of the Merger Agreement is hereby amended to replace each instance “Parent” with “Tribute and Parent” and each instance of “Parent’s” with “Tribute’s and Parent’s respective”.”
 
(m)  
Section 5.12 of the Merger Agreement is hereby deleted in its entirety and the remainder of Article 5 shall be renumbered accordingly.
 
(n)  
Section 5.13 of the Merger Agreement (after giving effect to Section 1(m) above, Section 5.12) is hereby amended and restated to read in its entirety as follows:
 
5.12           Certain Parent Shareholder Resolutions
 
 
7

 
 
Prior to Closing, Pozen and Parent shall procure the passing of resolutions of the shareholders of Parent providing for:
 
(a)           the amendment of its Articles of Incorporation and By-laws, which shall as far as is practicable be consistent with Pozen’s existing organizational documents;
 
  (b)           the approval of any other matters as are deemed necessary or expedient in connection with giving effect to the transactions contemplated by, or ancillary to, this Agreement.”
 
(o)  
Section 8.1(m) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“(m)           the issuance of the Parent Shares to Tribute Shareholders in exchange for their Tribute Common Shares, the issuance of Parent Convertible Notes to holders of Tribute Convertible Notes in exchange for their Tribute Convertible Notes and the issuance of Parent Options to Tribute Optionholders in exchange for their Tribute Options, all pursuant to the Arrangement, shall be exempt from the registration requirements of the 1933 Securities Act pursuant to Section 3(a)(10) thereof and shall be exempt or qualified under all applicable U.S. state securities laws, and such securities will not be subject to restrictions on transfer under the 1933 Securities Act and applicable state securities laws except such as may be imposed contractually by the Parties or by Rule 144 under the 1933 Securities Act with respect to (i) any of such securities of Parent issued to certain persons who are “affiliates” (as such term is defined in Rule 405 under the 1933 Securities Act) of Parent or who have been affiliates of Parent within ninety (90) days of the Arrangement Effective Date, and (ii) any of such securities of Parent issued and exchanged for securities issued by Tribute as part of the Financing.”
 
(p)  
Section 9.1(b) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
 
(b)
if to Parent:
 
Aralez Pharmaceuticals Inc.
c/o DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St. W
Toronto, Ontario
M5X 1E2
Canada

Attention:            Andrew Koven, President
Facsimile No.:      (919) 490-5552
E-mail:                  akoven@pozen.com

with a copy (which will not constitute notice) to:

DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, New Jersey 07078-2704
 
 
8

 

Attention:            Andrew Gilbert
Facsimile No.:      (973) 520-2573
E-mail:                   andrew.gilbert@dlapiper.com

(q)  
Section 7 of Schedule I (“Required Regulatory Approvals”) of the Merger Agreement is hereby amended and restated to read in its entirety as follows:
 
“7.           Nasdaq listing approval of Parent Shares including those issuable as Merger Consideration and Arrangement Consideration and underlying any of the Parent Options, MFI Note, Tribute Convertible Notes, Tribute Warrants and Tribute Compensation Options issued in connection with the Arrangement”
 
2.  
Miscellaneous.
 
(a)  
From and after the date hereof, all references in the Merger Agreement to “this Agreement” shall be deemed to mean the Merger Agreement as amended by this Amendment.
 
(b)  
Except as expressly amended hereby, the Agreement shall remain in full force and effect.
 
(c)  
Each party to this Amendment hereby represents that it has all requisite corporate power and authority to enter into and deliver this Amendment, to perform its obligations under the Amendment, and to consummate the transactions contemplated by this Amendment; that the execution and delivery of this Amendment and the consummation of the transactions contemplated by this Amendment by such party, as the case may be, have been duly authorized by all necessary corporate action on the part of such party and that this Amendment has been duly executed and delivered by such party and constitutes the legal, valid and binding obligation of such party enforceable against such party in accordance with its terms.
 
(d)  
The section headings in this Amendment are intended solely for convenience and shall be given no effect in the construction and interpretation hereof.
 
(e)  
This Amendment and all actions, proceedings or counterclaims (whether based on contract, tort or otherwise) arising out of or relating to this Amendment or the actions of the Parties in the negotiation, administration, performance and enforcement thereof, shall be governed by, and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of laws provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.
 
(f)  
This Amendment may be executed in counterparts, which together shall constitute one and the same Amendment.  The parties to this Amendment may execute more than one copy of this Amendment, each of which shall constitute an original.
 
* * * * *

[Signature Pages Follow]
 
 
9

 
 
IN WITNESS WHEREOF, Tribute, Former Parent, New Parent, Holdings, US Merger Sub, Can Merger Sub and the Company have caused this Amendment No. 2 to Agreement and Plan of Merger to be executed as of the date first written above by their respective officers thereunto duly authorized.


 
TRIBUTE PHARMACEUTICALS CANADA INC.
     
 
By:
/s/ Scott Langille
   
Name: Scott Langille
   
Title: Chief Financial Officer
     
 
ARALEZ PHARMACEUTICALS PLC
     
 
By:
/s/ William L. Hodges
   
Name: William L. Hodges
   
Title: Director
     
     
 
ARALEZ PHARMACEUTICALS INC.
     
 
By:
/s/ Andrew Koven
   
Name: Andrew Koven
   
Title: President
     
 
ARALEZ PHARMACEUTICALS HOLDINGS LIMITED
     
 
By:
/s/William L. Hodges
   
Name: William L. Hodges
   
Title: Director
     
 
 
10

 

 
 
ARLZ US ACQUISITION II CORP.
     
 
By:
/s/ Adrian Adams
   
Name: Adrian Adams
   
Title: President
     
 
ARLZ CA ACQUISITION CORP.
     
 
By:
/s/ Andrew Koven
   
Name: Andrew Koven
   
Title: President

 
 
POZEN INC.
     
 
By:
/s/ Adrian Adams
   
Name: Adrian Adams
   
Title: Chief Executive Officer
 
 
11

 
 
SCHEDULE II — AMENDED AND RESTATED PLAN OF ARRANGEMENT
 

AMENDED AND RESTATED FORM OF PLAN OF ARRANGEMENT UNDER SECTION 182 OF THE BUSINESS CORPORATIONS ACT (ONTARIO)

[See attached]
 
 
 
 

 
 

 
 
AMENDED AND RESTATED PLAN OF ARRANGEMENT
 
under Section 182 of the
Business Corporations Act (Ontario)
 
ARTICLE 1
INTERPRETATION
 
1.1          In this Plan of Arrangement, the following terms have the following meanings:
 
(a)  
Amalco” means Tribute as the successor of the amalgamation of Can Merger Sub and Tribute pursuant to Section 3.1(e).
 
(b)  
Amalco Shares” means the common shares in the capital of Amalco.
 
(c)  
Arrangement”, “herein”, “hereof”, “hereto”, “hereunder” and similar expressions mean and refer to the arrangement pursuant to Section 182 of the OBCA set forth in this Plan of Arrangement as supplemented, modified or amended, and not to any particular article, section or other portion hereof.
 
(d)  
Arrangement Agreement” means the agreement and plan of merger and arrangement dated as of June 8, 2015 as amended on each of August 19, 2015 and December 7, 2015 and all amendments thereto, among Parent, Tribute, Can Merger Sub, ARLZ US Acquisition II Corp. and POZEN Inc. with respect to the Arrangement.
 
(e)  
Arrangement Depositary” means Computershare Trust Company of Canada, or such other Person as may be designated by Parent and Tribute.
 
(f)  
Arrangement Resolution” means the special resolution to be considered and if thought fit, passed by the Tribute Shareholders at the Tribute Meeting to approve the Arrangement.
 
(g)  
Articles of Arrangement” means the articles of arrangement in respect of the Arrangement required under the OBCA to be filed with the Director after the Final Order has been granted giving effect to the Arrangement.
 
(h)  
Broker Warrants” means the Tribute Common Share purchase warrants issued in certificated form expiring on May 21, 2017.
 
(i)  
Business Day” means a day, other than a Saturday, Sunday or statutory holiday, when banks are generally open in the City of Toronto, in the Province of Ontario, for the transaction of banking business.
 
(j)  
Can Merger Sub” means ARLZ CA Acquisition Corp., a corporation formed under laws of the Province of Ontario, Canada.
 
(k)  
Certificate of Arrangement” means the certificate which may be issued by the Director pursuant to subsection 183(2) of the OBCA or, if no certificate is to be issued, the proof of filing in respect of the Arrangement.
 
(n)  
Continuing Optionholder” means a Tribute Optionholder who will, immediately subsequent to the Effective Time, be at least one of a director, officer, employee or consultant of Parent and/or an affiliate of Parent, as agreed by Parent.
 
(o)  
Court” means the Ontario Superior Court of Justice (Commercial List) or other court with jurisdiction to consider and issue the Interim Order and the Final Order.
 
(p)  
Credit Facility” means the Second Amended and Restated Credit Facility dated as of December 7, 2015 among Parent, Pozen, Tribute and certain lenders thereto.
 
 
1

 
 
(q)  
Director” means the Director appointed pursuant to section 278 of the OBCA.
 
(r)  
Dissent Rights” has the meaning ascribed thereto in section 5.1.
 
(s)  
Effective Date” means the date shown on the Certificate of Arrangement giving effect to the Arrangement.
 
(t)  
Effective Time” means the time at which the Articles of Arrangement are filed with the Director on the Effective Date.
 
(u)  
Exchange Ratio” means in respect of each Tribute Common Share, 0.1455 Parent Shares.
 
(v)  
Exchange Options” has the meaning provided in Subsection 3.1(c).
 
(w)  
Final Order” means the final order of the Court, in a form acceptable to Tribute and Parent, each acting reasonably, approving the Arrangement pursuant to subsection 182(5) of the OBCA to be applied for following the Tribute Meeting, as such order may be affirmed, amended or modified by the Court (with the consent of both Tribute and Parent, each acting reasonably) at any time prior to the Effective Date.
 
(x)  
Governmental Authority” means any international, multinational, federal, provincial, territorial, state, regional, municipal, local or other government or governmental body and any ministry, department, division, bureau, agent, official, agency, commission, board or authority of any government, governmental body, quasi-governmental or private body (including the TSXV, the TSX, the NASDAQ or any other applicable stock exchange), domestic or foreign, exercising any statutory, regulatory, expropriation or taxing authority under the authority of any of the foregoing and any domestic, foreign or international judicial, quasi-judicial or administrative court, tribunal, commission, board, panel, arbitrator or arbitral body acting under the authority of any of the foregoing.
 
(y)  
Indenture Warrants” means, collectively, the Tribute Common Share purchase warrants expiring on July 15, 2016 issued or, in the case of the Indenture Warrants to be issued on exercise of the Tribute Compensation Options, issuable, pursuant to the Tribute Warrant Indenture.
 
(z)  
Interim Order” means an interim order of the Court, in a form acceptable to Tribute and Parent, each acting reasonably, under subsection 182(5) of the OBCA containing declarations and directions with respect to the Arrangement, as such order may be affirmed, amended or modified by the Court (with the consent of both Tribute and the Parent, each acting reasonably).
 
(aa)  
Laws” means any and all laws, statutes, codes, ordinances (including zoning), approvals, rules, regulations, instruments, by-laws, notices, policies, protocols, guidelines, guidance, manuals, treaties or other requirements of any Governmental Authority having the force of law and any legal requirements arising under the common law or principles of law or equity.
 
(bb)  
MFI Note” means the unsecured convertible promissory note dated June 16, 2015 issued by Tribute to Nidhi Nijhawan.
 
(cc)  
OBCA” means the Business Corporations Act, (Ontario), as amended, including the regulations promulgated thereunder.
 
(dd)  
Optionholder Election Form” means the duly completed written election of an Optionholder, in form satisfactory to Parent, irrevocably electing that: (i) in the case of a Continuing Optionholder, certain of the Tribute Options held by such Continuing Optionholder are to be exchanged for Parent Options in accordance with the provisions of Subsection 3.1(h); and/or (ii) certain of the Tribute Options held by such Optionholder are to
 
 
2

 
 
be exchanged for Tribute Common Shares in accordance with the provisions of Subsection 3.1(c).
 
(ee)  
Parent” means Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada.
 
(ff)  
Parent Convertible Notes” means the senior secured convertible notes of Parent issued pursuant to the Credit Facility and the terms of the Arrangement.
 
(gg)  
Parent Option” means an option to purchase Parent Shares granted pursuant to the Parent Option Plan.
 
(hh)  
Parent Option Plan” means the long term incentive plan of Parent, including all amendments thereto.
 
(ii)  
Parent Share” means a common share in the capital of Parent.
 
(jj)  
Person” means an individual, partnership, association, body corporate, trust, unincorporated organization, government, regulatory authority, or other entity.
 
(kk)  
Pozen” means POZEN Inc., a corporation incorporated under the laws of the State of Delaware.
 
(ll)  
Rollover Options” has the meaning provided in Subsection 3.1(h).
 
(mm)  
Series B Warrants” means, collectively, the Tribute Common Share purchase warrants issued in certificated form and expiring on February 27, 2018, March 5, 2018 and March 11, 2018, as applicable.
 
(nn)  
Series K Warrants” means, collectively, the Tribute Common Share purchase warrants issued in certificated form and expiring on September 20, 2018.
 
(oo)  
Series M Warrants” means, collectively, the Tribute Common Share purchase warrants issued in certificated form and expiring on May 11, 2017.
 
(pp)  
Series S Warrants” means collectively, the Tribute Common Share purchase warrants issued in certificated form and expiring on August 8, 2018, February 4, 2021 and October 1, 2021, as applicable.
 
(qq)  
Tax Act” means the Income Tax Act (Canada), as the same may be amended, including the regulations promulgated thereunder.
 
(rr)  
Tribute” means Tribute Pharmaceuticals Canada Inc., a corporation amalgamated under the OBCA.
 
(ss)  
Tribute Common Share” means a common share in the capital of Tribute.
 
(tt)  
Tribute Common Shareholders” means the holders from time to time of the Tribute Common Shares.
 
(uu)  
Tribute Compensation Options” means the compensation options of Tribute which expire on July 16, 2016, each of which is exercisable into one Tribute Common Share and one-half of one Indenture Warrant.
 
(vv)  
Tribute Compensation Optionholders” means the holders from time to time of the Tribute Compensation Options.
 
 
3

 
 
(ww)  
Tribute Convertible Notes” means the senior secured convertible notes of Tribute issued pursuant to the Credit Facility.
 
(xx)  
 “Tribute Convertible Noteholders” means the holders from time to time of the Tribute Convertible Notes.
 
(yy)  
Tribute Dissenting Shareholder” means registered holders of Tribute Common Shares who validly exercise the Dissent Rights with respect to the Arrangement provided to them under the Interim Order and whose dissent rights remain valid immediately before the Effective Time.
 
(zz)  
Tribute Letter of Transmittal” means the letter of transmittal to be sent to the holders of Tribute Common Shares pursuant to which holders of Tribute Common Shares are required to deliver certificates representing their Tribute Common Shares to receive the Parent Shares, as applicable, issuable or payable to them pursuant to the Arrangement.
 
(aaa)  
Tribute Market Value” shall be equal to the closing price on the TSXV of a Tribute Common Share on the trading day immediately prior to the Effective Date.
 
(bbb)  
Tribute Meeting” means the special meeting of Tribute Common Shareholders to be held to consider, among other things, the Arrangement and related matters, and any adjournment thereof.
 
(ccc)  
Tribute Option Differential” means the amount by which the Tribute Market Value exceeds the exercise price of a particular Tribute Option.
 
(ddd)  
Tribute Optionholders” means the holders from time to time of the Tribute Options.
 
(eee)  
Tribute Option Plan” means the stock option plan of Tribute.
 
(fff)  
Tribute Options” means the options to purchase Tribute Common Shares granted pursuant to the Tribute Option Plan.
 
(ggg)  
Tribute Securities” means, collectively, the Tribute Common Shares, the Tribute Options, the Tribute Warrants, the Tribute Compensation Options, the Tribute Convertible Notes and the MFI Note.
 
(hhh)  
Tribute Securityholders” means, collectively, the Tribute Common Shareholders, the Tribute Optionholders, the Tribute Warrantholders, the Tribute Compensation Optionholders, the Tribute Convertible Noteholders and the holder of the MFI Note.
 
(iii)  
Tribute Warrant Indenture” means the warrant indenture dated July 15, 2014 between Tribute and Equity Financial Trust Company providing for the issuance of the Indenture Warrants.
 
(jjj)  
Tribute Warrantholders” means the holders from time to time of the Tribute Warrants.
 
(kkk)  
Tribute Warrants” means collectively, (i) the Indenture Warrants outstanding as of the Effective Time and those issuable pursuant to the Tribute Compensation Options; (ii) the Series B Warrants outstanding as of the Effective Time; (iii) the Series K Warrants outstanding as of the Effective Time; (iv) the Series M Warrants outstanding as of the Effective Time; (v) the Series S Warrants outstanding as of the Effective Time; and (vi) the Broker Warrants outstanding as of the Effective Time.
 
(lll)  
TSXV” means the TSX Venture Exchange.
 
(mmm)  
U.S. Securities Act” means the United States Securities Act of 1933, as amended.
 
 
4

 
 
Any capitalized terms used but not herein defined shall have the meanings ascribed thereto in the Arrangement Agreement.
 
1.2
The division of this Plan of Arrangement into articles and sections and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Plan of Arrangement.
 
1.3
Unless reference is specifically made to some other document or instrument, all references herein to articles and sections are to articles and sections of this Plan of Arrangement.
 
1.4
Unless the context otherwise requires, words importing the singular number shall include the plural and vice versa; and words importing any gender shall include all genders.
 
1.5
In the event that the date on which any action is required to be taken hereunder by any of the parties is not a Business Day in the place where the action is required to be taken, such action shall be required to be taken on the next succeeding day which is a Business Day in such place.
 
1.6
References in this Plan of Arrangement to any statute or sections thereof shall include such statute as amended or substituted and any regulations promulgated thereunder from time to time in effect.
 
1.7
All dollar amounts referred to in this Plan of Arrangement are in Canadian funds, unless otherwise indicated herein.
 

1.8
Time shall be of the essence in every matter or action contemplated hereunder.  All times expressed herein or in the Tribute Letter of Transmittal are local time (Toronto, Ontario) unless otherwise stipulated herein or therein.
 
ARTICLE 2
ARRANGEMENT AGREEMENT
 
2.1
This Plan of Arrangement is made pursuant to and is subject to the provisions and forms part of the Arrangement Agreement except in respect of the sequence of steps comprising the Arrangement, which shall occur in the order set out herein.
 
2.2
This Plan of Arrangement, upon the filing of the Articles of Arrangement and the issue of the Certificate of Arrangement, if any, shall become effective on, and be binding on and after, the Effective Time on: (i) the Tribute Securityholders; (ii) Tribute; (iii) Can Merger Sub; (iv) Parent; and (v) the Arrangement Depositary.
 
2.3
The Articles of Arrangement and Certificate of Arrangement shall be filed and issued, respectively, with respect to this Arrangement in its entirety. The Certificate of Arrangement shall be conclusive evidence that the Arrangement has become effective and that each of the provisions of Article 3 has become effective in the sequence set out therein. If no Certificate of Arrangement is required to be issued by the Director pursuant to subsection 183(2) of the OBCA, the Arrangement shall become effective on the date the Articles of Arrangement are filed with the Director pursuant to subsection 183(1) of the OBCA.
 
ARTICLE 3
ARRANGEMENT
 
3.1           Commencing at the Effective Time, each of the events set out below shall occur by operation of law and shall be deemed to occur in the following order without any further act or formality except as otherwise provided herein:
 
Tribute Dissenting Shareholders
 
(a)  
the Tribute Common Shares held by Tribute Dissenting Shareholders shall be deemed to have been transferred to Can Merger Sub (free of any claims) and cancelled and as at the Effective Time such Tribute Dissenting Shareholders shall cease to have any rights as Tribute Common Shareholders
 
 
5

 
 
other than the right to be paid the fair value of their Tribute Common Shares in accordance with Article 5;
 
Vesting of Tribute Options
 
(b)  
each Tribute Option outstanding immediately prior to the Effective Time, notwithstanding any contingent vesting provisions to which it might otherwise have been subject, shall be deemed to be fully vested;
 
Exchange of Tribute Options (No Rollover Election)
 
(c)  
if a Tribute Optionholder provides to Tribute, on or before the date which is three (3) Business Days prior to the Effective Date, a duly completed and executed Optionholder Election Form and therein designates that certain Tribute Options held by such Tribute Optionholder are subject to an exchange election (“Exchange Options”), each such Exchange Option will be deemed to be surrendered to Tribute in exchange for such number of Tribute Common Shares as is equal to the quotient obtained when the Tribute Option Differential applicable to such Exchange Option is divided by the Tribute Market Value;
 
(d)  
if a Tribute Optionholder does not deliver a duly completed and executed Optionholder Election Form in accordance with Subsection 3.1(c) or 3.1(h) or fails to make an election in respect of any Tribute Options held by such Tribute Optionholder, such Tribute Options not subject to an election shall be deemed to be (A) Exchange Options in the event the Tribute Option Differential applicable to such options is greater than zero and treated in the same manner as Subsection 3.1(c); or (B) surrendered to Tribute in exchange for a cash payment of $0.0001 from Tribute per applicable Tribute Option in the event the Tribute Option Differential applicable to such option is zero or less than zero;
 
Amalgamation of Can Merger Sub and Tribute
 
(e)  
Can Merger Sub and Tribute shall merge (the “Amalgamation”) to form one corporate entity with the same effect as if they were amalgamated under section 177 of the OBCA, except that the separate legal existence of Tribute will not cease and Tribute will survive the amalgamation, as more fully described in Section 3.3, and without limiting the foregoing, the separate legal existence of Can Merger Sub will cease without Can Merger Sub being liquidated or wound up, Can Merger Sub and Tribute will continue as one corporation, and the property of Can Merger Sub will become the property of Amalco. On the amalgamation of Can Merger Sub and Tribute to form Amalco pursuant to this Section 3.1(e):

(i)  
(A) each Can Merger Sub Share outstanding immediately prior to the Effective Time shall be exchanged for one Amalco Share, (B) the holder of the Can Merger Sub Shares so exchanged shall be added to the register of holders of Amalco Shares and (C) the Can Merger Sub Shares so exchanged shall be cancelled without any repayment of capital;

(ii)  
(A) each Tribute Common Share outstanding immediately prior to the Effective Time (other than Tribute Common Shares held by Tribute Dissenting Shareholders) shall be exchanged for 0.1455 of a Parent Share, (B) the holders of the Tribute Common Shares so exchanged shall be added to the register of holders of Parent Shares and (C) the Tribute Common Shares so exchanged shall be cancelled without any repayment of capital;

(iii)  
in consideration for Parent issuing and delivering, on behalf of Amalco, Parent Shares directly to former holders of Tribute Common Shares pursuant to Section 3.1(e)(ii), Amalco shall issue to Parent the number of Amalco Shares with an aggregate fair market value equal to the aggregate fair market value of the Parent Shares so issued and delivered and there shall be added to the stated capital account maintained by Parent for Parent Shares an amount equal to the aggregate “paid-up capital” (for the purposes of the Tax Act) of the Tribute Common Shares exchanged for Parent Shares pursuant to Section 3.1(e)(ii);
 
 
6

 
 
Exercise of Tribute Warrants and MFI Note
 
(f)  
after the Effective Time, on the due and proper exercise of the MFI Note by the holder thereof or the Tribute Warrants by a Tribute Warrantholder, such securities will entitle such holder to purchase or otherwise acquire, as the case may be, Parent Shares for no additional consideration beyond that set out in the MFI Note or the Tribute Indenture or the certificates evidencing such securities, as the case may be, subject to the application of the Exchange Ratio to the number of Parent Shares such holder is entitled to acquire and the exercise price of the Tribute Warrants and the MFI Note, all of which is in accordance with the provisions of the MFI Note, the Tribute Warrant Indenture and the certificates evidencing such securities, as the case may be;
 
Exercise of Tribute Compensation Options
 
(g)  
after the Effective Time, on the due and proper exercise of the Tribute Compensation Options by a Tribute Compensation Optionholder, such Tribute Compensation Options will entitle such Tribute Compensation Optionholder to purchase Parent Shares and Indenture Warrants for no additional consideration beyond that set out in the certificate evidencing such Tribute Compensation Options, subject to the application of the Exchange Ratio to the number of Parent Shares such holder is entitled to acquire and the exercise price of the Tribute Compensation Options, all of which is in accordance with the provisions of the certificates evidencing such Tribute Compensation Options;
 
Conversion of Tribute Options by Continuing Optionholders pursuant to Rollover Elections
 
(h)  
if a Continuing Optionholder provides to Parent and Tribute, on or before the date which is three (3) Business Days prior to the Effective Date, a duly completed and executed Optionholder Election Form and therein designates that certain Tribute Options held by such Continuing Optionholder are subject to a rollover election (“Rollover Options”), all such Rollover Options will be assumed by Parent and, for no consideration received by Parent, will be converted into Parent Options entitling the holder to purchase that number of Parent Shares as is equal to the number of Tribute Common Shares issuable pursuant to the Rollover Options so converted multiplied by the Exchange Ratio; the exercise price for each Parent Share issuable pursuant to such Parent Option will be equal to the exercise price of the Rollover Option so cancelled multiplied by the quotient obtained by dividing one (1) by the Exchange Ratio; and the expiry date of each such Parent Option will be the same as for each corresponding Rollover Option so converted;
 
Assignment and Assumption of Credit Facility
 
(i)  
the obligations of the Borrower (as defined in the Credit Facility) under the terms of the Credit Facility shall be assigned to and assumed by Parent pursuant to the terms of the Credit Facility;
 
Exchange of Tribute Convertible Notes
 
(j)  
the Tribute Convertible Notes held by the Tribute Convertible Noteholders shall be sold, assigned and transferred to Parent in exchange for Parent Convertible Notes issued pursuant to the Credit Facility having the same principal amount as the Tribute Convertible Notes so exchanged and a conversion price equal to a 32.5% premium over the Pozen Purchase Price.  For purposes of this Arrangement, the “Pozen Purchase Price” shall be equal to the lesser of (i) US$7.20, and (ii) a five percent (5%) discount off the five (5) day volume weighted average price per share of Pozen common stock as reported on Bloomberg Financial Markets, calculated over the five (5) trading days immediately preceding the date of Closing (as defined in the Arrangement Agreement), not to be less than US$6.25. In the event any of Pozen, Tribute or Parent announce a material event, whether by press release or the filing of a Form 8-K (other than results of any shareholder meeting) during the ten (10) day period immediately preceding Closing, then clause (ii) above shall be revised to read: “(ii) a five percent (5%) discount off the two (2) day volume weighted average price per share of Pozen common stock as reported on Bloomberg Financial Markets, calculated over the two (2) trading days immediately preceding the date of Closing, not to be less than US$6.25.”
 
3.2           With respect to each holder of Tribute Securities (other than Tribute Dissenting Shareholders), as the case may be, at the Effective Time:
 
(a)  
upon the exchange of Tribute Options for Tribute Common Shares or cash, as applicable, pursuant to Subsection 3.1(c) or 3.1(d):
 
(i)  
each such former Tribute Optionholder shall cease to be the holder of the Tribute Options so exchanged and the name of each such Tribute Optionholder shall be removed from the register of holders of Tribute Options;
 
 
7

 
 
(ii)  
each such former Tribute Optionholder entitled to Tribute Common Shares shall become a holder of the Tribute Common Shares so exchanged and shall be added to the register of holders of Tribute Common Shares; and
 
(iii)  
each such former Tribute Optionholder entitled to a cash payment from Tribute shall cease to have any rights in respect of such Tribute Options other than the right to receive the applicable cash payment in accordance with Subsection 3.1(d)(B);
 
(b)  
upon the due and proper exercise of the Tribute Warrants and the MFI Note which entitle the holder to purchase or otherwise acquire, as the case may be, Parent Shares pursuant to Subsection 3.1(f):
 
 
(i)
each such Tribute Warrantholder and the holder of the MFI Note, as applicable, shall be added to the register of holders of Parent Shares (or book-entry register as applicable) in such a manner as to record the number of Parent Shares (or book entry interests in respect of Parent Shares, as applicable) (A) issuable on payment of the exercise price of such Tribute Warrants, subject to the application of the Exchange Ratio to such number of Parent Shares issuable and exercise price, in accordance with the terms of the Tribute Warrant Indenture and the certificates evidencing the Tribute Warrants, as applicable, and (B) issuable on the conversion of the MFI Note into Parent Shares subject to the application of the Exchange Ratio to such number of Parent Shares issuable and the conversion price, in accordance with the terms of the MFI Note;
 
(c)  
upon the due and proper exercise of the Tribute Compensation Options which entitle the holder to purchase Parent Shares and Indenture Warrants pursuant to Subsection 3.1(g):
 
 
(i)
each such Tribute Compensation Optionholder shall be added to the register of holders of Parent Shares (or book-entry register as applicable) and Indenture Warrants in such manner as to record the number of Parent Shares (or book entry interests in respect of Parent Shares) issuable on payment of the exercise price of such Tribute Compensation Options, subject to the application of the Exchange Ratio to such number of Parent Shares issuable in accordance with the terms of the provisions of the certificates evidencing the Tribute Compensation Options;
 
(d)  
upon the exchange of Tribute Options into Parent Options pursuant to Subsection 3.1(h):
 
(i)           the name of each such former Tribute Optionholder shall be removed from the register of holders of Tribute Options; and
 
(ii)           each such former Tribute Optionholder shall become a holder of the Parent Options so converted and shall be added to the register of holders of Parent Options;
 
(e)  
upon the exchange of Tribute Convertible Notes for Parent Convertible Notes pursuant to subsection 3.1(j):
 
(i)  
the name of each such former holder of Tribute Convertible Notes shall be removed from the register of holders of Tribute Convertible Notes; and
 
(ii)  
each such former holder of Tribute Convertible Notes shall become a holder of the Parent Convertible Notes issued in exchange thereof and shall be added to the register of holders of Parent Convertible Notes.
 
3.3           Pursuant to Section 3.1(e), Can Merger Sub and Tribute shall merge to form one corporate entity, with the effect described below, and, unless and until otherwise determined in the manner required by Law, the following shall, and shall be deemed to, apply to Amalco without any further act or formality:
 
(a)  
the name of Amalco shall be Tribute Pharmaceuticals Canada Inc.;
 
 
8

 
 
(a)  
the articles of Amalco shall be substantially in the form of the articles of Can Merger Sub;
 
(b)  
the by-laws of Amalco shall be the same as the by-laws of Can Merger Sub;
 
(c)  
the registered office of Amalco shall be located at Suite 6000, 1 First Canadian Place PO Box 367, 100 King St. West,  Toronto, Ontario  M5X 1E2;
 
(d)  
there shall be no restrictions on the business that Amalco may carry on or on the powers it may exercise;
 
(e)  
Amalco shall be authorized to issue an unlimited number of common shares and an unlimited number of preferred shares issuable in series with the same rights, privileges, restrictions and conditions as the shares of Can Merger Sub;
 
(f)  
the transfer of Amalco Shares shall be restricted and no holder of Amalco Shares shall transfer any such Amalco Shares without either: (i) the express sanction of the holders of more than fifty percent of the voting shares of Amalco for the time being outstanding expressed by a resolution passed at a meeting of the shareholders or by an instrument or instruments in writing signed by the holders of more than fifty percent of such shares; or (ii) the express sanction of the directors of Amalco expressed by a resolution passed by the votes of a majority of the directors of Amalco at a meeting of the board of directors or signed by all of the directors entitled to vote on that resolution at a meeting of directors;
 
(g)  
the initial directors of Amalco shall be Andrew Koven, Scott Charles and Rob Harris;
 
(h)  
the first annual meeting of holders of Amalco Shares shall be held within 18 months of the Effective Date;
 
(i)  
the stated capital of the issued and outstanding Amalco Shares shall be equal to the sum of (i) the aggregate "paid-up capital" (for the purposes of the Tax Act) of the Can Merger Sub Shares immediately prior to the amalgamation and (ii) the aggregate fair market value of the Parent Shares issued in exchange for Tribute Common Shares pursuant to Section 3.1(e)(iii); and
 
 
(j)  
upon the Amalgamation pursuant to Section 3.1(e):
 
(i)  
the property of each of Can Merger Sub and Tribute shall continue to be the property of Amalco and for greater certainty, the Amalgamation shall not constitute a transfer or assignment of the property of Tribute;
 
(ii)  
all rights, contracts, permits and interests of Tribute or Can Merger Sub shall continue as rights, contracts, permits and interests of Amalco and, for greater certainty, the Amalgamation shall not constitute a transfer or assignment of the rights or obligations of either of Tribute or Can Merger Sub under any such rights, contracts, permits and interests;
 
(iii)  
Amalco shall continue to be liable for the obligations of Can Merger Sub and Tribute;
 
(iv)  
all existing causes of action, claims or liabilities to prosecution with respect to Can Merger Sub and Tribute shall be unaffected;
 
(v)  
all civil, criminal or administrative actions or proceedings pending by or against Can Merger Sub and Tribute may be continued to be prosecuted by or against Amalco; and
 
(vi)  
all convictions against, or rulings, orders or judgments in favour of or against Can Merger Sub and Tribute may be enforced by or against Amalco.
 
 
9

 
 
ARTICLE 4
U.S. SECURITIES ACT EXEMPTION
 
4.1
Notwithstanding any provision herein to the contrary, the Parties agree that this Plan of Arrangement will be carried out with the intention that all Parent Shares issued to Tribute Common Shareholders (including Tribute Common Shareholders that receive Tribute Common Shares in accordance with Subsection 3.1(c) or (d)) and Parent Options issued to Tribute Optionholders in accordance with Subsection 3.1(h), and Parent Convertible Notes issued to the Tribute Convertible Noteholders on completion of this Plan of Arrangement will be issued by the parties in reliance on the exemption from the registration requirements of the U.S. Securities Act as provided by Section 3(a)(10) thereof (the “Section 3(a)(10) Exemption”). In order to ensure the availability of the Section 3(a)(10) Exemption, the parties agree that the Arrangement will be carried out on the following basis:
 
(a)  
the Arrangement will be subject to the approval of the Court;
 
(b)  
prior to the hearing required to approve the Arrangement, the Court will be advised as to the intention of the parties to rely on the Section 3(a)(10) Exemption based on the Court’s approval of the Arrangement;
 
(c)  
the Court will be required to satisfy itself as to the fairness of the Arrangement to each of the Tribute Common Shareholders, Tribute Optionholders and the Tribute Convertible Noteholders;
 
(d)  
Parent, Can Merger Sub and Tribute will ensure Tribute Common Shareholders, Tribute Optionholders and the Tribute Convertible Noteholders entitled to receive securities upon the completion of the Arrangement will be given adequate notice advising them of their right to attend the hearing of the Court to give approval of the Arrangement and providing them with sufficient information necessary for them to exercise that right;
 
(e)  
the parties entitled to receive such securities will be advised that the Parent Shares, Parent Options and Parent Convertible Notes issued pursuant to the Arrangement have not been registered under the U.S. Securities Act or applicable state securities laws and will be issued in reliance on the Section 3(a)(10) Exemption and that the Parent Shares issuable upon exercise of the Parent Options or upon conversion of the Parent Convertible Notes will not be issued in reliance on the Section 3(a)(10) Exemption;
 
(f)  
the Final Order approving the Arrangement that is obtained from the Court will expressly state that the Arrangement is approved by the Court as being fair to the Tribute Common Shareholders, Tribute Optionholders and the Tribute Convertible Noteholders;
 
(g)  
the Interim Order approving the Tribute Meeting will specify that each Tribute Common Shareholder,  Tribute Optionholder and Tribute Convertible Noteholder will have the right to appear before the Court at the hearing of the Court to give approval of the Arrangement so long as they enter an appearance within a reasonable time; and
 
(h)  
the Final Order shall include a statement substantially to the following effect:
 
“This Order will serve as a basis to claim the exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), set forth in Section 3(a)(10) of the U.S. Securities Act for the issuance of Parent Shares to Tribute Common Shareholders in exchange for their Tribute Common Shares, the issuance of the Parent Options to Tribute Optionholders in exchange for their Tribute Options and the issuance of Parent Convertible Notes to the holders of Tribute Convertible Notes in exchange for their Tribute Convertible Notes, all pursuant to the Arrangement.”
 
 
10

 
 
ARTICLE 5
DISSENTING SHAREHOLDERS
 
5.1           Pursuant to the Interim Order, each registered Tribute Common Shareholder may exercise rights of dissent (“Dissent Rights”) pursuant to and in the manner set forth in section 185 of the OBCA, as modified by this Section 5.1 and the Interim Order; provided, however, that written objection to the Arrangement Resolution, in the manner contemplated by subsection 185(6) of the OBCA, must be sent to and received by Tribute by no later than 4:00 p.m. (Toronto time) on the second Business Day immediately prior to the Tribute Meeting.  Tribute Common Shareholders who duly exercise such rights of dissent and who:
 
(a)  
are ultimately determined to be entitled to be paid fair value for the Tribute Common Shares in respect of which they have exercised Dissent Rights will be deemed to have irrevocably transferred such Tribute Common Shares to Can Merger Sub pursuant to Section 3.1(a) in consideration of such fair value; or
 
(b)  
are ultimately not entitled, for any reason, to be paid fair value for the Tribute Common Shares in respect of which they have exercised Dissent Rights will be deemed to have participated in the Arrangement on the same basis as a Tribute Common Shareholder who has not exercised Dissent Rights, as at and from the time specified in Section 3.1(e) and be entitled to receive only the consideration set forth in Section 3.1(e);
 
but in no case will Tribute or Can Merger Sub or any other person be required to recognize such holders as holders of Tribute Common Shares after the completion of the steps set forth in Section 3.1(a) or 3.1(e), as the case may be, and each Tribute Dissenting Shareholder will cease to be entitled to the rights of a Tribute Common Shareholder in respect of the Tribute Common Shares in relation to which such Tribute Dissenting Shareholder has exercised Dissent Rights and the central securities register of Tribute will be amended to reflect that such former holder is no longer the holder of such Tribute Common Shares as and from the Effective Time.  For greater certainty, and in addition to any other restriction under section 185 of the OBCA, a Tribute Common Shareholder who has voted, or instructed a proxyholder to vote, against the Arrangement Resolution shall not be entitled to exercise Dissent Rights with respect to the Arrangement.
 
ARTICLE 6
OUTSTANDING CERTIFICATES AND FRACTIONAL SECURITIES
 
6.1
At or before the Effective Time, Can Merger Sub will cause Parent to deposit with the Arrangement Depositary for the benefit of the Tribute Common Shareholders one or more certificates or other entitlements representing the aggregate number of Parent Shares required to be delivered by Can Merger Sub to the Tribute Common Shareholders pursuant to Sections 3.1(e) (calculated without reference to whether any Tribute Common Shareholder has exercised Dissent Rights).
 
6.2
From and after the Effective Time, certificates formerly representing Tribute Securities that were exchanged under Section 3.1 shall represent only the right to receive (a) the consideration to which the holders are entitled under the Arrangement, or (b) as to those held by Tribute Dissenting Shareholders (other than those Tribute Dissenting Shareholders deemed to have participated in the Arrangement pursuant to Section 5.1(b)), to receive the fair value of the Tribute Common Shares represented by such certificates.
 
6.3
Subject to the provisions of the Tribute Letter of Transmittal, Parent shall, as soon as practicable following the later of the Effective Date and the date of deposit by a former Tribute Common Shareholder of a duly completed Tribute Letter of Transmittal and the certificates representing such Tribute Common Shares, either:
 
(a)  
forward or cause to be forwarded by first class mail (postage prepaid) to such former holder at the address specified in the Tribute Letter of Transmittal; or
 
(b)  
if requested by such holder in the Tribute Letter of Transmittal, make available or cause to be made available at the Arrangement Depositary for pickup by such holder,
 
 
11

 
 
certificates representing the number of Parent Shares issued to such holder under the Arrangement, but only to the extent that Parent issues Parent Shares in certificated form or as otherwise determined by the Memorandum and Articles of Association of Parent.
 
6.4
If any certificate which immediately prior to the Effective Time represented an interest in outstanding Tribute Common Shares that were exchanged pursuant to Section 3.1 has been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to have been lost, stolen or destroyed, the Arrangement Depositary will issue and deliver in exchange for such lost stolen or destroyed certificate the consideration to which the holder is entitled pursuant to the Arrangement (and any dividends or distributions with respect thereto) as determined in accordance with the Arrangement. The Person who is entitled to receive such consideration shall, as a condition precedent to the receipt thereof, give a bond to each of Tribute and Parent and their respective transfer agents, which bond is in form and substance satisfactory to each of the Tribute and Parent and their respective transfer agents, or shall, to the extent agreed by Tribute and Parent, otherwise indemnify Tribute and Parent and their respective transfer agents against any claim that may be made against any of them with respect to the certificate alleged to have been lost, stolen or destroyed.
 
6.5
All dividends or other distributions, if any, made with respect to any Tribute Common Shares allotted and issued pursuant to the Arrangement but for which a certificate has not been issued shall be paid or delivered to the Arrangement Depositary to be held by the Arrangement Depositary, in trust, for the registered holder thereof. Subject to Section 6.3, the Arrangement Depositary shall pay and deliver to any such registered holder, as soon as reasonably practicable after application therefor is made by the registered holder to the Arrangement Depositary in such form as the Arrangement Depositary may reasonably require, such dividends and distributions to which such holder is entitled, net of applicable withholding and other taxes.
 
 6.6
Any certificate formerly representing Tribute Common Shares that is not deposited with all other documents as required by this Plan of Arrangement on or before the sixth anniversary of the Effective Date shall cease to represent a right or claim of any kind or nature including the right of the holder of such shares to receive Parent Shares (and any dividend and distributions thereon). In such case, such Parent Shares (together with all dividends and distributions thereon) shall be returned to Parent and such Parent Shares shall be sold by Parent for the account of Parent in accordance with the relevant provisions of Parent’s Memorandum and Articles of Association.
 
6.7
No certificates representing fractional Parent Shares or Tribute Common Shares shall be issued under this Arrangement. In lieu of any fractional shares: (a) each registered holder of Tribute Common Shares otherwise entitled to a fractional interest in a Parent Share will receive the nearest whole number of Parent Shares (with fractions equal to exactly 0.5 being rounded up); and (b) each registered holder of Tribute Options otherwise entitled to a fractional interest in a Tribute Common Share will receive the nearest whole number of Tribute Common Shares (with fractions equal to exactly 0.5 being rounded up).
 
ARTICLE 7
AMENDMENTS
 
7.1
Parent or Tribute may amend this Plan of Arrangement at any time and from time to time prior to the Effective Time, provided that each such amendment must be: (i) set out in writing; (ii) approved by the other party; (iii) filed with the Court and, if made following the Tribute Meeting, approved by the Court; and (iv) communicated to holders of Tribute Securities, if and as required by the Court.
 
7.2
Any amendment to this Plan of Arrangement may be proposed by Parent or Tribute at any time prior to or at the Tribute Meeting (provided that the other party shall have consented thereto) with or without any other prior notice or communication, and if so proposed and accepted by the Tribute Common Shareholders voting at the Tribute Meeting (other than as may be required under the Interim Order), shall become part of this Plan of Arrangement for all purposes.
 
7.3
Parent and Tribute may amend, modify and/or supplement this Plan of Arrangement at any time and from time to time after the Tribute Meeting and prior to the Effective Time with the approval of the Court.
 
7.4
Any amendment, modification or supplement to this Plan of Arrangement may be made prior to or following the Effective Time by Parent and Tribute; provided that, it concerns a matter which, in the
 
 
12

 
 
reasonable opinion of Parent and Tribute, is of an administrative nature required to better give effect to the implementation of this Plan of Arrangement and is not adverse to the financial or economic interests of any former holder of Tribute Common Shares.
 
ARTICLE 8
WITHHOLDING RIGHTS
 
8.1
Parent, Tribute, Can Merger Sub and the Arrangement Depositary shall be entitled to deduct and withhold from any consideration otherwise payable to any Tribute Securityholders (including Tribute Dissenting Shareholders) such amounts as Parent, Tribute, Can Merger Sub or the Arrangement Depositary determines, acting reasonably, are required or permitted pursuant to the Tax Act, the United States Internal Revenue Code of 1986, or any provision of federal, provincial, territorial, state, local or foreign tax law, in each case, as amended. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes hereof as having been paid to the Tribute Securityholder in respect of which such deduction and withholding was made; provided that, such withheld amounts are actually remitted to the appropriate taxing authority.
 
ARTICLE 9
FURTHER ASSURANCES
 
10.1
Notwithstanding that the transactions and events set out herein shall occur and be deemed to occur in the order set out in this Plan of Arrangement without any further act or formality, each of the parties to the Arrangement Agreement shall make, do and execute, or cause to be made, done and executed, all such further acts, deeds, agreements, transfers, assurances, instruments or documents as may reasonably be required by any of them in order further to document or evidence any of the transactions or events set out herein. Tribute and Parent may agree not to implement this Plan of Arrangement, notwithstanding the passing of the resolution approving the Arrangement by the Tribute Common Shareholders and the receipt of the Final Order.
 

 

 

13

EX-10.1 4 tbuff_ex101.htm SECOND AMENDED AND RESTATED FACILITY AGREEMENT tbuff_ex101.htm
Exhibit 10.1
 
SECOND AMENDED AND RESTATED FACILITY AGREEMENT
 
This SECOND AMENDED AND RESTATED FACILITY AGREEMENT (this “Agreement”), dated as of December 7, 2015, by and among Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“Parent”), POZEN Inc., a corporation formed under the laws of the State of Delaware (“Pozen”), Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (“Tribute” and collectively with Parent and Pozen, each a “Credit Party” and collectively, the “Credit Parties”), and the lenders set forth on the signature page of this Agreement (together with their successors and assigns, the “Lenders” and, together with the Credit Parties, the “Parties”).
 
W I T N E S S E T H:
 
WHEREAS, Pozen, Tribute, the Lenders and certain other parties previously executed and delivered that certain Facility Agreement, dated as of June 8, 2015, as amended and restated on October 29, 2015 (the “Original Facility Agreement”);
 
WHEREAS, in connection with the Transactions (as defined below), the Arrangement Agreement (as defined below) has been amended and restated;
 
WHEREAS, the parties hereto desire to amend and restate the Original Facility Agreement to reflect the foregoing;
 
WHEREAS, the Borrower wishes to borrow from the Lenders up to Two Hundred Seventy Five Million Dollars ($275,000,000) for the purpose described in Section 2.1;
 
WHEREAS, pursuant to the Arrangement Agreement, Pozen, Tribute, Luxembourg FinCo (defined below) and certain other entities shall become wholly owned subsidiaries of Parent and this Agreement and the Obligations hereunder shall be assigned to and assumed by Parent;

WHEREAS, Parent, Pozen, Tribute, Luxembourg FinCo and each other Subsidiary of Parent shall guaranty the Obligations (defined below); and

WHEREAS, the Lenders desire to make loans to the Borrower for the purposes set forth in Section 2.1.
 
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the Parties hereto agree as follows:
 
ARTICLE 1
 
DEFINITIONS
 
Section 1.1 General Definitions.  Wherever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms have the following meanings:
 
 
 

 
 
Acquisition Loans” shall have the meaning provided therefor in Section 2.3.
 
Acquisition Notes” means the Secured Notes issued to the Lenders evidencing the Acquisition Loans in the form attached hereto as Exhibit A-3.
 
Adjusted EBITDA” means, with respect to Parent for any Test Period, Parent’s EBITDA plus (i) to the extent deducted in determining Consolidated Net Income for such Test Period, (A) fees and expenses directly incurred or paid in connection with (x) the transactions contemplated by this Agreement, (y) any Permitted Acquisition and (z) to the extent permitted hereunder, issuances or incurrence of Indebtedness, issuances of equity interests or refinancing transactions and modifications of instruments of Indebtedness, (B) any non-recurring charges, costs, fees and expenses directly incurred or paid directly as a result of discontinued operations (other than such charges, costs, fees and expenses to the extent constituting losses arising from such discontinued operations), (C) restructuring charges or reserves, including write-downs and write-offs, including any one-time costs incurred in connection with Permitted Acquisitions and costs related to the closure, consolidation and integration of facilities, information technology infrastructure and legal entities, and severance and retention bonuses as reasonably approved by the Required Lenders, (D) the amount of cost savings and synergies projected by Parent in good faith to be realized as a result of a Permitted Acquisition, in each case within the four consecutive fiscal quarters following the consummation of a Permitted Acquisition (or following the consummation of the squeeze-out merger in the case of a Permitted Acquisition structured as a two-step transaction), as the case may be, calculated as though such cost savings and synergies had been realized on the first day of the Test Period and net of the amount of actual benefits received during such period from the Permitted Acquisition; provided that (1) no cost savings or synergies shall be added pursuant to this clause (D) to the extent duplicative of any expenses or charges otherwise added to Adjusted EBITDA, whether through a pro forma adjustment or otherwise, for such period, (2) subject to the last paragraph of Section 5.1, a duly completed certificate signed by an authorized officer of Parent shall be delivered to the Lenders, specifying such cost savings and synergies in reasonable detail and certifying that such cost savings and synergies are reasonably expected and factually supportable in the good faith judgment of Parent, and (3) the cost savings or synergies pursuant to this clause (D) shall not exceed the amount of such expected costs savings or synergies publicly disclosed by Parent or the public successor (if applicable) in any filings with the SEC with respect to such Permitted Acquisition, minus (ii) to the extent included in Consolidated Net Income for such Person for such Test Period, any non-recurring income or gains directly as a result of discontinued operations.
 
Affiliate” shall have the meaning provided therefor in the Notes.
 
Agreement Date” means the date of this Agreement.
 
Applicable Laws” means all statutes, rules and regulations of Governmental Authorities in the United States, Canada or elsewhere applicable to the Credit Parties.
 
Arrangement Agreement” means that certain Agreement and Plan of Merger and Arrangement dated as of June 8, 2015, as amended on August 19, 2015, and on December 7, 2015 among Parent, Pozen, Tribute, ARLZ US Acquisition II Corp. and ARLZ CA Acquisition Corp.
 
 
2

 
 
Authorizations” has the meaning set forth in Section 3.1(r).
 
Borrower” shall mean Tribute until the filing of the Articles of Arrangement pursuant to the Arrangement Agreement and thereafter shall mean Parent.
 
Business Day” means a day on which banks are required to be open for business in the cities of New York, NY, Toronto, Ontario and Vancouver, B.C.
 
Canadian Security Documents” means the Security Agreement to be entered into between Tribute, all other Canadian Subsidiaries and the Lenders, substantially in the form of Exhibit B attached hereto, with such changes reasonably acceptable to Lenders, and all instruments, documents and agreements executed and delivered in connection therewith required to perfect Liens on the assets of Tribute.
 
Code” means the Internal Revenue Code of 1986, as amended, and any Treasury Regulations promulgated thereunder.
 
Collateral” shall have the meaning provided therefor in the Security Documents.
 
Commission” means the United States Securities and Exchange Commission.
 
Common Shares” shall mean the common shares of Tribute and Parent, as applicable.
 
Common Share Equivalents” means any securities of Parent which would entitle the holder thereof to acquire at any time Common Shares, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares or other securities that entitle the holder to receive, directly or indirectly, Common Shares.
 
Consolidated Net Income” means, with respect to Parent for any Test Period, net income (or loss) for Parent and its Subsidiaries for such Test Period, determined on a consolidated basis in accordance with GAAP (after deduction for minority interests); provided that, in making such determination, there shall be excluded (i) the net income of any other Person that is not a Subsidiary of Parent (or is accounted for by Parent by the equity method of accounting) except to the extent of actual payment of cash dividends or distributions by such Person to Parent or one of its Subsidiaries during such Test Period, (ii) the net income (or loss) of any other Person acquired by, or merged with, such Person or any of its Subsidiaries for any period prior to the date of such acquisition or merger, and (iii) the net income of any Subsidiary of Parent to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary of such net income is not at the time permitted by operation of the terms of its charter, certificate of incorporation or formation or other constituent document or any agreement or instrument or Applicable Laws.
 
Conversion Failure” shall have the meaning provided therefor in the Convertible Notes.
 
Convertible Notes” means the Senior Secured Convertible Notes issued to the Lenders evidencing the Initial Loans in substantially the forms attached hereto as Exhibit A-1 (evidencing the Tribute Convertible Notes until the filing of the Articles of Arrangement) and Exhibit A-2 (evidencing the Parent Convertible Notes from and after the filing of the Articles of Arrangement).
 
 
3

 
 
Conversion Shares” shall mean the shares issuable upon conversion of the Convertible Notes.
 
Default” means any event which, at the giving of notice, lapse of time or fulfillment of any other applicable condition (or any combination of the foregoing), would constitute an Event of Default.
 
Disbursement Condition” means Tribute (and Parent immediately following the filing of the Articles of Arrangement under the Arrangement Agreement) shall have authorized and reserved for issuance a number of Common Shares sufficient to cover all shares issuable on conversion of the Convertible Notes (computed without regard to any limitations on the number of shares that may be issued on exercise).
 
Dollars” and the “$” sign mean the lawful currency of the United States of America.
 
EBITDA” means, with respect to Parent for any Test Period, Consolidated Net Income for such Person for such Test Period plus (i) to the extent deducted in determining Consolidated Net Income for such Person for such Test Period, (A) interest expense, (B) provision for taxes paid or accrued, (C) depreciation and amortization, (D) non-cash expenses related to stock based compensation, (E) extraordinary non-cash expenses or losses incurred other than in the ordinary course of business, (F) any unrealized losses in respect of any interest rate hedge agreements, and (G) adjustments relating to purchase price allocation accounting, minus (ii) to the extent included in Consolidated Net Income for such Person for such Test Period, (A) interest income (to the extent not netted against interest expense in the calculation of interest expense), (B) income tax credits and refunds (to the extent not netted from tax expenses), (C) extraordinary non-cash income or gains realized other than in the ordinary course of business, and (D) any unrealized income or gains in respect of any interest rate hedge agreements (to the extent not included in clause (i)(F)) above or netted against interest expense in the calculation of interest expense).
 
Employment Agreement” means each of the Employment Agreements dated as of May 31, 2015 between Pozen and each of Adrian Adams and Andrew Koven.
 
Equity Agreement” means the Share Subscription Agreement dated as of June 8, 2015 as amended and restated on December 7, 2015, among Lenders, Parent and the other Persons party thereto.
 
Equity Investment” means the investment by Lenders or their Affiliates and other Persons in the Common Shares pursuant to the Equity Agreement.
 
Event of Default” has the meaning given to it in Section 5.4.
 
Exchange Act” means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.
 
 
4

 
 
Excluded Taxes” means with respect to any Lender, (a) income Taxes imposed on (or measured by) such Lender’s net income, franchise Taxes and branch profit Taxes, in each case imposed by the United States of America, or by the jurisdiction (or any political subdivision thereof) under the laws of which such Lender is organized or incorporated or in which the applicable lending office of such Lender is located, (b) Other Connection Taxes, (c) Other Taxes that arise with respect to the onward transfer of the Conversion Shares by a Lender, but for greater certainty not including any Taxes or Other Taxes (other than Taxes described in paragraphs (a), (b) or (d) of this definition of “Excluded Taxes”) arising as a result of the issuance of Conversion Shares to a Lender pursuant to the Conversion Notes, or (d) any U.S. federal withholding Taxes imposed under FATCA due to such Lender’s non-compliance with Section 2.6(e).
 
Excluded Transaction” means any of the following transactions:
 
The entering into any collaborative arrangement, licensing, joint venture, partnership, royalty agreement or similar agreements or other research, development, manufacturing or other commercial exploitation arrangements relating to Parent or any Subsidiary’s Intellectual Property or other assets (provided, that Parent has a reasonable basis for believing that the downstream economics potentially to be received by Parent and its Subsidiaries in connection with such collaborative arrangement, licensing, joint venture, partnership, royalty agreement or similar agreements or other research, development, manufacturing or other commercial exploitation arrangements relating to the IP, when combined with the potential downstream economics of rights in the IP retained by Parent and its Subsidiaries are adequate to enable Borrower to timely satisfy all obligations of the Borrower and its Subsidiaries under this Agreement), including, without limitation, but subject to the conditions set forth above, (1) any grant to any entity engaged in, or owned by an entity engaged in, the pharmaceutical or biotechnology industry of a license or option to obtain a license to any of Parent’s or any Subsidiary’s Intellectual Property or other assets, provided that Parent or a Subsidiary (and not any third party or any of Parent’s equity holders) directly receives from such entity all consideration paid or payable by such entity in consideration of such grant, which consideration may, but need not, include (without limitation) upfront, milestone, royalty and profit-sharing payments, (2) any grant of a license or option to obtain a license to any entity that intends to research, develop, commercialize or manufacture products or services covered by such Intellectual Property or other assets whether directly or through Parent, any Subsidiary or another entity, and (3) any arrangement or transfers of assets for the manufacture, research, promotion and development of Parent’s or any Subsidiary’s products and clinical trial management, and data analysis and similar activities in support of Parent’s or any Subsidiary’s development programs.
 
FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any intergovernmental agreements with respect thereto, any current or future regulations or official interpretations thereof, and any agreements entered into pursuant to Section 1471(b)(1) of the Code.
 
Final Payment” means such amount as may be necessary to repay the outstanding principal amount of the Notes and any other Obligations owing by the Borrower to the Lenders
 
 
5

 
 
pursuant to the Loan Documents.“GAAP” means generally accepted accounting principles consistently applied as set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable stature and authority within the accounting profession).
 
Governmental Authority” means any government, quasi-governmental agency, governmental department, ministry, cabinet, commission, board, bureau, agency, court, tribunal, regulatory authority, instrumentality, judicial, legislative, fiscal, or administrative or public body or entity, whether domestic or foreign, federal, provincial, state or local, having jurisdiction over the matter or matters and Person or Persons in question.
 
Guaranty” means the guaranty of the Obligations to be executed by each Guarantor in favor of Lenders substantially in the form of Exhibit C attached hereto, with such changes reasonably acceptable to Lenders.
 
Guarantor” means Parent, each Subsidiary of Parent and each other Person that executes a Guaranty.
 
Indebtedness” means the following:
 
(i) all indebtedness for borrowed money;
 
(ii) the deferred purchase price of assets or services (other than payables) which in accordance with GAAP would be shown to be a liability (or on the liability side of a balance sheet);
 
(iii) all guarantees of Indebtedness;
 
(iv) all letters of credit issued or acceptance facilities established for the account of Parent and any of its Subsidiaries, including without duplication, all drafts drawn thereunder;
 
(v) all capitalized lease obligations;
 
(vi) all indebtedness of another Person secured by any Lien on any property of Parent or its Subsidiaries, whether or not such indebtedness has been assumed or is recourse (with the amount thereof, in the case of any such indebtedness that has not been assumed by Parent or its Subsidiaries, being measured as the lower of (x) fair market value of such property and (y) the amount of the indebtedness secured); and
 
(vii) indebtedness created or arising under any conditional sale or title retention agreement.
 
Indemnified Person” has the meaning given to it in Section 6.12(a).
 
Indemnified Taxes” means all Taxes including Other Taxes, other than Excluded Taxes.
 
 
6

 
 
Indemnity” has the meaning given to it in Section 6.12(a).
 
Initial Funding Date” shall have the meaning set forth in Section 2.2.
 
Initial Loans” means the Loans made available by the Lenders to the Borrower pursuant to Section 2.2 in the aggregate principal amount of Seventy Five Million Dollars ($75,000,000) or, as the context may require, the principal amount thereof from time to time outstanding.
 
Interest Rate” means 2.5% per annum with respect to the Initial Loans and 12.5% per annum with respect to the Acquisition Loans.
 
IP” and “Intellectual Property” have the meaning given to it in Section 3.1(n).
 
IRS” means the United States Internal Revenue Service.
 
Irish Security Document” means that certain Irish law debenture dated the date of the Initial Funding Date among each Irish Subsidiary of Parent and Lenders, substantially in the form of Exhibit D attached hereto, with such changes thereto reasonably acceptable to Lenders.
 
Lien” means any lien, pledge, preferential arrangement, mortgage, security interest, deed of trust, charge, assignment, hypothecation, title retention, or other encumbrance on or with respect to property or interest in property having the practical effect of constituting a security interest, in each case with respect to the payment of any obligation with, or from the proceeds of, any asset or revenue of any kind.
 
Loans” means the Initial Loans and the Acquisition Loans.
 
Loan Documents” means this Agreement, the Notes, the Guaranties, the Pledge Agreement, the Security Documents, the Registration Rights Agreement, and any other document or instrument delivered in connection with any of the foregoing and dated the Agreement Date or subsequent thereto, whether or not specifically mentioned herein or therein.
 
Loss” has the meaning given to it in Section 6.12(a).
 
Luxembourg FinCo” means Luxembourg FinCo, a limited liability company organized under the laws of the Grand Duchy of Luxembourg.
 
Major Transaction” has the meaning set forth in the Convertible Notes.
 
Material Adverse Effect” means a material adverse effect on (a) the business, operations, condition (financial or otherwise), or assets of Parent or any of its Subsidiaries, (b) the validity or enforceability of any provision of any Loan Document, (c) the ability of Parent or any of its Subsidiaries to timely perform the Obligations or (d) the rights and remedies of the Lenders under any Loan Document; provided, however, any adverse effect that results directly or indirectly from general economic, business, financial or market conditions shall not be deemed to be a Material Adverse Effect.
 
Nijhawan Note” means the unsecured convertible promissory note in the aggregate principal amount of C$5,000,000 issued by Tribute to Nidhi Nijhawan on June 16, 2015.
 
 
7

 
 
Material Contract” means any contract of any Credit Party that has been filed or was required to have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.
 
Notes” means the Convertible Notes and the Acquisition Notes.
 
Obligations” means all obligations and liabilities (monetary or otherwise) of Parent, Borrower and their Subsidiaries arising under or in connection with this Agreement and the other Loan Documents.
 
Organizational Documents” means the Certificate of Incorporation, Articles, Notices of Articles, Bylaws, memorandum and articles of association or similar documents, each as amended to date, of the Credit Parties or any of their Subsidiaries, as the context may require.
 
Other Connection Taxes” means with respect to any Lender, Taxes imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such Tax (except a connection arising from such Lender having executed, delivered or performed its obligations under the Loan Documents).
 
Other Taxes” means any and all present or future stamp or documentary taxes or any other excise or property taxes, duties, other charges or similar levies, and all liabilities with respect thereto, together with any interest, additions to tax or penalties applicable thereto (including by reason of any delay in payment) arising from any payment made hereunder or from the execution, delivery, registration or enforcement of, or otherwise with respect to, any Loan Document or the delivery to a Lender of the Conversion Shares, except any such Taxes imposed with respect to an assignment (other than an assignment made in connection with the exercise of remedies following an Event of Default).
 
Parent” means Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada.
 
Parent Convertible Notes” shall have the meaning set forth in Section 5.1(l).
 
Permitted Acquisition” means any transaction or series of related transaction by which Parent or any of its Subsidiaries acquires all or substantially all of the assets of a Person or going business, division, or line of business or product or acquires equity interests of any Person having at least a majority of combined voting power of the then outstanding equity interests of such Person; provided,
 
(i)           immediately prior to, and after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or would result therefrom;
 
(ii)           all transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable laws and in conformity with all applicable Authorizations;
 
(iii)           Borrower shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Parent, each of the actions set forth in Section 5.1(ix);
 
 
8

 
 
(iv)           Subject to the last paragraph of Section 5.1, Borrower shall have delivered to Lenders at least ten (10) Business Days prior to such proposed acquisition, an executed term sheet and/or commitment letter (setting forth in reasonable detail the terms and conditions of such acquisition) and, at the request of any Lender, such other information and documents that any Lender may request, including, without limitation, executed counterparts of the respective agreements, instruments or other documents pursuant to which such acquisition is to be consummated, to the extent available (including, without limitation, any related management, non-compete, employment, option or other material agreements), any schedules to such agreements, instruments or other documents and all other material ancillary agreements, instruments or other documents to be executed or delivered in connection therewith;
 
(v)           any Person or assets or division acquired in accordance herewith shall be in same business or lines of business in which Parent and/or its Subsidiaries are engaged as of the Initial Funding Date or a business or line of business complimentary thereto;
 
(vi)           the acquisition shall have been approved by the board of directors or other governing body of the Person acquired or the Person from whom such assets or division is acquired; and
 
(vii)           the Adjusted EBITDA of Parent for the Test Period determined as of the date of the definitive documentation for such transaction or transactions on a pro forma basis as if such Permitted Acquisition had occurred at the beginning of such Test Period is greater than Adjusted EBITDA of Parent for such Test Period without giving such pro forma effect.
 
Permitted Indebtedness” means:
 
(i) The Obligations;
 
(ii) Indebtedness in respect of netting services, overdraft protections and other similar and customary services in connection with deposit accounts;
 
(iii) Performance bonds, surety bonds, letters of credit, security deposits and similar instruments incurred in the ordinary course of business;
 
(iv) Guarantees with respect to any Permitted Indebtedness;
 
(v) Indebtedness in respect of purchase money financing, capital lease obligations and equipment financing facilities covering existing and newly-acquired equipment, including for the acquisition, installation, qualification and validation of such equipment up to the aggregate amount, together with Indebtedness permitted by clause (vi) below, not in excess of $5,000,000 outstanding at any time;
 
(vi) Indebtedness acquired pursuant to or incurred in connection with a Permitted Acquisition up to the aggregate amount, together with Indebtedness permitted by clause (v) above, not in excess of $5,000,000 outstanding at any
 
 
9

 
 
time; provided that such Indebtedness has a rate of interest no greater than the market rate of interest for comparable Indebtedness and a maturity which is not less than 180 days after the latest maturity date of the Loans;
 
(vii) Unsecured Indebtedness up to an aggregate principal amount of $300,000,000 subordinated to the Obligations by written agreement in form and substance acceptable to Lenders, which has an interest rate no greater than the market rate of interest for comparable Indebtedness and a maturity which is not less than 180 days after the latest maturity date of the Loans;
 
(viii) Unsecured convertible Indebtedness up to an aggregate principal amount of $300,000,000 subordinated to the Obligations by written agreement in form and substance acceptable to Lenders, which has a rate of interest no greater than the market rate of interest for comparable Indebtedness and a maturity which is not less than 180 days after the latest maturity date of the Loans; and
 
(ix) Losses on hedging obligations or other derivative instruments entered into solely for the purpose of hedging foreign currency or interest rate risk and not for speculative purposes.
 
Permitted Liens” means:
 
(i) Liens in favor of the Lenders;
 
(ii) Statutory Liens created by operation of Applicable Laws;
 
(iii) Liens arising in the ordinary course of business and securing obligations not in excess of the aggregate sum of $1,000,000 that are not more than 60 days past due or are being contested in good faith by appropriate proceedings diligently pursued;
 
(iv) Liens for taxes, assessments or governmental charges or levies not past due and payable or that are being contested in good faith by appropriate proceedings;
 
(v) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default;
 
(vi) Liens in favor of financial institutions arising in connection with any Credit Party’s or any of its Subsidiaries’ accounts maintained in the ordinary course held at such institutions to secure standard fees for services charged by, but not financing made available by, such institutions;
 
(vii) Pledges or deposits in connection with workers’ compensation, unemployment insurance and other social security legislation;
 
(viii) Easements, rights of way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial
 
 
10

 
 
in amount, and which do not in any case materially interfere with the conduct of the business of the applicable Person;
 
(ix) Liens of a collection bank arising under Section 4-210 of the Uniform Commercial Code (or equivalent in foreign jurisdictions) on items in the course of collection; and
 
(x) Liens securing Indebtedness pursuant to clause (v) of the definition of Permitted Indebtedness.
 
Person” means and includes any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.
 
Pledge Agreement” means the Pledge Agreement to be entered into as of the Initial Funding Date by the entity which holds the equity interests in Pozen, Tribute and each other Subsidiary of Parent in favor of Lenders, substantially in the form of Exhibit E attached hereto, with such changes reasonably acceptable to Lenders.
 
PPSA” means the Personal Property Security Act (Ontario), the Personal Property Security Act (British Columbia) and to the extent applicable, equivalent legislation of any other jurisdiction in Canada.
 
Principal Trading Markets” means the Trading Markets on which the Common Shares are listed on and quoted for trading, which, as of the date of this Agreement, shall be the NASDAQ Global Market and the Toronto Stock Exchange.
 
Register” has the meaning set forth in Section 1.4 (b).
 
Registration Rights Agreement” means that certain Registration Rights Agreement dated as of June 8, 2015 between Lenders and Parent, as amended and restated on October 29, 2015 and December 7, 2015.
 
Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale by the Lenders of the Registrable Securities (as defined in the Registration Rights Agreement).
 
Required Lenders” means, at any time, Lenders holding Loans representing more than 50% of the sum of the Loans outstanding.
 
Restricted Lender” means the initial Lenders party to this Agreement and their Affiliates and any assignee of any interest in a Note that notifies the Borrower in writing that it wishes to be deemed a Restricted Lender.
 
Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
 
 
11

 
 
SEC Reports” shall have the meaning set forth in Section 5.1(v).
 
Securities” means the Convertible Notes and the Conversion Shares.
 
Securities Act” means the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.
 
Security Agreement” means that certain Security Agreement to be entered into as of the Initial Funding Date among Pozen, all other U.S. Subsidiaries of Parent, the other grantors from time to time party thereto and Lenders, substantially in the form of Exhibit F attached hereto, with such changes reasonably acceptable to Lenders.
 
Security Documents” means the Security Agreement, the Irish Security Agreement, the Canadian Security Documents and all other instruments, documents and agreements executed or delivered in connection therewith required to perfect Liens on the assets of Borrower and Guarantors.
 
Subsidiary or Subsidiaries” means, as to any Person, any entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at the time directly or indirectly owned or controlled by such Person, or one or more of the Subsidiaries of the Person, or a combination thereof.
 
Tax Affiliate” means (a) Parent and its Subsidiaries and (b) any Affiliate of the Parent with which Parent files or is required to file consolidated, combined or unitary tax returns.
 
Taxes” means all present or future taxes, levies, imposts, stamp or other duties, deductions, charges or withholdings and all liabilities with respect thereto, (including by reason of any delay in payment).
 
Test Period” means, at any date of determination, the period of four consecutive fiscal quarters of Parent then ended for which financial statements have been filed with the SEC.
 
Trading Market” means whichever of the New York Stock Exchange, the NYSE Alternext (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, the Toronto Stock Exchange or the OTC Bulletin Board on which the Common Shares are listed or quoted for trading on the date in question.
 
Transactions” shall mean the transactions contemplated by the Arrangement Agreement and the Equity Agreement, including, but not limited to the Equity Investment.
 
Tribute Convertible Notes” shall have the meaning set forth in Section 5.1(l).
 
Section 1.2 Interpretation.  In this Agreement, unless the context otherwise requires, all words and personal pronouns relating thereto shall be read and construed as the number and gender of the party or parties requires and the verb shall be read and construed as agreeing with the required word and pronoun; the division of this Agreement into Articles and Sections and the
 
 
12

 
 
use of headings and captions is for convenience of reference only and shall not modify or affect the interpretation or construction of this Agreement or any of its provisions; the words “herein,” “hereof,” “hereunder,” “hereinafter” and “hereto” and words of similar import refer to this Agreement as a whole and not to any particular Article or Section hereof; the words “include,” “including,” and derivations thereof shall be deemed to have the phrase “without limitation” attached thereto unless otherwise expressly stated; references to a specified Article, Exhibit, Section or Schedule shall be construed as a reference to that specified Article, Exhibit, Section or Schedule of this Agreement; and any reference to any of the Loan Documents means such document as the same shall be amended, supplemented or modified and from time to time in effect.
 
Section 1.3 Business Day Adjustment.  If the day by which any payment or other performance is due to be made is not a Business Day, that payment or performance shall be made by the next succeeding Business Day.
 
Section 1.4 Registration.
 
(a) The Borrower shall record on its books and records the amount of the Loans, the interest rate applicable, all payments of principal and interest thereon and the principal balance thereof from time to time outstanding.
 
(b) The Borrower shall establish and maintain at its address referred to in Section 6.2, a record of ownership (the “Register”) in which the Borrower agrees to register by book entry the interests (including any rights to receive payment hereunder) of each Lender in the Loan, and any assignment of any such interest, and (ii) accounts in the Register in accordance with its usual practice in which it shall record (1) the names and addresses of the Lenders (and any change thereto pursuant to this Agreement), (2) the amount of the Loan and each funding of any participation therein, (3) the amount of any principal or interest due and payable or paid, and (4) any other payment received by the Lenders from the Borrower and its application to the Loan.
 
(c) Notwithstanding anything to the contrary contained in this Agreement, the Loans (including any Notes evidencing the Loans) are a registered obligation, the right, title and interest of the Lenders and their assignees in and to the Loans shall be transferable only upon notation of such transfer in the Register and no assignment thereof shall be effective until recorded therein. This Section 1.4 shall be construed so that the Loans are at all times maintained in “registered form” within the meaning of Sections 163(f), 871(h)(2) and 881(c)(2) of the Code.
 
(d) The Borrower and the Lenders shall treat each Person whose name is recorded in the Register as a Lender for all purposes of this Agreement. Information contained in the Register with respect to any Lender shall be available for access by the Borrower or such Lender at any reasonable time and from time to time upon reasonable prior notice.
 
 
13

 
 
ARTICLE 2
 
AGREEMENT FOR THE LOAN
 
Section 2.1 Use of Proceeds.  The proceeds of the Initial Loan shall be used for working capital and general corporate purposes and the proceeds of the Acquisition Loans shall be used solely to fund Permitted Acquisitions.
 
Section 2.2 Initial Loans.  Subject to the conditions set forth in Section 4.1 and this Section 2.2, the Lenders shall disburse Initial Loans in the amount of $75,000,000 to the Borrower on a date (“Initial Funding Date”) not less than three (3) Business Days following the satisfaction of the conditions set forth in Section 4.1.  Lenders shall fulfill the Initial Loans in accordance with their respective allocations set forth on Schedule 1 hereto.  In the event the conditions to the Initial Loan have not been satisfied by April 30, 2016, the Lenders shall not have any further obligations under this Agreement.
 
Section 2.3 Acquisition Loans.  Subject to the conditions set forth in Section 4.2 at any time and from time to time after the Initial Funding Date and prior to April 30, 2017; upon not less than three (3) Business Days’ written request (“Acquisition Loan Request”) by Borrower to Lenders, Lenders shall make additional advances to Borrower (each an “Acquisition Loan” and collectively the “Acquisition Loans”) up to the aggregate sum of $200,000,000 for the payment of the purchase price of any Permitted Acquisition.  Lenders shall fulfill the Acquisition Loans in accordance with their respective allocations set forth on Schedule 1 hereto.
 
Section 2.4 Payment.
 
(a) Borrower shall repay the outstanding principal amount of the Initial Loans, together with all accrued and unpaid interest thereon on the sixth anniversary of the Initial Funding Date.  Parent shall repay the outstanding principal amount of each Acquisition Loan, together with all accrued and unpaid interest thereon on the sixth anniversary of the funding of each such Acquisition Loan.  Except as specifically provided herein, the Convertible Notes shall not be prepayable.  The Acquisition Notes shall be prepayable in whole or in part at any time following the end of the sixth month after the funding date of the applicable Acquisition Loan and prior to the maturity of such Acquisition Loan (provided that any Acquisition Loan incurred to refinance Indebtedness incurred before the Initial Funding Date with respect to a Permitted Acquisition may be prepaid in whole or in part at any time prior to maturity) at 101% of the principal amount of such Acquisition Loan to be prepaid, plus all accrued and unpaid interest on such Acquisition Loan to be prepaid.
 
(b) Lenders shall have the right to convert all or any part of the principal amount of their Convertible Notes into Common Shares in accordance with the terms of the Convertible Notes.  Upon the Share Delivery Date (as defined in the Convertible Notes) Borrower shall pay to Lenders all accrued and unpaid interest on the principal amount of the Convertible Notes converted into Common Shares.
 
 
14

 
 
Section 2.5 Payments.  All payments by the Borrower under any of the Loan Documents shall be made without setoff or counterclaim.  Payments of any amounts due to the Lenders under this Agreement shall be made in Dollars in immediately available funds prior to 11:00 a.m. New York City time on such date that any such payment is due, at such bank or places as the Lenders shall from time to time designate in writing at least five (5) Business Days prior to the date such payment is due.  The Borrower shall pay all and any costs (administrative or otherwise) imposed by banks, clearing houses, or any other financial institution, in connection with making any payments under any of the Loan Documents, except for any costs imposed by the Lenders’ banking institutions.
 
Section 2.6 Taxes.
 
(a) Any and all payments hereunder or under any other Loan Document shall be made, in accordance with this Section 2.6, free and clear of and without deduction for any and all present or future Taxes except as required by applicable law. If Borrower (or another applicable Credit Party) shall be required by law to deduct any Taxes from or in respect of any sum payable hereunder or under any other Loan Document and such Taxes are Indemnified Taxes, (i) the sum payable hereunder or thereunder shall be increased by as much as shall be necessary so that after making all required deductions (including deductions for Indemnified Taxes applicable to additional sums payable under this Section 2.6(a)),  each Lender shall receive an amount equal to the sum it would have received had no such deductions been made (any and all such additional amounts payable shall hereafter be referred to as the “Additional Amounts”), (ii) Borrower shall make such deductions, and (iii) Borrower shall pay the full amount deducted to the relevant Governmental Authority in accordance with applicable law. Within thirty (30) days after the date of any payment of such Taxes, Borrower shall furnish to the applicable Lender the original or a certified copy of a receipt evidencing payment thereof or other evidence of such payment reasonably satisfactory to such Lender.
 
(b) Borrower agrees to pay and authorizes each Lender to pay in its name (but without duplication), all Other Taxes. Within 30 days after the date of any payment of Other Taxes, Borrower shall furnish to the applicable Lender the original or a certified copy of a receipt evidencing payment thereof or other evidence of such payment reasonably satisfactory to such Lender.
 
(c) Without duplication of Section 2.6(a) or Section 2.6(b), Borrower shall reimburse and indemnify, within ten (10) days after receipt of demand therefor, each Lender for all Indemnified Taxes (including all Indemnified Taxes imposed on amounts payable under this Section 2.6(c)) paid by such Lender, whether or not such Indemnified Taxes were correctly or legally asserted. A certificate of the applicable Lender(s) setting forth the amounts to be paid thereunder and delivered to Borrower shall be conclusive, absent manifest error.
 
(d) If any Party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.6 (including by the payment of Additional Amounts), it shall
 
 
15

 

pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (d) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this paragraph (d), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (d) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.
 
(e) If a payment made to a Lender under any Loan Document would be subject to withholding Tax under FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA, such Lender shall deliver to the Borrower or its designated agent at such time or times reasonably requested by the Borrower or its designated agent such U.S. tax forms and such additional documentation reasonably requested by the Borrower or its agent as may be necessary for the Borrower or its agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment.
 
Notwithstanding anything else to the contrary in any of the Loan Documents or the Arrangement Agreement, the provisions of this Section 2.6 shall also apply mutatis mutandis to all Taxes (whether or not such Taxes are Excluded Taxes) incurred by the Lenders as a result of (i) the assignment by the Borrower of the Loan Documents to the Parent pursuant to the Arrangement Agreement, and (ii) the sale, assignment and transfer by the Lenders of the Conversion Notes to the Parent pursuant to the Arrangement Agreement.
 
Section 2.7 Fee and Costs.  Notwithstanding anything to the contrary contained in the Equity Agreement, the Credit Parties (excluding Tribute prior to the closing of the transactions contemplated by the Arrangement Agreement), jointly and severally agree to reimburse the Lenders for reasonable, documented expenses for attorneys, accountants and other professional advisors, and other out-of-pocket expenses incurred by Lenders in connection with their due diligence, negotiation and documentation of the transactions contemplated by the Loan Documents and all amendments and modifications thereto, whether or not consummated; provided that Credit Parties’ obligation to reimburse Lenders for such fees and expenses in connection with the negotiation, documentation and closing of this Agreement and the other Loan Documents shall not exceed the aggregate amount of $300,000.  At Lender’s election, such reimbursed amounts may be deducted from the Initial Loans.
 
 
16

 
 
Section 2.8 Interest.  The outstanding principal amount of the Loans shall bear interest at the Interest Rate (calculated on the basis of the actual number of days elapsed in each month).  Interest shall be paid quarterly in arrears commencing on April 1, 2016 and on the first Business Day of each January, April, July and October thereafter (each, an “Interest Payment Date”).
 
Section 2.9 Interest on Late Payments.  Without limiting the remedies available to the Lenders under the Loan Documents or otherwise, to the maximum extent permitted by applicable law, if the Borrower fails to make a required payment of principal or interest with respect to the Loan when due or to timely comply with Section 5.1(v) of this Agreement (regardless of any cure period provided in Section 5.4(b) of this Agreement), the Borrower shall pay interest, in respect of such principal and interest at the rate per annum equal to the Interest Rate plus ten percent (10%) for so long as such payment remains outstanding or such covenant is not timely cured.  Such interest shall be payable on demand.
 
Section 2.10 Compliance with Interest Act (Canada) and Criminal Code (Canada)
 
(a) For the purposes of disclosure pursuant to the Interest Act (Canada), where rates of interest or fees provided in this Agreement or any Loan Document are to be computed on the basis of any period of time less than a calendar year, then the equivalent annual rates are the rates or fees so computed multiplied by the actual number of days in the applicable calendar year and divided by the number of days in such other period of time.
 
(b) If any provision of this Agreement would obligate the Borrower to make any payment of interest or other amount payable to any Lender in an amount or calculated at a rate which would result in a receipt by that Lender of interest or yield at a criminal rate (as such terms are construed under the Criminal Code (Canada)), then notwithstanding such provision, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest or yield, as the case may be, as would not result in a receipt by that Lender of interest at a criminal rate, such adjustment to be effected by that Lender, to the extent necessary, as follows:
 
(i) Firstly, by reducing the number or rate of interest required to be paid to the affected Lender hereunder; and
 
(ii) Thereafter, by reducing any fees, commissions, premiums and other amounts required to be paid to the affected Lender which would constitute interest for purpose of Section 347 of the Criminal Code (Canada).
 
If, after giving effect to all adjustments contemplated by this Section 2.10(b), any Lender shall have received an amount in excess of the maximum permitted by this Section 2.10(b), then the affected Lender shall reimburse Borrower in an amount equal to such excess.
 
Any amount or rate of interest referred to in this Section 2.10(b) shall be determined in accordance with generally accepted actuarial practices and principles as an effective annual rate of interest over the term of the applicable Loan on
 
 
17

 
 
the assumption that any payments of interest or other amounts payable that fall within the meaning of “interest” (as defined in the Criminal Code (Canada)) shall, if they relate to a specific period of time, be pro-rated over that period of time and otherwise be pro-rated over the period from the date of the advance of the relevant Loan to the date on which all obligations of the Borrower in respect of such Loan have been paid and discharged in full, and, in the event of a dispute, a certificate of a Fellow of the Canadian Institute of Actuaries appointed by the Required Lenders shall be conclusive for the purposes of such determination.
 
ARTICLE 3
 
REPRESENTATIONS AND WARRANTIES
 
Section 3.1 Representations and Warranties of the Credit Parties.  Except with respect to Section 3.1(ee) below, to which the Parent solely represents and warrants, each Credit Party represents and warrants to the Lenders that, except as set forth in a Schedule to this Agreement:
 
(a) Each Credit Party and each of its Subsidiaries are conducting their business in compliance with their Organizational Documents, which are in full force and effect.
 
(b) No Default or Event of Default has occurred.
 
(c) Each Credit Party and each of its Subsidiaries (i) are capable of paying their debts as they fall due, have not admitted their inability to pay their debts as they fall due, (ii) are not bankrupt or insolvent or deemed to be bankrupt or insolvent under Applicable Laws and (iii) have not taken action, and no such action has been taken by a third party, for any Credit Parties’ or any of its Subsidiaries’ winding up, dissolution, or liquidation, examinership or similar executory or judicial proceeding or for the appointment of a liquidator, custodian, receiver, receiver-manager, trustee, administrator, examinership or other similar officer for any Credit Party or any of its Subsidiaries or any or all of their assets or revenues.
 
(d) Except as disclosed on Schedule 3.1(d), which Liens shall be terminated on or prior to the Initial Funding Date, no Lien exists on any Credit Parties’ or any of its Subsidiaries’ assets, except for Permitted Liens.
 
(e) The obligations of Tribute and Parent to make any payment under this Agreement (together with all charges in connection therewith) is absolute and unconditional.
 
(f) Except with respect to the Nijhawan Note, which shall be repaid in full at or prior to maturity, without extension, or converted prior thereto pursuant to its terms, and except as disclosed on Schedule 3.1(f) which Indebtedness will be repaid on or about the Initial Funding Date, no Indebtedness of any Credit Party or any of its Subsidiaries exists other than Permitted Indebtedness.
 
(g) Tribute is validly existing as a corporation in good standing under the laws of the Province of Ontario, Canada.  Pozen is validly existing as a corporation
 
 
18

 
 
in good standing under the laws of the State of Delaware.  Parent is validly existing as a corporation in good standing under the laws of the Province of British Columbia, Canada.  Each Credit Party and each of its Subsidiaries have full power and authority to own their properties, conduct their business and enter into the Loan Documents and to consummate the transactions contemplated under the Loan Documents, and are duly qualified to do business as a foreign entity and are in good standing in each jurisdiction where the failure to be so qualified could reasonably be expected to result in a Material Adverse Effect.
 
(h) There is not pending or, to the knowledge of any Credit Party, threatened, any action, suit, investigation, hearings or other proceeding before any Governmental Authority (a) to which any Credit Party or any of its Subsidiaries is a party or (b) which has as the subject thereof any assets owned by any Credit Party or any of its Subsidiaries, except, as would not reasonably be expected to have a Material Adverse Effect.  There are no current or, to the knowledge of any Credit Party, pending, legal, governmental or regulatory enforcement actions, suits or other proceedings to which any Credit Party or any of its Subsidiaries or any of their assets is subject, except, as would not reasonably be expected to have a Material Adverse Effect.
 
(i) Each Credit Party has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Loan Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.  Each Credit Parties’ execution and delivery of each of the Loan Documents to which it is a party and the consummation by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Notes and the reservation for issuance and the  subsequent issuance of the Conversion Shares upon exercise of the Convertible Notes) have been duly authorized by all necessary action on the part of each Credit Party, and no further action is required by any Credit Party, its directors or its stockholders in connection therewith other than in connection with the Required Approvals (as defined below). Each of the Loan Documents to which it is a party has been (or upon delivery will have been) duly executed by each Credit Party and each of its Subsidiaries and is, or when delivered by each Credit Party and each of its Subsidiaries a party thereto, in accordance with the terms hereof, will constitute the legal, valid and binding obligation of such Credit Party and its Subsidiaries party thereto enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, examinership, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. The execution, delivery and performance of the Loan Documents by the Credit Parties and their Subsidiaries and the consummation of the transactions therein contemplated (including, but not limited to, the delivery of the Convertible Notes and the reservation for issuance and subsequent issuance of the Conversion Shares) will not (A) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any Lien (other than pursuant to the Loan Documents) upon any assets of any Credit Party or any of its Subsidiaries pursuant to, any agreement to which any Credit Party or any of its Subsidiaries is a party or by which any Credit Party or any of its Subsidiaries are bound or to which any of the
 
 
19

 
 
assets of any Credit Party or any of its Subsidiaries is subject, (B) result in any violation of or conflict with the provisions of the Organizational Documents or (C) result in the violation of any Applicable Law or (D) result in the violation of any judgment, order, rule, regulation or decree of any Governmental Authority.  No consent, approval, authorization or order of, or registration or filing with any Governmental Authority is required for the execution, delivery and performance of any of the Loan Documents or for the consummation by any Credit Party and any of its Subsidiaries of the transactions contemplated thereby except for such registrations and filings in connection with (i) the filing with the Commission of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable Canadian provincial and US state securities laws, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Markets for the issuance and sale of the Securities and the listing of the Conversion Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) filings contemplated by the Security Documents and (vi) those that are required to be obtained in connection with the Transactions or that have been made or obtained prior to the Initial Funding Date (the “Required Approvals”).
 
(j) As of their respective filing dates, or to the extent corrected by a subsequent restatement or amendment, the SEC Reports filed by any Credit Party comply in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  No Credit Party has ever been an issuer subject to Rule 144(i) under the Securities Act.  Each of the Material Contracts to which any Credit Party is a party or to which the property or assets of any Credit Party are subject will be filed as an exhibit to the SEC Reports.
 
(k) Other than the actions required under the Registration Rights Agreement with respect to the Registration Statement or with respect to the Transactions, no Authorization is required for (i) the execution and delivery of this Agreement, the other Loan Documents, or (ii) the consummation of the transactions contemplated hereby and thereby.
 
(l) Each Credit Party and each of its Subsidiaries holds, and is operating in good standing (where applicable) and in compliance in all material respects with, all franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental Authority (collectively, “Necessary Documents”) required for the conduct of its business and all Necessary Documents are valid and in full force and effect; and neither any Credit Party nor any of its Subsidiaries has received written notice of any revocation or modification of any of the Necessary Documents and neither any Credit Party nor any of its Subsidiaries has any reason to believe that any of the Necessary Documents will not be renewed in the ordinary course of business, and each Credit Party and each of its Subsidiaries are in compliance in all
 
 
20

 
 
material respects with all applicable federal, state, local and foreign laws, regulations, orders and decrees applicable to the conduct of its business.
 
(m) Each Credit Party and each of its Subsidiaries have good and marketable title to all of their assets free and clear of all Liens except Permitted Liens and those Liens set forth in Schedule 3.1(d).  The property held under lease by each Credit Party and each of its Subsidiaries is held under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of any Credit Party or any of its Subsidiaries.
 
(n) Except as set forth on Schedule 3.1(n), each Credit Party and each of its Subsidiaries own or have the right to use pursuant to a valid and enforceable written license, implied license or other legally enforceable right, all of the Intellectual Property (as defined below) that is necessary for the conduct of their business as currently conducted and the manufacture, importation and sale of products being developed by such Credit Party or any of its Subsidiaries (the “IP”).  The IP that is registered with or issued by a Governmental Authority is valid and enforceable; there is no outstanding, pending, or threatened action, suit, other proceeding or claim by any third person challenging or contesting the validity, scope, use, ownership, enforceability, or other rights of any Credit Party or any of its Subsidiaries in or to any IP and neither any Credit Party nor any of its Subsidiaries has received any written notice regarding, any such action, suit, or other proceeding.  Neither any Credit Party nor any of its Subsidiaries has infringed or misappropriated any material rights of others.  There is no pending or threatened action, suit, other proceeding or claim by others that any Credit Party or any of its Subsidiaries infringes upon, violates or uses the Intellectual Property rights of others without authorization, and neither any Credit Party nor any of its Subsidiaries has received any written notice regarding, any such action, suit, other proceeding or claim.  Except as set forth on Schedule 3.1(n), neither any Credit Party nor any of its Subsidiaries is a party to or bound by any options, licenses, or agreements with respect to IP other than licenses for computer software acquired in the ordinary course of business.  The term “Intellectual Property” as used herein means (i) all patents, patent applications, patent disclosures and inventions (whether patentable or unpatentable and whether or not reduced to practice), (ii) all trademarks, service marks, trade dress, trade names, slogans, logos, and corporate names and Internet domain names, together with all of the goodwill associated with each of the foregoing, (iii) copyrights, copyrightable works, and licenses, (iv) registrations and applications for registration for any of the foregoing, (v) computer software (including but not limited to source code and object code), data, databases, and documentation thereof, (vi) trade secrets and other confidential information, (vii) other intellectual property, and (viii) copies and tangible embodiments of the foregoing (in whatever form and medium).
 
(o) Neither any Credit Party nor any of its Subsidiaries is in violation of the Organizational Documents, or in breach of or otherwise in default under, and no event has occurred which, with notice or lapse of time or both, would constitute such breach or other default in the performance of any agreement or condition contained in any agreement under which it may be bound, or to which any of its assets is subject.
 
 
21

 
 
(p) All US and Canadian federal, provincial, state, local and foreign income and franchise and other material Tax returns, reports and statements (collectively, the “Tax Returns”) required to be filed by any Tax Affiliates have been filed with the appropriate Governmental Authorities, all such Tax Returns are true and correct in all material respects, and all Taxes, assessments and other governmental charges and impositions reflected therein and all other material Taxes, assessments and other governmental charges otherwise due and payable have been paid prior to the date on which any liability may be added thereto for non-payment thereof except for those contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves are maintained on the books of the appropriate Tax Affiliate in accordance with GAAP or other applicable accounting principles, standards and procedures that such Tax Affiliate uses to compile its financial statements.  As of the Agreement Date, no Tax Return is under audit or examination by any Governmental Authority, and no Tax Affiliate has received written notice from any Governmental Authority of any audit or examination or any assertion of any material claim for Taxes.
 
(q) Other than as set forth in Schedule 3.1(q) neither any Credit Party nor any of its Subsidiaries has granted rights to market or sell its products or services to any other Person, and are not bound by any agreement that affects the exclusive right of any Credit Party or any of its Subsidiaries to develop, license, market or sell its products or services, in each case including rights relating to products under development by any Credit Party or any of its Subsidiaries.
 
(r) Each Credit Party and each of its Subsidiaries:  (A) at all times has complied in all materials respects with all Applicable Laws; (B) has not received any warning letter or other correspondence or notice from any Governmental Authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto reasonably required in connection with the business of any Credit Party or any of its Subsidiaries by any Applicable Laws (together, the “Authorizations”); (C) possesses and complies with the Authorizations, which are valid and in full force and effect; (D) has not received written notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorization and has no knowledge that any Governmental Authority is considering such action; (E) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as reasonably required by any Applicable Laws or Authorizations.
 
(s) Each of Pozen and Tribute maintains or, in the case of Parent, as of the Initial Funding Date will maintain a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
 
 
22

 
 
(t) (i) To the knowledge of each Credit Party, no “prohibited transaction” as defined under Section 406 of ERISA or Section 4975 of the Code that is not exempt under ERISA Section 408 or Section 4975 of the Code, under any applicable regulations and published interpretations thereunder or under any applicable prohibited transaction, individual or class exemption issued by the Department of Labor, has occurred with respect to any Employee Benefit Plan, except for such transactions as would not have a Material Adverse Effect, (ii) at no time within the last seven (7) years has any Credit Party or any ERISA Affiliate maintained, sponsored, participated in, contributed to or has or had any liability or obligation in respect of any Employee Benefit Plan subject to Section 302 of ERISA, Title IV of ERISA, or Section 412 of the Code or any “multiemployer plan” as defined in Section 3(37) of ERISA or any multiple employer plan for which any Credit Party or any ERISA Affiliate has incurred or could incur liability under Section 4063 or 4064 of ERISA, (iii) no Employee Benefit Plan represents any current or future liability for retiree health, life insurance, or other retiree welfare benefits except as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or similar state law, (iv) each Employee Benefit Plan is and has been operated in compliance with its terms and all applicable laws, including but not limited to ERISA and the Code, except for such failures to comply that would not have a Material Adverse Effect, (v) no event has occurred (including a “reportable event” as such term is defined in Section 4043 of ERISA) and no condition exists that would subject any Credit Party or any ERISA Affiliate to any tax, fine, lien, penalty or liability imposed by ERISA, the Code or other applicable law, except for any such tax, fine, lien, penalty or liability that would not, individually or in the aggregate, have a Material Adverse Effect, (vi) no Credit Party maintains any Foreign Benefit Plan, (vii) no Credit Party has any obligations under any collective bargaining agreement.  As used in this clause (t), “Employee Benefit Plan” means any material “employee benefit plan” within the meaning of Section 3(3) of ERISA, and all stock purchase, stock option, stock-based severance, employment, change-in-control, medical, disability, fringe benefit, bonus, incentive, deferred compensation, employee loan and all other employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA, under which (A) any current or former employee, director or independent contractor of any Credit Party or any of its Subsidiaries has any present or future right to benefits and which are contributed to, sponsored by or maintained by any Credit Party or any of its respective Subsidiaries or (B) no Credit Party nor any of its Subsidiaries has had or has any present or future obligation or liability on behalf of any such employee, director or independent contractor; “ERISA” means the Employee Retirement Income Security Act of 1974, as amended; “ERISA Affiliate” means any member of any Credit Party’s controlled group as defined in Code Section 414 (b), (c), (m) or (o); and “Foreign Benefit Plan” means any Employee Benefit Plan mandated by a Governmental Authority other than the United States of America is subject to the laws or a jurisdiction outside of the United States, including for greater certainty any “registered pension plan” as defined under Section 248(l) of the Income Tax Act (Canada) which is sponsored, maintained, funded, contributed to or required to be contributed to, or administered for the employees or former employees of any Credit Party or any Subsidiary thereof.
 
(u) Each Credit Party’s Subsidiaries are set forth in Schedule 3.1(u).
 
 
23

 
 
(v) All of the issued and outstanding shares of capital stock of each Credit Party are duly authorized and validly issued, fully paid and non-assessable, have been issued in compliance with all federal, provincial and state and foreign securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities that have not been waived in writing; the Parent Convertible Notes and the Tribute Convertible Notes and the Conversion Shares issuable upon the Parent Convertible Notes and Tribute Convertible Notes have been duly authorized and, and the Conversion Shares, when issued and delivered in accordance with the terms of the Convertible Notes will have been validly issued and will be fully paid. Parent and Tribute have each reserved from their duly authorized capital stock a sufficient number of Common Shares to issue the Conversion Shares underlying the Parent Convertible Notes and Tribute Convertible Notes, respectively, free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Loan Documents or imposed by applicable securities laws and except for those created by the Lenders.  Assuming the accuracy of the representations and warranties of the Lenders in this Agreement and, in the case of each Credit Party, the representations and warranties of the other Credit Parties set forth in Section 3.1 of this Agreement, the Securities will be issued in compliance with all applicable US and Canadian federal, provincial and state securities laws and will be exempt from the prospectus requirements of applicable Canadian securities laws.  Tribute has been a "reporting issuer" (as such term is defined in Canadian securities laws) in a jurisdiction of Canada for the four (4) months preceding the date of this Agreement and will be a reporting issuer not in default immediately preceding the issue of the Tribute Convertible Notes. Borrower shall, so long as any of the Convertible Notes are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Convertible Notes, the number of Common Shares issuable upon such conversion (without taking into account any limitations on the conversion of the Convertible Notes as set forth therein).  There are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of any common shares pursuant to the Organizational Documents of any Credit Party or any agreement to which any Credit Party or any of their Subsidiaries is a party or by which any Credit Party or any of their Subsidiaries is bound and all of the foregoing rights have been fully waived in respect of the issuance of the Parent Convertible Notes and Tribute Convertible Notes and the Conversion Shares thereunder. As of the date hereof, each of Borrower’s, Pozen’s and Parent’s respective outstanding shares of capital stock, options and warrants are accurately set forth in Schedule 3.1(v) to this Agreement, and, except as set forth in such Schedule, there are no other (i) options issuable or issued under Borrower’s, Pozen’s or Parent’s respective option plans, or (ii) any other options, warrants, agreements, contracts or other rights in existence to purchase or acquire from Parent or any Subsidiary of Parent any shares of the capital stock of Parent or any Subsidiary of Parent. Schedule 3.1(v) to this Agreement also sets forth the pro forma outstanding shares of capital stock, options and warrants of Parent as of Closing (assuming no further exercise of outstanding options and warrants of Borrower and/or Pozen).
 
(w) The issuance of the Notes and the Conversion Shares will not obligate any Credit Party to issue Common Shares or other securities to any Person (other than the Lenders) and will not result in a right of any holder securities of any Credit Party to adjust the exercise, conversion, exchange or reset price or other right under any of such securities.  There are no stockholders’ agreements, voting agreements or other similar agreements with respect to the capital stock of any Credit Party or, to the knowledge of any Credit Party, between or among any Credit Party or the stockholders of any Credit Party.
 
 
 
 
24

 
 
(x) Assuming the accuracy of the representations and warranties of the Lenders set forth in Section 3.3 of this Agreement and, in the case of each Credit Party, the representations and warranties of the other Credit Parties set forth in Section 3.1 of this Agreement, no registration under the Securities Act is required for the offer and sale of the Securities and the Acquisition Notes under the Loan Documents.  The issuance and sale of the Securities and the Acquisition Notes hereunder complies and will comply in all material respect with and does not and will not contravene the rules and regulations of the Principal Trading Markets.
 
(y) Neither Tribute nor Parent is registered, and immediately after issuance of any Notes, neither Tribute nor Parent will be required to be registered as an “investment company” within the meaning of the Investment Company Act of 1940, as amended, under such Act.  Borrower shall conduct its business in a manner so that it will not be required to be registered under the Investment Company Act of 1940, as amended.
 
(z) Other than the Lenders or pursuant to the Transactions, no Person has any right to cause Parent or Tribute to effect the registration under the Securities Act of any securities of Borrower other than those securities which are currently registered on an effective registration statement on file with the Commission.
 
(aa) From and after the Initial Funding Date, Parent’s Common Shares shall be registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and Borrower shall not have taken any action designed to terminate the registration of the Common Shares under the Exchange Act nor shall Borrower have received any notification that the Commission is contemplating terminating such registration.  From and after the Initial Funding Date, Borrower will be in compliance with all listing and maintenance requirements of the Principal Trading Markets.
 
(bb) None of Parent, Pozen or Tribute or, to Parent’s, Pozen’s or Tribute’s knowledge, any person acting on behalf of Parent, Pozen or Tribute, has offered or sold any of the Securities by any form of “general solicitation” or “general advertising”, as such terms are used in Rule 502(c) of Regulation D under the Securities Act.
 
(cc) Each Credit Party is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it. Each Credit Party other than Parent has, and as of the Initial Funding Date Parent shall have established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for it and designed such disclosure controls and procedures to ensure that information required to be disclosed by it in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Each Credit Party’s other than Parent’s certifying officers have, and as of the Initial Funding Date Parent’s certifying officers shall have evaluated the effectiveness of the its disclosure controls and procedures as of the end of the period covered by its most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). Each Credit
 
 
25

 
 
Party presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in Tribute’s or Pozen’s internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or are reasonably likely to materially affect, its internal controls over financial reporting.
 
(dd) The charts depicting the pre and post merger organization structure for Parent and its Subsidiaries (“Organization Charts”) and description of the proposed structure steps to effectuate the Transactions (“Transaction Steps”)  provided to Lenders on the Agreement Date are true, complete and accurate descriptions of the post merger organization structure of Parent and its Subsidiaries and the steps required to effectuate the Transactions.
 
(ee) Assuming compliance with (i) that certain Agreement and Plan of Merger and Arrangement, dated as of June 8, 2015, as amended on August 19, 2015 and the date hereof (the “Merger Agreement”), by and among the Credit Parties and certain other parties thereto, (ii) that certain Amended and Restated Plan of Arrangement attached as Schedule II to the Merger Agreement (the "Plan of Arrangement") and (iii) this Agreement, upon issuance of the Parent Convertible Notes, the Parent Convertible Notes will have been duly and validly issued pursuant to an exemption from the registration requirements of the Securities Act as provided by Section 3(a)(10) thereof and will be exempt from the prospectus requirements of applicable Canadian securities laws. The first trade in Parent Convertible Notes and Conversion Shares will be exempt from the prospectus requirements of applicable Canadian securities laws subject to compliance with applicable Canadian securities laws at the time of resale.
 
Section 3.2 Acknowledgment.  Each Credit Party acknowledges that it has made the representations and warranties referred to in Section 3.1 with the intention of persuading the Lenders to enter into the Loan Documents and that the Lenders have entered into the Loan Documents on the basis of, and in full reliance on, each of such representations and warranties, each of which shall survive the execution of this Agreement until the Obligations are paid in full and each representation or warranty related to the Conversion Shares shall be deemed to be continuously made at all times until the Obligations are paid in full.
 
Section 3.3 Representations and Warranties of the Lenders.  Each Lender, severally and not jointly, represents and warrants to Borrower and Parent as of the Agreement Date that:
 
(a) Such Lender is duly organized and validly existing under the laws of the jurisdiction of its formation.
 
(b) Each Loan Document to which it is a party has been duly authorized, executed and delivered by such Lender and constitutes the valid and legally binding obligation of such Lender, enforceable in accordance with its terms, except as such enforceability may be limited by (i) applicable insolvency, bankruptcy,
 
 
26

 
 
reorganization, moratorium or other similar laws affecting creditors’ rights generally, and (ii) applicable equitable principles (whether considered in a proceeding at law or in equity).
 
(c) Such Lender has full power and authority to make the Loans and to enter into and perform its other obligations under each of the Loan Documents and carry out the other transactions contemplated thereby.
 
(d) The Tribute Convertible Notes and the Conversion Shares to be issuable thereunder will be acquired for such Lender’s own account, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, except pursuant to sales registered or in a transaction exempted under the Securities Act, and such Lender has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to such Lender’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws.  Nothing contained herein shall be deemed a representation or warranty by such Lender to hold the Securities for any period of time and such Lender reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the Securities Act.
 
(e) Such Lender can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.
 
(f) Such Lender understands that the Tribute Convertible Notes and the Conversion Shares thereunder are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from Parent in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances.
 
(g) Such Lender is an “accredited investor” as such term is defined in Regulation D promulgated under the Securities Act and National Instrument 45-106 – Prospectus Exemptions promulgated by the Canadian Securities Administrators.
 
ARTICLE 4
 
CONDITIONS OF DISBURSEMENT OF LOANS
 
Section 4.1 Conditions to the Disbursement of Loans.  The obligation of the Lenders to make the Initial Loans shall be subject to the fulfillment of the following conditions:
 
(a) The Lenders shall have received sufficient copies of each Loan Document originally executed and delivered by each Credit Party and its Subsidiaries party thereto for each Lender;
 
 
27

 
 
(b) The Lenders shall have received (i) sufficient copies of each Organization Document executed and delivered by each Credit Party and its Subsidiaries, as applicable, and, to the extent applicable, certified as of a recent date by the appropriate governmental official, for each Lender, each dated the Initial Funding Date or a recent date prior thereto; (ii) signature and incumbency certificates of the officers of such Person executing the Loan Documents to which it is a party; (iii) resolutions of the board of directors or other governing body of each Credit Party and its Subsidiaries approving and authorizing the execution, delivery and performance of this Agreement and the other Loan Documents to which it is a party or by which it or its assets may be bound , certified as of the Initial Funding Date by an authorized officer as being in full force and effect without modification or amendment; (iv) a good standing certificate (or appropriate comparable confirmation in the relevant jurisdiction) from the applicable Governmental Authority of each Credit Party and each of its Subsidiary’s jurisdiction of incorporation, organization or formation and in each jurisdiction in which it is qualified as a foreign corporation or other entity to do business, and (v) such other documents as Lenders may reasonably request;
 
(c) Each Credit Party and each of its Subsidiaries shall have obtained all Authorizations and all consents of other Persons, in each case that are necessary or advisable in connection with the transactions contemplated by the Arrangement Agreement, Loan Documents and the Equity Agreement and each of the foregoing shall be in full force and effect and in form and substance reasonably satisfactory to Lenders.  All applicable waiting periods shall have expired without any action being taken or threatened by any competent authority which would restrain, prevent or otherwise impose adverse conditions on the transactions contemplated by the Arrangement Agreement, Loan Documents or the Equity Agreement or the financing thereof and no action, request for stay, petition for review or rehearing, reconsideration, or appeal with respect to any of the foregoing shall be pending, and the time for any applicable agency to take action to set aside its consent on its own motion shall have expired;
 
(d) Lenders shall have received evidence of the compliance by Parent and its Subsidiaries  of their obligations under the Security Documents (including, without limitation, their obligations to authorize or execute, as the case may be, and deliver UCC financing statements, PPSA financing statements or equivalent foreign filings, originals of securities, instruments and chattel paper and any agreements governing deposit and/or securities accounts as provided therein and a duly executed authorization to pre-file UCC-1 financing statements, PPSA financing statements (or foreign equivalents), together with other documents as may be necessary to perfect the security interests purported to be created by the Security Documents;
 
(e) Lenders shall have received opinions of counsel with respect to the creation and perfection of the security interests in favor of Lenders in such Collateral and such other matters governed by the laws of each jurisdiction in which Parent or any Subsidiary or any Collateral is located as Lenders may reasonably request, in each case in form and substance reasonably satisfactory to Lenders;
 
 
28

 
 
(f) Lenders shall have received a certificate from Parent and each Subsidiary’s insurance broker or other evidence satisfactory to it that all insurance required to be maintained pursuant to the Security Documents is in full force and effect, together with endorsements naming the Lenders as additional insureds and loss payees thereunder;
 
(g) Lenders  shall have received originally executed copies of the favorable written opinions of counsel for Parent and its Subsidiaries as to such matters as Lenders may reasonably request and otherwise in form and substance reasonably satisfactory to Lenders;
 
(h) No Default or Event of Default shall have occurred;
 
(i) All of the representations and warranties set forth in Section 3.1 shall be true and correct as if made on the Initial Funding Date;
 
(j) Tribute shall have the status of a reporting issuer not in default immediately preceding the issue of the Tribute Convertible Notes and until the time the Plan of Arrangement is effected;
 
(k) The Disbursement Condition shall have been satisfied;
 
(l) The Common Shares shall have been listed on the Trading Market;
 
(m) All conditions precedent to the Transactions set forth in the Equity Agreement and Arrangement Agreement shall have been satisfied and the Transactions contemplated thereby shall have been completed other than the filing of the Articles of Arrangement and the Certificate of Merger;
 
(n) No Material Adverse Effect shall have occurred;
 
(o) Each of the Employment Agreements shall have been executed and shall be in full force and effect;
 
(p) The Indebtedness of Tribute to SWK Funding LLC and any Indebtedness incurred by Tribute shall be repaid in full out of the proceeds of the Initial Loans and Acquisition Loans on or prior to the Initial Funding Date (or shall have been otherwise repaid) and all Liens securing such Indebtedness released;
 
(q) The final organizational structure of the Credit Parties shall be as set forth in the Organization Charts, with such modifications thereto as are consented to by the Required Lenders (such consent not to be unreasonably withheld or delayed) and the Transactions shall have been completed in accordance with the Transaction Steps, with such modifications thereto as are consented to by the Required Lenders (such consent not to be unreasonably withheld or delayed); and
 
(r) No material modifications to the terms of the Arrangement Agreement and Plan of Arrangement attached as Schedule II thereunder, as provided in the Arrangement Agreement as in effect as of the date hereof, shall have occurred. 
 
 
29

 

Section 4.2 Condition to the Disbursement of Acquisition Loans.  The obligation of the Lenders to make an Acquisition Loan shall be subject to the fulfillment of the following conditions:
 
(a) Lenders shall have received an Acquisition Loan Request and a certification by an authorized officer of Parent that the proposed acquisition is a Permitted Acquisition;
 
(b) Lenders shall have received Acquisition Notes executed by Parent in the aggregate principal amount of the Acquisition Loan;
 
(c) All conditions precedent to the closing of the Permitted Acquisition shall have been satisfied except for the funding of the purchase price with the proceeds of such Acquisition Loan;
 
(d) No Default or Event of Default shall have occurred or would be created by such Permitted Acquisition; and
 
(e) All of the representations and warranties in Section 3.1 shall be true and correct as if made on the date of funding of each such Acquisition Loan.
 
ARTICLE 5
 
PARTICULAR COVENANTS AND EVENTS OF DEFAULT
 
Section 5.1 Affirmative Covenants.  Unless the Required Lenders shall otherwise agree:
 
(a) Parent shall and shall cause its Subsidiaries to maintain their existence and qualify and remain qualified to do their business as currently conducted, except for any merger or dissolution of a Subsidiary in accordance with Section 5.2(a) or where the failure to maintain such qualification would not reasonably be expected to have a Material Adverse Effect.
 
(b) Parent shall and shall cause its Subsidiaries to comply in all material respects with all Applicable Laws.
 
(c) Parent shall obtain and shall cause its Subsidiaries to make and keep in full force and effect all Authorizations.
 
(d) Parent shall promptly notify the Lenders of the occurrence of (i) any Default or Event of Default and (ii) any claims, litigation, arbitration, mediation or administrative or regulatory proceedings that are instituted or threatened against Parent or any of its Subsidiaries concurrently with any public disclosure of any such event, and (iii) each event which, at the giving of notice, lapse of time, determination of materiality or fulfillment of any other applicable condition (or any combination of the foregoing), would constitute an event of default (however described) under any Loan Document.
 
 
30

 
 
(e) Each Credit Party will timely file with the SEC (subject to appropriate extensions made under Rule 12b-25 of the Exchange Act) any annual reports, quarterly reports and other periodic reports required to be filed pursuant to Section 13 or 15(d) of the Exchange Act (“SEC Reports”).
 
(f) Parent shall, so long as any of the Convertible Notes are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Convertible Notes, the number of Common Shares issuable upon such conversion (without taking into account any limitations on the conversion of the Notes as set forth therein).
 
(g) For so long as a Lender owns Notes or Common Shares, upon the request of such Lender, Borrower shall furnish any information reasonably requested by such Lender (and not generally available by reference to Parent’s publicly available SEC filings) to confirm whether or not Borrower is a passive foreign investment company (“PFIC”) under the Code; provided, however, that Parent shall not be obligated to furnish any information that it has not already publicly disclosed.  In addition, for each taxable year of Borrower during any portion of which the Notes are outstanding or any Lender holds Common Shares, Borrower shall make due inquiry of its tax advisors on an annual basis regarding its status as a PFIC and, if Borrower’s tax advisors determine that Borrower became a PFIC for any such taxable year, shall notify each Lender in writing, of the determination that Borrower has become a PFIC for such taxable year by no later than 75 days following the close of such taxable year.  With respect to (a) any taxable year in respect of which Borrower was determined to be a PFIC and (b) each subsequent taxable year during any part of which the Notes are outstanding or any Lender holds Common Shares, the Borrower shall promptly provide each Lender with all information that is required by a United States person holding Common Shares in order to make a valid election to treat the Borrower as a “qualified electing fund” for the purposes of the Code, including a “PFIC Annual Information Statement” as described in Treasury Regulation section 1.1295-(1)(g)(1) (or any successor Treasury Regulation) and all representations and statements required by such Statement, and will take any other steps necessary to facilitate such election.  The Borrower understands and agrees that time is of the essence in complying with the foregoing deadlines, and that any failure by the Borrower to so comply will be materially adverse to each Lender.  Each Lender shall promptly respond to any written inquiry from the Borrower requesting the Lender to inform the Borrower whether it owns any Common Shares.
 
(h) In the event that any Person becomes a Subsidiary of Parent, Parent shall (a) concurrently with such Person becoming a Subsidiary cause such Subsidiary to become a Guarantor hereunder and a Grantor under the Security Agreement, and (b) take all such actions and execute and deliver, or cause to be executed and delivered, all such documents, instruments, agreements, and certificates as are necessary to grant and to perfect a first priority Lien in favor of Lenders in any assets owned by such Person and in all equity interests of Parent in such Subsidiary.
 
 
31

 
 
(i) The Parent shall provide, free from preemptive rights, out of the Parent’s authorized but unissued shares or shares held in treasury, sufficient Common Shares to provide for conversion of the Convertible Notes held by the Lenders from time to time as such Convertible Notes are presented for conversion (assuming that at the time of computation of such number of Common Shares, all such Convertible Notes would be converted by Lenders into Conversion Shares without regard to any limitation on conversion).
 
(j) The Parent covenants that it will cause all Common Shares issued upon conversion of the Convertible Notes held by the Lenders to be fully paid and free from all taxes, liens and charges with respect to the issue thereof.
 
(k) The Parent will cause any Common Shares issuable under the Convertible Notes (whether upon conversion or otherwise) to be listed on whatever stock exchange(s) the Common Shares are listed, on the date a Lender becomes a record holder of such Common Shares.
 
(l) Upon consummation of the Transactions, the Convertible Notes issuable hereunder by Tribute in substantially the form of Exhibit A-1 (the “Tribute Convertible Notes”) shall, pursuant to the Plan of Arrangement attached as Schedule II to the Arrangement Agreement, automatically and without any action by any parties, be cancelled and deemed exchanged for the Convertible Notes issuable by Parent pursuant to the Plan of Arrangement attached as Schedule II to the Arrangement Agreement, in substantially the form of Exhibit A-2 (the “Parent Convertible Notes”). On the Initial Funding Date, the Parent shall deliver the Parent Convertible Notes to the Lenders. Upon consummation of the Transactions, the obligations of Tribute attached as Schedule II to this Agreement shall be automatically assumed by Parent without any further action, and the provisions of this Agreement shall be interpreted consistent with such assumption.
 
(m) Notwithstanding anything set forth in the definition of Permitted Acquisition or elsewhere in this Agreement to the contrary, if any notice or information required to be furnished contains material non-public information (any such notice or information, a “Public Notice”), the Borrower, instead of delivering such Public Notice to all the Lenders shall promptly deliver such Public Notice to each Lender that is not a Restricted Lender and promptly notify each Restricted Lender in writing or orally that Borrower desires to deliver to such Restricted Lender a Public Notice.  Within five Business Days of receipt of such notification the Restricted Lender may either (i) refuse the delivery of such Public Notice, in which case Borrower’s obligations with respect to such Public Notice and such Restricted Lender shall be deemed satisfied, or (ii) enter into good faith negotiations with the Parent to agree to the time period within which the Borrower will make the material non-public information contained in such Public Notice publicly available by including such information in a filing with the SEC.  If Borrower and such Restricted Lender agree on such time period, the Borrower shall promptly deliver to such Restricted Lender such Public Notice and shall cause Parent to include the applicable material non-public information in a public filing with the SEC within such agreed to time period.  The failure to agree on such time period will be deemed to satisfy Borrower’s obligations with respect to such Public Notice and such Restricted Lender.
 
(n) Tribute shall prepare and file a business acquisition report with respect to the acquisition by Tribute of certain pharmaceutical products from Novartis AG announced in the press release of Tribute dated October 2, 2014.
 
(o) The Credit Parties covenant and agree that the Nijhawan Note (i) shall be repaid in full at or prior to maturity, or (ii) shall be converted into equity in accordance with its terms at or prior to maturity, without extension.
 
 
32

 
 
Section 5.2 Negative Covenants. Unless the Required Lenders shall otherwise agree:
 
(a) Parent shall not and shall not permit any Subsidiary to (i) liquidate, or be wound up provided that a Subsidiary may merge into Parent or any other Subsidiary, or (ii) enter into any merger, consolidation or reorganization, unless (x) Parent or a Subsidiary is the surviving corporation or, (y) subject to Section 5.3 and the terms of the Notes, if the survivor is a Person other than Parent or a Subsidiary, such Person assumes the Obligations of Borrower under this Agreement and the other Loan Documents.  Parent shall not establish any Subsidiary unless such Subsidiary executes and delivers to the Lenders, a Guaranty and the Security Documents in form acceptable to the Lenders and takes all steps necessary to create and perfect a first priority Lien in favor of Lenders on all of its assets and Parent takes all steps necessary to create and perfect a first priority Lien in favor of Lenders in all equity interests in such Subsidiary;
 
(b) Parent shall not and shall not permit any Subsidiary to (i) enter into any partnership, joint venture, syndicate, pool, profit-sharing or royalty agreement or other combination, or engage in any transaction with an Affiliate (other than a Subsidiary), whereby its income or profits are or might be, shared with another Person (other than a Subsidiary), (ii) enter into any management contract or similar agreement whereby a substantial part of its business is managed by another Person; or (iii) make any cash dividend or distribute, or permit the dividend or distribution of, any of its assets, including its intangibles, to any of its shareholders in such capacity or its Affiliates (other than a Subsidiary) (except for distributions in which Lenders participate  pursuant to the provisions of the Notes); provided, however, that Parent or any Subsidiary may enter into Excluded Transactions;
 
(c) Parent shall not and shall not permit any Subsidiary to (i) create, incur or suffer any Lien upon any of its assets, except Permitted Liens, or (ii) assign, sell, transfer or otherwise dispose of, any Loan Document or its rights and obligations thereunder;
 
(d) Parent shall not and shall not permit any Subsidiary to create, incur, assume, guarantee or be liable with respect to any Indebtedness, except for Permitted Indebtedness;
 
(e) Parent shall not and shall not permit any Subsidiary to acquire any assets (i) (other than Permitted Acquisitions (after disregarding, solely for purposes of this Section 5.2(e), the requirements set forth in clause (vii) of the definition of Permitted Acquisition) and (ii) other than assets acquired in the ordinary course of business, directly or indirectly, in one or more related transactions, for a consideration, in cash or other property (valued at its fair market value) not greater than $1,000,000;
 
 
33

 
 
(f) Parent shall not and shall not permit any Subsidiary to sell or otherwise transfer the products being developed or sold by Parent or any Subsidiary or any material assets associated therewith, other than in Excluded Transactions; and
 
(g) Parent shall not issue any equity securities (i) senior to its common shares or (ii) convertible or exercisable for equity securities senior to its common shares.
 
Section 5.3 Major Transaction.  The Borrower shall give the Lenders notice of a Major Transaction at least thirty (30) days prior to the consummation thereof but in any event not later than five (5) business days following the first public announcement thereof.  Each Lender, within the Major Transaction Conversion Period (as defined in the Convertible Notes), in the exercise of its sole discretion, may deliver a notice to the Parent (the “Put Notice”), that either or both of the Parent Convertible Notes and Acquisition Notes shall be due and payable in cash (collectively, the “Major Transaction Payment”).  If any of the Lenders deliver a Put Notice, then simultaneously with consummation of such Major Transaction, the Parent shall make such Major Transaction Payment to each such Lender.  The Parent shall not consummate any Major Transaction without complying with the provisions of this Section 5.3.
 
Section 5.4 General Acceleration Provision upon Events of Default.  If one or more of the events specified in this Section 5.4 shall have happened and be continuing beyond the applicable cure period (each, an “Event of Default”), the Required Lenders, by written notice to the Borrower (an “Acceleration Notice”), may declare the principal of, and accrued and unpaid interest on, all of the Notes or any part of any of them (together with any other amounts accrued or payable under the Loan Documents) to be, and the same shall thereupon become, immediately due and payable, without any further notice and without any presentment, demand, or protest of any kind, all of which are hereby expressly waived by the Borrower, and take any further action available at law or in equity, including, without limitation, the sale of the Loan and all other rights acquired in connection with the Loan:
 
(a) The Borrower shall have failed to make payment of (i) principal when due, or (ii) interest or any other amounts due under the Notes or any other Obligations within five (5) Business Days of their due date.
 
(b) (i) Any Credit Party shall have failed to comply with the due observance or performance of any covenant contained in this Agreement (other than the covenant described in (a) above or as otherwise expressly provided in this Section 5.4) or in the other Loan Documents and such default is not remedied by the Borrower or waived by the Lenders within fifteen (15) days (inclusive of any extension periods or cure periods contained in any such covenant or provided by Applicable Laws) after the earlier of (A) receipt by any Credit Party of notice from the Lenders of such default, or (B) actual knowledge of any Credit Party of such default.
 
(c) Any representation or warranty made by any Credit Party or any of its Subsidiaries in any Loan Document shall be incorrect, false or misleading in any material respect (except to the extent that such representation or warranty is qualified by
 
 
34

 
 
reference to materiality or Material Adverse Effect, to which extent it shall be incorrect, false or misleading in any respect) as of the date it was made or deemed made.
 
(d) (i)  Any Credit Party or any of its Subsidiaries shall generally be unable to pay its debts as such debts become due or be deemed to be unable to pay its debts, or shall admit in writing its inability to pay its debts as they come due or shall make a general assignment for the benefit of creditors; (ii) any Credit Party or any of its Subsidiaries shall declare a moratorium on the payment of its debts; (iii) the commencement by any Credit Party or any of its Subsidiaries of proceedings to be adjudicated bankrupt or insolvent, or the consent by it to the commencement of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization, examinership, intervention or other similar relief under any applicable law, or the consent by it to the filing of any such petition or to the appointment of an intervenor, receiver, receiver-manager, liquidator, assignee, trustee, sequestrator, examiner (or other similar official) of all or substantially all of its assets; (iv) the commencement against any Credit Party or any of its Subsidiaries of a proceeding in any court of competent jurisdiction under any bankruptcy or other applicable law (as now or hereafter in effect) seeking its liquidation, winding up, dissolution, reorganization, examinership, arrangement, adjustment, or the appointment of an intervenor, receiver, receiver-manager, liquidator, assignee, trustee, sequestrator, examiner (or other similar official), and any such proceeding shall continue undismissed, or any order, judgment or decree approving or ordering any of the foregoing shall continue unstayed or otherwise in effect, for a period of forty five (45) days; (v) the making by any Credit Party or any of its Subsidiaries of an assignment for the benefit of creditors, or the admission by it in writing of its inability to pay its debt generally as they become due; or (vi) any other event shall have occurred which under any applicable law would have an effect analogous to any of those events listed above in this subsection.
 
(e) One or more judgments against any Credit Party or any Subsidiary or attachments against any of their respective property, which in the aggregate exceed $1,000,000 (net of any anticipated insurance proceeds), and such judgment(s) remains unpaid, unstayed on appeal, undischarged, unbonded or undismissed for a period of thirty (30) days from the date of entry of such judgment.
 
(f) Any Authorization held by any Credit Party or any of its Subsidiaries shall have been suspended, cancelled or revoked, and such suspension, cancellation or revocation would reasonably be expected to have a Material Adverse Effect.
 
(g) Any Authorization necessary for the execution, delivery or performance of any Loan Document or for the validity or enforceability of any of the Obligations is not given or is withdrawn or ceases to remain in full force or effect.
 
(h) There is a failure to perform under any agreement to which any Credit Party is a party resulting in the acceleration by a third party of the maturity of any Indebtedness in an amount in excess of $5,000,000.
 
 
35

 
 
(i) The validity of any Loan Document shall be contested by any Credit Party or any Subsidiary, or any Applicable Law shall purport to render any material provision of any Loan Document invalid or unenforceable or shall purport to prevent or materially delay the performance or observance by any Credit Party of the Obligations.
 
(j) The Common Shares of Parent cease to be listed on the Principal Trading Markets or the Common Shares cease to be registered under Section 12 of the Exchange Act.
 
(k) The occurrence of a Conversion Failure.
 
Section 5.5 Automatic Acceleration on Dissolution or Bankruptcy.  Notwithstanding any other provisions of this Agreement, if an Event of Default under Section 5.4(d) shall occur, the principal of the Notes (together with any other amounts accrued or payable under this Agreement) shall thereupon become immediately due and payable without any presentment, demand, protest or notice of any kind, all of which are hereby expressly waived by the Borrower.
 
Section 5.6 Recovery of Amounts Due.  If any amount payable hereunder is not paid as and when due, the Borrower hereby authorizes the Lenders to proceed, to the fullest extent permitted by applicable law, without prior notice, by right of set-off, banker’s lien or counterclaim, against any moneys or other assets of any Credit Party to the full extent of all amounts payable to the Lenders.
 
ARTICLE 6
 
MISCELLANEOUS
 
Section 6.1 Lender Agreement.  Each of the Lenders agrees that, for a period from the date hereof and ending on the earlier of (i) Closing (as defined in the Arrangement Agreement), (ii) termination of the Arrangement Agreement, and (iii) April 30, 2016, it shall not short the securities of Pozen or Tribute.   In addition, each Lender further agrees that during the ten (10) days immediately preceding the Closing (as defined in the Arrangement Agreement) it shall not trade in the securities of either Pozen or Tribute.
 
 
36

 
 
Section 6.2 Notices.  Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile or by electronic mail and shall be effective five (5) days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, or when received by electronic mail in each case addressed to a party.  The addresses for such communications shall be:
 
If to Credit Parties:
 
Aralez Pharmaceuticals Inc.
Suite 6000 - 100 King St. West
Toronto, Ontario M5X 1E2
Attention:  President

With a copy (which shall not constitute notice) to:
 
DLA Piper LLP (US)
51 John F. Kennedy Parkway
Short Hills, New Jersey  07078-2704
Fax:  (973) 520-2573
Email:  Andrew.gilbert@dlapiper.com
Attn:  Andrew Gilbert
 
With a copy (which shall not constitute notice) to:
 
Tribute Pharmaceuticals Canada Inc.
151 Steeles Ave. East
Milton, Ontario, Canada  L9T1Y1
Fax:  (519) 434-4382
Email:  rob.harris@tributepharma.com
Attn:  Robert Harris, President and Chief Executive Officer
 
 
37

 
 
If to the Lenders:
 
Deerfield Management Company, L.P.
780 Third Avenue, 37th Floor
New York, NY 10017
Fax: (212) 599-3075
Email: dclark@deerfield.com
Attn: David J. Clark

With a copy (which shall not constitute notice) to:
 
Katten Muchin Rosenman LLP
575 Madison Avenue
New York, New York 10022
Fax:  (212) 940-8776
Email:  mark.fisher@kattenlaw.com
Attn:  Mark I. Fisher, Esq.
 
Section 6.3 Waiver of Notice.  Whenever any notice is required to be given to the Lenders or the Borrower under any of the Loan Documents, a waiver thereof in writing signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice.
 
Section 6.4 Reimbursement of Legal and Other Expenses.  If any amount owing to the Lenders under any Loan Document shall be collected through enforcement of this Agreement, any Loan Document or restructuring of the Loan in the nature of a work-out, settlement, negotiation, or any process of law, or shall be placed in the hands of third Persons for collection, the Borrower shall pay (in addition to all monies then due in respect of the Loan or otherwise payable under any Loan Document) all reasonable and documented external attorneys’ and other fees and out-of-pocket expenses incurred in respect of such collection.
 
Section 6.5 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware applicable to contracts made and to be performed in such State.  Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of Delaware.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.  Each party hereby irrevocably waives personal service of process and consents to process being
 
 
38

 
 
served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.  The parties hereby waive all rights to a trial by jury.
 
Section 6.6 Successors and Assigns.  This Agreement shall bind and inure to the respective successors and assigns of the Parties, except that (a) a Credit Party may not assign or otherwise transfer all or any part of its rights under the Loan Documents without the prior written consent of the Required Lenders, and (b) a Lender may assign its Notes upon three (3) days prior notice to Borrower.  Upon a Lender’s assignment of a Note such Lender shall provide notice of the transfer to Borrower for recordation in the Register pursuant to Section 1.4.  Upon receipt of a notice of a transfer of an interest in a Note, Borrower shall record the identity of the transferee and other relevant information in the Register and the transferee shall (to the extent of the interests transferred to such transferee) have all the rights and obligations of, and shall be deemed, a Lender hereunder.  Upon consummation of the Transactions, Tribute shall be deemed to have assigned its rights and obligations under this Agreement and the other Loan Documents to Parent and Parent shall be deemed to have assumed all of the rights and obligations of Tribute under this Agreement and the other Loan Documents.
 
Section 6.7 Entire Agreement.  The Loan Documents and the Equity Agreement contain the entire understanding of the Parties with respect to the matters covered thereby and supersede any and all other written and oral communications, negotiations, commitments and writings with respect thereto.  The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by the authorized officer of each Party.
 
Section 6.8 Severability.  If any provision of this Agreement shall be invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
 
Section 6.9 Counterparts.  This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies and facsimile copies thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.
 
Section 6.10 Survival.
 
(a) This Agreement and all agreements, representations and warranties made in the Loan Documents, and in any document, certificate or statement delivered pursuant thereto or in connection therewith shall be considered to have been relied upon by the other Parties and shall survive the execution and delivery of this Agreement and the
 
 
39

 
 
making of the Loan hereunder regardless of any investigation made by any such other Party or on its behalf, and shall continue in force until all amounts payable under the Loan Documents shall have been fully paid in accordance with the provisions thereof, and the Lenders shall not be deemed to have waived, by reason of making the Loans, any Event of Default that may arise by reason of such representation or warranty proving to have been false or misleading, notwithstanding that the Lenders may have had notice or knowledge of any such Event of Default or may have had notice or knowledge that such representation or warranty was false or misleading at the time the Loans were made.
 
(b) The obligations of the Borrower under Sections 1.4 and 2.6 and the obligations of the Borrower and the Lenders under this Article 6 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, or the termination of this Agreement or any provision hereof.
 
(c) Notwithstanding anything in this Agreement to the contrary, in the event that the Arrangement Agreement is terminated prior to completion of the transactions contemplated thereby, Tribute shall be released from all of its obligations under this Agreement and this Agreement shall terminate as to Tribute.
 
Section 6.11 No Waiver.  Neither the failure of, nor any delay on the part of, any Party in exercising any right, power or privilege hereunder, or under any agreement, document or instrument mentioned herein, shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege hereunder, or under any agreement, document or instrument mentioned herein, preclude other or further exercise thereof or the exercise of any other right, power or privilege; nor shall any waiver of any right, power, privilege or default hereunder, or under any agreement, document or instrument mentioned herein, constitute a waiver of any other right, power, privilege or default or constitute a waiver of any default of the same or of any other term or provision.  No course of dealing and no delay in exercising, or omission to exercise, any right, power or remedy accruing to the Lenders upon any default under this Agreement, or any other agreement shall impair any such right, power or remedy or be construed to be a waiver thereof or an acquiescence therein; nor shall the action of the Lenders in respect of any such default, or any acquiescence by it therein, affect or impair any right, power or remedy of the Lenders in respect of any other default.  All rights and remedies herein provided are cumulative and not exclusive of any rights or remedies otherwise provided by law.
 
Section 6.12 Indemnity.
 
(a) Each Credit Party (excluding Tribute prior to the closing of the transactions contemplated by the Arrangement Agreement) shall, at all times, indemnify and hold each Lender harmless (the “Indemnity”) and each of their respective directors, partners, officers, employees, agents, counsel and advisors (each, an “Indemnified Person”) in connection with any losses, claims (including the reasonable attorneys’ fees incurred in defending against such claims), damages, liabilities, penalties, or other expenses arising out of, or relating to, the Loan Documents, the extension of credit hereunder or the Loans or the use or intended use of the Loans, which an Indemnified Person may incur or to which an Indemnified Person may become subject (each, a “Loss”).  The Indemnity shall not apply to the extent that a court or arbitral tribunal of competent jurisdiction issues a final judgment that such Loss resulted from the gross negligence or willful misconduct of the Indemnified Person.  The Indemnity is
 
 
40

 
 
independent of and in addition to any other agreement of any Credit Party under any Loan Document to pay any amount to the Lenders, and any exclusion of any obligation to pay any amount under this subsection shall not affect the requirement to pay such amount under any other section hereof or under any other agreement. This Section 6.12 shall not apply with respect to Taxes (which are governed by Section 2.6) other than any Taxes that represent losses, claims or damages arising from any non-Tax claim.
 
(b) Promptly after receipt by an Indemnified Person under this Section 6.12 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Loss in respect thereof is to be made against the indemnifying person under this Section 6.12, deliver to Borrower a written notice of the commencement thereof, and Borrower shall have the right to participate in, and, to the extent Borrower so desires, to assume control of the defense thereof with counsel mutually satisfactory to Borrower and the Indemnified Person, as the case may be.
 
(c) An Indemnified Person shall have the right to retain its own counsel with the documented reasonable fees and out-of-pocket expenses to be paid by the indemnifying person, if, in the reasonable opinion of counsel for the Indemnified Person, the representation by such counsel of the Indemnified Person and Borrower would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding.  Credit Parties shall pay for only one separate legal counsel for the Indemnified Persons. The failure of an Indemnified Person to deliver written notice to the Borrower within a reasonable time of the commencement of any such action shall not relieve Credit Parties of any liability to the Indemnified Person under this Section 6.12, except to the extent that Credit Parties are actually prejudiced in its ability to defend such action.  The indemnification required by this Section 6.12 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.
 
Section 6.13 No Usury.  The Loan Documents are hereby expressly limited so that in no contingency or event whatsoever, whether by reason of acceleration or otherwise, shall the amount paid or agreed to be paid to the Lenders for the Loan exceed the maximum amount permissible under applicable law.  If from any circumstance whatsoever fulfillment of any provision hereof, at the time performance of such provision shall be due, shall involve transcending the limit of validity prescribed by law, then, ipso facto, the obligation to be fulfilled shall be reduced to the limit of such validity, and if from any such circumstance the Lenders shall ever receive anything which might be deemed interest under applicable law, that would exceed the highest lawful rate, such amount that would be deemed excessive interest shall be applied to the reduction of the principal amount owing on account of the Loans, or if such deemed excessive interest exceeds the unpaid balance of principal of the Loans, such deemed excess shall be refunded to the Borrower.  All sums paid or agreed to be paid to the Lenders for the Loan shall, to the extent permitted by applicable law, be deemed to be amortized, prorated, allocated and spread throughout the full term of the Loans until payment in full so that the deemed rate of interest on account of the Loans is uniform throughout the term thereof.  Except as set forth in Section 2.10, the terms and provisions of this Section shall control and supersede every other provision of this Agreement and the Notes.
 
 
41

 
 
Section 6.14 Several Obligations.  The obligations of the Lenders under the Loan Documents shall be several and not joint.
 
Section 6.15 Further Assurances.  Each Credit Party covenants and agrees to take all necessary action to consummate the transactions contemplated by this Agreement and to fulfill all requirements to the Initial Loans set forth in Section 4.1, including the execution and delivery of the Convertible Notes, contemporaneous with the closing of the Transactions.  From time to time, the Borrower shall perform any and all acts and execute and deliver to the Lenders such additional documents as may be necessary or as requested by the Lenders to carry out the purposes of any Loan Document or any or to preserve and protect the Lenders’ rights as contemplated therein.
 
Section 6.16 Judgment Currency.  To the extent permitted by applicable law, the obligations of any Credit Party in respect of any amount due under this Agreement shall, notwithstanding any payment in any other currency (the “Other Currency”) (whether pursuant to a judgment or otherwise), be discharged only to the extent of the amount in the currency in which it is due (the “Agreed Currency”) that Lenders may purchase with the sum paid in the Other Currency (after any premium and costs of exchange) on the Business Day immediately after the day on which Lender receives the payment.  If the amount in the Agreed Currency that may be so purchased for any reason falls short of the amount originally due, the Credit Parties shall pay all additional amounts, in the Agreed Currency, as may be necessary to compensate for the shortfall.  Any obligation of a Credit Party not discharged by that payment shall, to the extent permitted by applicable law, be due as a separate and independent obligation and, until discharged as provided in this Section 6.16, continue in full force and effect.
 
Section 6.17Amendment and Restatement; Costs of Amendment and Restatement.  This Agreement is an amendment and restatement of and is in substitution and replacement for the Original Facility Agreement.  The costs and expenses of the Amended and Restated Facility Agreement, dated as of October 29, 2015 and this Agreement, including all costs incurred by the Lenders in connection therewith and herewith, shall be joint and several obligations of the Credit Parties (excluding Tribute prior to the closing of the transactions contemplated by the Arrangement Agreement) and shall be in addition to the obligation of the Credit Parties pursuant to Section 2.7.  The provisions of this Section 6.17 are without prejudice to the obligations of the Credit Parties under Section 2.6.

 
[SIGNATURE PAGE FOLLOWS]
 
 
42

 


 IN WITNESS WHEREOF, the Lenders and the Credit Parties have caused this Agreement to be duly executed as of the date first written above.
 
CREDIT PARTIES:
 
ARALEZ PHARMACEUTICALS INC.
 
By: /s/ Andrew Koven
Name: Andrew Koven
Title: President
 
POZEN INC.
 
By: /s/ Adrian Adams
Name: Adrian Adams
Title: Chief Executive Officer
 
TRIBUTE PHARMACEUTICALS CANADA INC.
 
By: /s/ Scott Langille
Name: Scott Langille
Title: Chief Financial Officer
 
 
LENDERS:
 
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
 
By: /s/ David J. Clark
Name: David J. Clark
Title: Authorized Signatory
 
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
 
By:  /s/ David J. Clark
Name: David J. Clark
Title: Authorized Signatory
 
[Second Amended and Restated Facility Agreement]
 
 
43

 
 
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
 
By:  /s/ David J. Clark
Name: David J. Clark
Title: Authorized Signatory
 
[Second Amended and Restated Facility Agreement]
 
 
44

 
 
SCHEDULE 1
 
LENDER
ALLOCATION OF LOANS, PREPAYMENTS*
Deerfield Private Design Fund III, L.P.
50%
Deerfield International Master Fund, L.P.
28%
Deerfield Partners, L.P.
22%
 
*  Lenders may, from time to time reallocate the percentages among themselves without the consent of Credit Parties.
 
[Second Amended and Restated Facility Agreement]
 
 
45

 

Exhibit A-1

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4(1) AND A HALF” SALE.

THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF DECEMBER 7, 2015, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.

UNLESS PERMITTED UNDER APPLICABLE CANADIAN SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [__, 2016] [INSERT THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE CONVERTIBLE NOTE ISSUANCE DATE].  WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL [INSERT DATE].”

SENIOR SECURED CONVERTIBLE NOTE

Issuance Date: ________, 2016
Principal: U.S. $___________

FOR VALUE RECEIVED,  TRIBUTE PHARMACEUTICALS CANADA INC., a corporation formed under the laws of the Province of Ontario, Canada (the “Company”), hereby promises to pay to [ ], or its registered assigns (the “Holder”) the principal amount of _______________________($________) (the “Principal”) pursuant to, and in accordance with, the terms of that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, by and among the Company, the Lenders party thereto and the other parties thereto (together with all exhibits and schedules thereto and as may be amended, restated, modified and supplemented from time to time, the “Facility Agreement”). The Company hereby promises to pay accrued and unpaid Interest (as defined below) and premium, if any, on the Principal on the dates, at the rates and in the manner provided for in the Facility Agreement. This
 
 
46

 
 
Senior Secured Convertible Note (including all Senior Secured Convertible Notes issued in exchange, transfer or replacement hereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, this “Note”) is one of the Senior Secured Convertible Notes issued pursuant to the Facility Agreement (collectively, including all Senior Secured Convertible Notes issued in exchange, transfer or replacement thereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, the “Notes”). All capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Facility Agreement.
 
This Note is subject to mandatory prepayment on the terms specified in the Facility Agreement. Except as expressly provided in the Facility Agreement, the Company has no right, but under certain circumstances may have an obligation, to make payments of Principal prior to the sixth anniversary of the Issuance Date. At any time an Event of Default exists, the Principal of this Note, together with all accrued and unpaid Interest and any applicable premium due, if any, may be declared, or shall otherwise become, due and payable in the manner, at the price and with the effect provided in the Facility Agreement.

1.            Definitions.

(a)            Certain Defined Terms. For purposes of this Note, the following terms shall have the following meanings:

(i)            “Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder will be deemed to be an Affiliate of such Holder. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii)            “Capital Stock” means, for any entity, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity, but for the avoidance of doubt, excluding any debt securities convertible into such stock.

(iii)            “Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote, in the election of directors of such person or (b) if such Person is not a corporation, to vote or otherwise participate in the election of the governing body, partners, managers or others that will control the management or policies of such person.
 
(iv)            “Common Shares” means the common shares of the Company.

 
47

 
 
(v)            “Conversion Amount” means the Principal to be converted, redeemed or otherwise with respect to which this determination is being made.

(vi)            “Conversion Price” means, as of any Conversion Date or other date of determination, $[____]1 per Share, subject to adjustment as provided herein and subject to appropriate adjustment to reflect any subdivision of outstanding Common Shares (by any stock split, share or stock dividend, recapitalization or otherwise) or combination of outstanding Common Shares (by consolidation, combination, reverse stock split or otherwise), repayment or reduction of capital or other event giving rise to an adjustment of the nominal amount of such Common Shares hereafter.

(vii)            “Dollars” or “$” means United States Dollars.

(viii)            “Eligible Market” means the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock Exchange, the NYSE Alternext, the Toronto Stock Exchange, or the Nasdaq Capital Market.

(ix)            “Exchange Act” means the Securities Exchange Act of 1934, as amended.

(x)            “Interest” means any interest (including any default interest) accrued on the Principal pursuant to the terms of this Note and the Facility Agreement.

(xi)            “Issuance Date” means _____, 2016, regardless of any exchange or replacement hereof.

(xii)            “Major Transaction” means any of the following events:

(A)            a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Shares immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold at least 50% of the Common Shares or (b) no longer have the ability to elect at least 50% of the members of the board of directors of the Company or (2) as a result of which Common Shares shall be converted into or re-designated as (or the Common Shares become entitled to receive) the same or a different number of shares of the same or another class or classes of stock or securities of the Company or another entity (other than to the extent the Common Shares are changed or exchanged solely to reflect a change in the Company’s jurisdiction of incorporation); or

(B)            the sale or transfer (other than to a wholly owned subsidiary of the Company) of (i) all or substantially all of the assets of the Company or (ii) assets of the Company for a purchase price equal to more than 50% of the Enterprise Value (as defined below) of the Company. For purposes of this clause (B), “Enterprise Value” shall mean (I) the product of (x) the number of issued and outstanding Common Shares on the date the Company delivers the Major Transaction Notice (as defined below in Section 3(b)) multiplied by
 

1 Conversion Price shall equal a 32.5% premium over the product of the Pozen Purchase Price multiplied by .1455.  The “Pozen Purchase Price” shall be equal to the lesser of (i) $7.20, and (ii) a five percent (5%) discount off the five (5) day volume weighted average price as reported on Bloomberg Financial Markets  (“VWAP”) per share of Pozen common stock, calculated over the five (5) trading days immediately preceding the date of Closing (as defined in the Merger Agreement), not to be less than $6.25. In the event any of Pozen, Tribute or Aralez announce a material event, whether by press release or the filing of a Form 8-K (other than results of any shareholder meeting) during the ten (10) day period immediately preceding Closing, then clause (ii) above shall be revised to read: “(ii) a five percent (5%) discount off the two (2) day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, calculated over the two (2) trading days immediately preceding the date of Closing, not to be less than $6.25.”
 
 
48

 
 
(y) the per share closing price of the Common Shares on such date plus (II) the amount of the Company’s debt as shown on the latest financial statements filed with the SEC (the “Current Financial Statements”) less (III) the amount of cash and cash equivalents of the Company as shown on the Current Financial Statements; or
 
(C)            a “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than the Company, files a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect “beneficial owner” as defined in Rule 13d-3 under the Exchange Act of the Company’s Common Equity representing more than 50% of the voting power of the Company’s Common Equity;

provided, however, that a transaction or transactions described above shall not constitute a Major Transaction, if at least 90% of the consideration received or to be received by the holders of Common Shares, excluding cash payments for fractional shares, in connection with such transaction or transactions, consists of freely tradable, unrestricted common shares, ordinary shares or ADRs (“Equity Shares”) of a Qualified Issuer (as defined below) that are listed on an Eligible Market or will be so listed when issued or exchanged in connection with such transaction or transactions and if as a result of such transaction or transactions the obligations of the Company under the Notes and the Facility Agreement are assumed by such Qualified Issuer, and such notes thereafter become convertible at any time and from time to time, pursuant to the terms hereof, into such Equity Shares, including with such appropriate revisions to the Conversion Price and to Schedule I hereto to reflect the conversion ratio to be received by holders of Common Shares in such transaction as shall be reasonably satisfactory to the Holder. An issuer is a Qualified Issuer if, as of the 5th Trading Date prior to the announcement of the foregoing transaction (1) its Market Cap (as defined below) is at least $5 billion and (2) the rating assigned to its long term debt by S&P is at least “A” or its debt has an equivalent rating on Moody’s or a comparable rating agency. Market Cap shall mean the product of the number of outstanding Equity Securities and the Volume Weighted Average Price of such securities, both determined as of the foregoing 5th Trading Day.

(xiii)            “Major Transaction Company Shares” shall have the meaning set forth in Section 3(a) hereof.

(xiv)            “Major Transaction Conversion Period” means the period beginning upon receipt by the Holder of a Major Transaction Notice (as defined below) and ending (1) in the case of a Successor Major Transaction (as defined below), five (5) Trading Days prior to consummation of the Major Transaction and (2) in the case of a Company Share Major Transaction (as defined below), any time until the later of (x) the six (6) year anniversary of the Funding Date and (y) the one-year anniversary of the applicable Company Share Major Transaction.

(xv)           “Maturity Date” means the sixth anniversary of the Issuance Date, subject to the terms specified in the Facility Agreement.
 
 
49

 
 
(xvi)            “Person” means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a joint stock company, a trust, an unincorporated organization or a government or agency or a political subdivision thereof.
 
(xvii)            “Principal” means the outstanding principal amount of this Note as of any date of determination.

(xviii)            “Principal Market” means the Eligible Market on which the Common Shares are primarily listed on and quoted for trading, which as of the Issuance Date, shall be the NASDAQ Stock Market LLC.

(xix)            “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement registering Conversion Shares (as defined below), (B) the Company fails to use its best efforts to obtain effectiveness with the SEC, prior to the Registration Deadline (as defined in the Registration Rights Agreement), of any Registration Statements (as defined in the Registration Rights Agreement) that are required to be filed pursuant to Section 2(a) of the Registration Rights Agreement registering Conversion Shares, or fails to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statements required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement registering Conversion Shares on or before the Additional Filing Deadline or fails to use its best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline, (D) the Company fails to file any amendment to any Registration Statement registering Conversion Shares, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement registering Conversion Shares within twenty (20) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its best efforts to cause such amendment and/or new Registration Statement to become effective within forty-five (45) days of the applicable Registration Trigger Date, (E) any Registration Statement required to be filed under the Registration Rights Agreement registering Conversion Shares, after its initial effectiveness and during the Registration Period (as defined in the Registration Rights Agreement), lapses in effect or sales of any Conversion Shares constituting Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and to obtain effectiveness with the SEC of an additional Registration Statement registering Conversion Shares or amended Registration Statement required pursuant to Sections 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), and (F) the Company fails to provide a commercially reasonable written response to any comments to the foregoing Registration Statements submitted by the SEC within twenty (20) days of the date that such SEC comments are received by the Company.

(xx)            “Registration Rights Agreement” means that certain Registration Rights Agreement dated as of June 8, 2015, as amended and restated on October 29, 2015 and December 7, 2015, among the Company and the Lenders party to the Facility Agreement.
 
 
50

 

(xxi)            “Required Note Holders” means Holders of at least 50.1% of the aggregate principal amount of the Notes outstanding.

(xxii)            “SEC” means the Securities and Exchange Commission.

(xxiii)           “Securities Act” means the Securities Act of 1933, as amended.

(xxiv)           “Shares” means Common Shares.

(xxv)            “Successor Entity” means any Person purchasing the Company’s assets or Common Shares in a Major Transaction, or any successor entity resulting from such Major Transaction.

(xxvi)            “Trading Day” means any day on which the Common Shares are traded for any period on the Principal Market.

(xxvii)           “VolumeWeighted Average Price” for any security as of any date means the volume weighted average sale price of such security on the Principal Market as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Note Holders and the Company (“Bloomberg”) or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority, Inc. or on the “over the counter” Bulletin Board (or any successor) or in the “pink sheets” (or any successor) by the OTC Markets Group, Inc. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Company and the Holders of a majority in interest of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes.

2.            Conversion Rights. This Note may be converted into Shares on the terms and conditions set forth in this Section 2 and, where applicable, Section 3.

(a)            Conversion at Option of the Holder. On or after the date hereof, the Holder shall be entitled to convert all or any part of the Principal into, and the Company shall issue, fully paid Shares, ranking pari passu with the fully paid Shares then in issue (the “Conversion Shares”) in accordance with this Section 2 and, if applicable, Section 3, at the Conversion Rate (as defined in Section 2(b)); provided that the Company will not be required to issue Conversion Shares with respect to a Conversion Notice with respect to less than the lesser
 
 
51

 
 
of (i) $1,000,000 principal amount of this Note and (ii) the principal amount outstanding under this Note. The Company shall not issue any fraction of a Share upon any conversion. If the issuance would result in the issuance of a fraction of a Share, then the Company shall round such fraction of a Share up or down to the nearest whole share (with 0.5 rounded up). Notwithstanding anything herein to the contrary, the Company shall not issue to the Holder, and the Holder may not acquire, a number of Shares upon conversion of this Note or otherwise issue any Common Shares pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of Shares then beneficially owned by the Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Shares would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 9.985% of the total number of Common Shares then issued (excluding treasury shares) (the “9.985% Cap”); provided, however, that the 9.985% Cap shall only apply to the extent that Common Shares are deemed to constitute an “equity securities” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to the Holder the number of Shares then outstanding.
 
(b)            Conversion Rate. The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section 2 shall be determined according to the following formula (the “Conversion Rate”):

_______Conversion Amount_______
Conversion Price

The Conversion Rate shall be subject to adjustment in connection with a Major Transaction Conversion (as defined below) in accordance with and subject to the provisions of Section 3 hereof.

(c)            Mechanics of Conversion. The conversion of this Note shall be conducted in the following manner:

(i)            Holder’s Delivery Requirements. To convert a Conversion Amount into Conversion Shares on any date (the “Conversion Date”), the Holder shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A or, in the case of a Major Transaction Conversion for Major Transaction Company Shares (as defined below), a Major Transaction Conversion Notice (such applicable notice, the “Conversion Notice”) to the Company (Attention: [__________, __________________, Fax: (___) ___-____, Email: __________@________.com)], and (B) if required by Section 2(c)(vi), surrender to a common carrier for delivery to the Company, no later
 
 
52

 
 
than three (3) Business Days after the Conversion Date, the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii)            Company’s Response. Upon receipt or deemed receipt by the Company of a copy of a Conversion Notice, the Company (I) shall immediately send, via facsimile or electronic mail, a confirmation of receipt of such Conversion Notice to the Holder and the Company’s designated transfer agent (the “Transfer Agent”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein and (II) on or before the second (2nd) Trading Day following the date of receipt or deemed receipt by the Company of such Conversion Notice or, in the case of Major Transaction Company Shares, within the period provided in Section 3(d) (the “Share Delivery Date”); (A) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program and provided that the Holder is eligible to receive Shares through DTC, credit such aggregate number of Conversion Shares to which the Holder shall be entitled to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (B) if the foregoing shall not apply, issue and deliver to the address as specified in the Conversion Notice, a share or stock certificate (as the case may be), registered in the name of the Holder or its designee, for the number of Conversion Shares to which the Holder shall be entitled. If this Note is submitted for conversion, and the Principal represented by this Note is greater than the Principal being converted, then the Company shall, as soon as practicable and in no event later than three (3) Trading Days after receipt of this Note (the “Note Delivery Date”) and at its own expense, issue and deliver to the Holder a new Note representing the Principal not converted and cancel this Note. This Note and the Conversion Shares will be free-trading, and freely transferable, and will not contain a legend restricting the resale or transferability of the Conversion Shares if the Unrestricted Conditions (as defined below) are met.
 
(iii)            Dispute Resolution. In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Company shall instruct the Transfer Agent to issue to the Holder the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Holder via facsimile or electronic mail within two (2) Business Days of receipt or deemed receipt of the Holder’s Conversion Notice or other date of determination. If the Holder and the Company are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Holder, then the Company shall promptly (and in any event within two (2) Business Days) submit via facsimile or electronic mail (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Company and the Required Note Holders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Company’s independent registered public accounting firm, as the case may be. The Company shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error. Notwithstanding anything herein to the contrary, any such final
 
 
53

 
 
determination in respect of a dispute in connection with a Major Transaction in which the Company is not the surviving parent entity, shall be made prior to consummation of such Major Transaction.

(iv)            Record Holder. The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such Shares upon delivery of the Conversion Notice via facsimile, electronic mail or otherwise in accordance with the terms hereof.
 
(v)            Company’s Failure to Timely Convert.

(A)            Cash Damages. If within three (3) Business Days after the Company’s receipt of the facsimile or electronic mail copy of a Conversion Notice or deemed receipt of a Conversion Notice the Company shall fail to issue and deliver a certificate to the Holder for, or credit the Holder’s or its designee’s balance account with DTC with, the number of Conversion Shares (free of any restrictive legend if the Unrestricted Conditions (as defined below) are met) to which the Holder is entitled upon the Holder’s conversion of any Conversion Amount, then in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement, the Company shall pay additional damages to the Holder for each 30-day period (prorated for any partial period) after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of, the product of (I) the number of Conversion Shares not issued to the Holder or its designee on or prior to the Share Delivery Date and to which the Holder is entitled and (II) the Volume Weighted Average Price of an Common Share on the Share Delivery Date (such product is referred to herein as the “Share Product Amount. Alternatively, subject to Section 2(c)(iii), at the election of the Holder made in the Holder’s sole discretion, the Company shall pay to the Holder, in lieu of the additional damages referred to in the preceding sentence (but in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement), 105% of the amount by which (A) the Holder’s total purchase price (including brokerage commissions, if any) for the Shares purchased to make delivery in satisfaction of a sale by the Holder of the Conversion Shares to which the Holder is entitled but has not received upon a conversion exceeds (B) the net proceeds received by the Holder from the sale of the Shares to which the Holder is entitled but has not received upon such conversion. If the Company fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Holder entitled to such payments shall have the right at any time, so long as the Company continues to fail to make such payments, to require the Company, upon written notice, to immediately issue, in lieu of such cash damages, the number of Shares equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price in effect on such Conversion Date as specified by the Holder in the Conversion Notice.

(B)            Void Conversion Notice. If for any reason the Holder has not received all of the Conversion Shares prior to the fifteenth (15th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “Conversion Failure”), then the Holder, upon written notice to the Company (a “Void Conversion Notice”),
 
 
54

 
 
may void its Conversion Notice with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Holder’s Conversion Notice; provided, that the voiding of the Holder’s Conversion Notice shall not affect the Company’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section 2(c)(v)(A) or otherwise.

(C)            Event of Default. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.
 
(vi)            Book-Entry. Notwithstanding anything to the contrary set forth herein, upon conversion or redemption of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Company unless all of the Principal is being converted or redeemed. The Holder and the Company shall maintain records showing the Principal converted or redeemed and the dates of such conversions or redemptions or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon any such partial conversion or redemption. Notwithstanding the foregoing, if this Note is converted or redeemed as aforesaid, the Holder may not transfer this Note unless the Holder first physically surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Note of like tenor, registered as the Holder may request, representing in the aggregate the remaining Principal represented by this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or redemption of any portion of this Note, the Principal of this Note may be less than the principal amount stated on the face hereof.

(d)            Taxes. The Company shall pay any and all Other Taxes that may be payable with respect to the issuance and delivery of Conversion Shares upon the conversion of this Note. For greater certainty, the provisions of Section 2.6 of the Facility Agreement shall apply with respect to any and all Taxes with respect to payments by the Company (or any other applicable Credit Party) hereunder, including with respect to the delivery of Conversion Shares upon the conversion of this Note.

(e)            Legends.

(i)            Restrictive Legend. The Holder understands that until such time as this Note or the Conversion Shares have been registered under the Securities Act and applicable state securities laws as contemplated by the Registration Rights Agreement or otherwise may be sold pursuant to Rule 144 under the Securities Act or an exemption from registration under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Note and the Conversion Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such securities):
 
 
55

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4(1) AND A HALF” SALE.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF DECEMBER 7, 2015, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

The Holder understands that this Note and the Conversion Shares, as applicable, shall bear a restrictive legend in substantially the following form pursuant to applicable Canadian securities laws (and a stop-transfer order may be placed against transfer of the certificates for such securities):

“UNLESS PERMITTED UNDER APPLICABLE CANADIAN SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [__, 2016] [INSERT THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE CONVERTIBLE NOTE ISSUANCE DATE]. WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL [INSERT DATE].”
 
(ii)            Removal of Restrictive Legends. This Note and the certificates evidencing the Conversion Shares (including any Major Transaction Company Shares), as applicable, shall not contain any United States legend restricting the transfer thereof (including the United States legend set forth above in subsection 2(e)(i)): (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of the Conversion Shares is effective under the Securities Act, or (B) following any sale of such Note and/or Conversion Shares pursuant to Rule 144, or (C) if such Note or Conversion Shares, as the case may be, are eligible for sale under Rule 144(b)(1), (D) if
 
 
56

 
 
such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date (as defined below), or at such other time as any of the Unrestricted Conditions have been satisfied, if required by the Company’s transfer agent to effect the issuance of this Note or the Conversion Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of any of the Conversion Shares, then such Conversion Shares shall be issued free of all United States legends. The Company agrees that following the Effective Date or at such time as any of the Unrestricted Conditions are met or such United States legend is otherwise no longer required under this Section 2(e), it will, no later than five (5) Trading Days following the delivery (the “Unlegended Shares Delivery Deadline”) by the Holder to the Company or the Transfer Agent of this Note and a certificate representing Conversion Shares, as applicable, issued with a restrictive United States legend (such third Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to such Holder this Note and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other United States legends. For purposes hereof, “Effective Date” shall mean the date that the Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC. The Canadian law securities legend shall be removed promptly following ________, 2016. [INSERT DATE THAT IS 4 MONTHS AND A DAY AFTER THE ISSUANCE DATE]

(iii)            Sale of Unlegended Shares. Holder agrees that the removal of the restrictive United States legend from this Note and any certificates representing securities as set forth in Section 2(e)(i) above is predicated upon the Company’s reliance that the Holder will sell this Note or any Conversion Shares, as applicable, pursuant to either the registration requirements of the Securities Act and applicable state securities laws, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f)            Dividend, Subdivision, Combination or Reclassification. If the Company shall, at any time or from time to time, (A) declare a dividend on the Common Shares, or capitalization of profits or reserves, payable in shares of its Capital Stock (including Common Shares), other than a dividend for which the Holder would be entitled to participate pursuant to Section 6, (B) subdivide the outstanding Common Shares into a larger number of Common Shares, (C) consolidate or combine the outstanding Common Shares into a smaller number of shares of its Common Shares or (D) issue any shares of its Capital Stock in a reclassification of the Common Shares (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), or (E) repay or reduce its capital or otherwise adjust the nominal value of its Shares, then in each such case, the Conversion Price in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination or reclassification shall be adjusted so that the Holder of this Note upon conversion after such date shall be entitled to receive the aggregate number and kind of shares of its Capital Stock which, if this Note had been converted immediately prior to such date, such holder would have owned upon such conversion and been entitled to receive by virtue of such dividend,
 
 
57

 
 
subdivision, combination or reclassification. Any such adjustment shall become effective immediately after the record date of such dividend or the effective date of such subdivision, combination or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur. If a dividend on the Common Shares, or capitalization of profits or reserves, payable in shares of its Capital Stock (including Common Shares) is declared and such dividend is not paid, the Conversion Price shall again be adjusted to be the Conversion Price, in effect immediately prior to such record date (giving effect to all adjustments that otherwise would be required to be made pursuant to this Section 2 from and after such record date).

3.            Rights Upon Major Transaction. Notwithstanding anything herein to the contrary, the provisions of this Section 3 shall not apply prior to the issuance of the Parent Convertible Notes (as defined in the Facility Agreement). In the event that a Major Transaction occurs, then the Holder, at its option, may (i) require the Company to repay all or a portion of the principal amount outstanding on the Holder’s Notes plus all accrued and unpaid Interest thereon, in accordance with Section 5.3 of the Facility Agreement or (ii) convert all or a portion of the principal amount outstanding in accordance with the provisions of this Section 3 (a “Major Transaction Conversion”) and cause the Company to pay to the Holder all accrued and unpaid Interest under this Note. The Holder shall have the right to waive its rights under this Section 3 with respect to such Major Transaction.

(a)            Major Transaction Conversion. In the event that a Major Transaction occurs, then (1) in the case of a transaction covered by the provisions of clause (A) of the definition of “Major Transaction”, in which the Common Shares of the Company are converted into the right to receive cash, securities of another entity and/or other assets (a “Successor Major Transaction”), the Holder, at its option, may convert, in whole or in part, the outstanding principal amount under this Note into the right to receive upon consummation of the Major Transaction, the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that the Holder would have received had such Holder converted the Major Transaction Conversion Amount (as defined below) into Base Conversion Shares and Additional Conversion Shares (as defined below and without regard to the 9.985% Cap) immediately prior to the consummation of such Major Transaction (the “Successor Consideration”) and (2) in the case of any other Major Transactions not covered under clause (1) above (a “Company Share Major Transaction”), the Holder shall have the right to convert, in whole or in part, and from time to time, the outstanding principal amount under this Note into Base Conversion Shares and Additional Conversion Shares (“Major Transaction Company Shares”).

(b)            Base Conversion Shares and Additional Conversion Shares. Notwithstanding anything herein to the contrary, with respect to any conversion or deemed conversion effected in connection with a Major Transaction pursuant to this Section 3, the aggregate total number of Major Transaction Company Shares into which all or any portion of the principal amount of this Note may be converted or, the aggregate number of conversion shares to be used for calculating the Successor Consideration, as applicable, shall be calculated to be the sum of (a) the number of Common Shares into which the principal amount of this Note then being converted would otherwise be converted as calculated under Section 2 hereof (such number of shares, the “Base Conversion Shares”), plus (b) the number of Common Shares
 
 
58

 
 
equal to the product of (x) the Additional Share Coefficient (as such term is defined and determined for each $1,000 of principal amount of this Note on Schedule I attached hereto and made a part hereof) for such Major Transaction and (y) a fraction the numerator of which is the amount of the principal amount of this Note then being converted and the denominator of which is $1,000 (such number of Common Shares calculated in accordance with this clause (b), the Additional Conversion Shares”).
 
(c)            Notice; Major Transaction Conversion Election. At least thirty (30) days prior to the consummation of any Major Transaction (other than a transaction described in clause (C) of the definition of “Major Transaction”), but, in any event, within five (5) Business Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via (i) facsimile or electronic mail and (ii) overnight courier to the Holder (a “Major Transaction Notice”). At any time during the Major Transaction Conversion Period, the Holder may elect to effect a Major Transaction Conversion by delivering written notice thereof (“Major Transaction Conversion Notice”) to the Company, which Major Transaction Conversion Notice shall indicate the portion of the Note (the “Major Transaction Conversion Amount”), calculated with reference to the principal amount outstanding that the Holder is electing to treat as a Major Transaction Conversion. For the avoidance of doubt, the Holder shall be permitted to make successive conversions and send successive Major Transaction Conversion Notices in respect of a Company Share Major Transaction from time to time at any time during the Major Transaction Conversion Period; provided that the Company will not be required to issue Conversion Shares with respect to a Major Transaction Conversion Notice with respect to less than the lesser of (i) $1,000,000 principal amount of this Note and (ii) the principal amount outstanding under the Note.

(d)            Settlement of Major Transaction Conversion. Following the receipt of a Major Transaction Conversion Notice from the Holder, the Company shall not effect a Successor Major Transaction that is being treated as a Major Transaction Conversion unless at the time of the execution of the definitive documentation relating to such Major Transaction it obtains the written agreement of the Successor Entity that payment or issuance of the Successor Consideration plus accrued and unpaid interest through the date of payment, shall be made to the Holder prior to consummation of such Major Transaction and such payment or issuance, as the case may be, shall be a condition precedent to consummation of such Major Transaction. Concurrently upon closing of such Successor Major Transaction, the Company shall pay or issue, as the case may be, or shall instruct any escrow agent for the transaction to pay or issue, and will cause the Successor Entity to issue and/or pay, the applicable Successor Consideration, plus accrued and unpaid interest through the date of payment. Any Major Transaction Company Shares issuable in respect of a Company Share Major Transaction shall be issued to the Holder within three (3) Trading Days following the date of each Major Transaction Conversion Notice.
 
(e)            Damages. Following the receipt of a Major Transaction Conversion Notice from the Holder, in the event that the Company attempts to consummate a Successor Major Transaction without obtaining the written agreement of the Successor Entity
 
 
59

 
 
described in subsection (d) above, the Holder shall have the right to apply for an injunction in any state or federal courts sitting in the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Successor Consideration is satisfied to the Holder in full.

Notwithstanding anything to the contrary contained herein and without derogating any obligations or rights herein, until the Holder receives its appropriate payment or securities, plus any accrued and unpaid interest under this Note, in accordance with the provisions of this Section 3, this Note may be converted, in whole or in part, by the Holder into Shares, or in the event that such payments and/or shares have not been delivered prior to the consummation of the Successor Major Transaction in which the Company is not the surviving parent entity, Common Shares (or their equivalent) of the Successor Entity at an appropriate conversion price based upon the prevailing Conversion Rate (as adjusted hereunder) at the time of such Major Transaction and price per share or conversion ratio received by holders of Common Shares in the Major Transaction.

4.            Registration Failures. Upon any Registration Failure, in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement, the Registration Rights Agreement and this Note, the Company shall pay additional damages to the Holder for each 30-day period (prorated for any partial period) after the date of such Registration Failure in an amount in cash equal to one and one-half percent (1.5%) of such Holder’s original principal amount of this Note on the date of such Registration Failure. Such payments shall accrue until the earlier of (i) such time as the Registration Failure has been cured and (ii) the date on which all of the Conversion Shares may be sold without restriction under Rule 144 (including, without limitation, volume restrictions and without the need for the availability of current public information under Rule 144). All such payments that accrue under this Section 4 shall be payable no later than five (5) business days following such date of accrual.

5.            Voting Rights. Except as required by law, the Holder shall have no voting rights with respect to any of the Conversion Shares until delivery of the Conversion Notice relating to the conversion of this Note upon which such Conversion Shares are issuable.

6.            Participation. The Holder, as the holder of this Note, shall be entitled to receive such dividends paid and distributions of any kind made to the holders of Common Shares to the same extent as if the Holder had converted this Note into Common Shares (without regard to any limitations on exercise herein or elsewhere and without regard to whether or not a sufficient number of shares are authorized and reserved to effect any such exercise and issuance) and had held such Common Shares on the record date for such dividends and distributions. Payments under the preceding sentence shall be made concurrently with the dividend or distribution to the holders of Common Shares.

7.           Certain Provisions Related to Common Shares Issued Hereunder.
 
(a)           Sufficient Common Shares.  The Company shall provide, free from preemptive rights, out of the Company’s authorized but unissued shares or shares held in treasury, sufficient Common Shares to provide for conversion of the Notes held by the Holder from time to time as such Notes are presented for conversion (assuming that at the time of
 
 
60

 
 
computation of such number of Common Shares, all such Notes would be converted by the Holder into Conversion Shares (without regard to the 9.985% Cap)).
 
(b)           Fully-Paid.  The Company covenants that all Common Shares issued upon conversion of Notes held by the Holder will be fully paid by the Company and free from all taxes, liens and charges with respect to the issue thereof.
 
8.            Amendment; Waiver. The terms and provisions of this Note shall not be amended or waived except in a writing signed by the Company and the Required Note Holders.

9.            Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note, the Facility Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief). No remedy contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy, and nothing herein shall limit the Holder’s right to pursue actual damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

10.            Specific Shall Not Limit General; Construction. No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Company and all purchasers of Notes pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

11.            Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

12.            Notices. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.2 of the Facility Agreement.

13.            Restrictions on Transfer.

(a)            Registration or Exemption Required. This Note has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Regulation D. None of the Note or the Conversion Shares may be pledged, transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws including, without limitation, a so-called “4(1) and a half” transaction.
 
 
61

 

(b)            Assignment. Subject to Section 13(a), the Holder may sell, transfer, assign, pledge, hypothecate or otherwise dispose of this Note, in whole or in part. Other than in respect of the exchange of this Note for the Parent Convertible Note, Holder shall deliver a written notice to Company, substantially in the form of the Assignment attached hereto as Exhibit B, indicating the Person or Persons to whom the Note shall be assigned and the respective principal amount of the Note to be assigned to each assignee. The Company shall effect the assignment within five (5) Trading Days (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Note or Notes of like tenor and terms for the appropriate principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Holder. The provisions of this Note are intended to be for the benefit of all Holders from time to time of this Note, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4(1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for the Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4(1) and half” transaction.
 
14.            Obligations of the Company. For so long as any conversion rights under this Note remain capable of being exercised, the Company will (a) keep available for issue out of its authorized but unissued shares capital free from pre-emptive rights such number of Common Shares as would enable the Conversion Shares to be issued in full, and (b) will not, without the consent of the Holder, make any alteration to its articles of association which could have a material adverse effect on the rights attaching to the Common Shares or the rights of the Holder.

15.            Payment of Collection, Enforcement and Other Costs. If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Holder in any bankruptcy, reorganization, receivership of the Company or other proceedings affecting Company creditors’ rights and involving a claim under this Note, then the Company shall pay the costs incurred by the Holder for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements.

16.            Cancellation. After all Principal, Interest and other amounts at any time owed under, or on account of, this Note have been paid in full or converted into Shares in accordance with the terms hereof, this Note shall automatically be deemed cancelled, shall be surrendered to the Company for cancellation and shall not be reissued.

17.            Registered Note. In order to qualify as a “registered note” for purposes of the Code, transfer of this Note may be effected only by (i) surrender of this Note to the Company and the re-issuance of this Note to the transferee, or the Company’s issuance to the Holder of a new note in the same form as this Note but with the transferee denoted as the Holder, or (ii) the recording of the identity of the transferee by the Affiliate of the Holder that is maintaining a record ownership register of this Note as a non-fiduciary agent of, and on behalf
 
 
62

 
 
of, the Company for the tax purposes set forth herein. Such Affiliate in its capacity as such agent shall notify the Company in writing immediately upon any change in such identity. Any attempted transfer in violation of the relevant provisions of this Note shall be void and of no force and effect. Until there has been a valid transfer of this Note and of all of the rights hereunder by the Holder in accordance with this Note, the Company shall deem and treat the Holder as the absolute beneficial owner and holder of this Note and of all of the rights hereunder for all purposes (including, without limitation, for the purpose of receiving all payments to be made under this Note).
 
18.            Waiver of Notice. To the extent permitted by law, the Company hereby waives demand, notice, presentment, protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Facility Agreement.

19.            Governing Law. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note and all disputes arising hereunder shall be governed by, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware and without prejudice to the applicability of the laws of the Province of British Columbia, Canada or Ontario, Canada, as the case may be and, in either case, under the federal laws of Canada applicable thereunder, to the issuance of Shares pursuant to the Note. The Company (a) agrees that any legal action or proceeding with respect to this Note or any other agreement, document, or other instrument executed in connection herewith, shall be brought exclusively in any state or federal court located within Wilmington, Delaware, (b) irrevocably waives any objections which the Company may now or hereafter have to the venue of any suit, action or proceeding arising out of or relating to this Note, or any other agreement, document, or other instrument executed in connection herewith, brought in the aforementioned courts, (c) further irrevocably waives any claim that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum and (d) hereby consents that personal service of summons or other legal process may be made as set forth in Section 6.5 of the Facility Agreement. EACH OF THE COMPANY AND THE HOLDER (BY ACCEPTANCE HEREOF) IRREVOCABLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING BROUGHT TO ENFORCE ANY PROVISION OF THIS NOTE OR ANY OTHER TRANSACTION DOCUMENT.

20.            Interpretative Matters. Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a stock split, stock dividend, stock combination or other similar event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such event.
 
 
63

 

21.            Execution. A facsimile, telecopy, PDF or other reproduction of this Note may be delivered by the Company, and an executed copy of this Note may be delivered by the Company by facsimile, electronic mail or other similar electronic transmission device pursuant to which the signature of or on behalf of the Company can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. The Company hereby agrees that it shall not raise the execution of facsimile, PDF or other reproduction of this Note, or the fact that any signature was transmitted by facsimile, electronic mail or other similar electronic transmission device, as a defense to the Company’s execution of this Note. Notwithstanding the foregoing, the Company shall be required to deliver an originally executed Note to the Holder.
 
 [Signature page follows]
 
 
64

 

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the date first set forth above.

GIVEN UNDER THE COMMON SEAL OF TRIBUTE PHARMACEUTICALS CANADA INC.

 
   
 
 
[Title]
 
     
     
 
   
 
 
[Title]
 
 
 
65

 
 
Exhibit A
 
CONVERSION NOTICE

Reference is made to the Senior Secured Convertible Note (the “Note”) of Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (the “Company”), in the original principal amount of $[__________]. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into Common Shares (the “C Shares”), of the Company, as of the date specified below.
 
 
Date of Conversion:                                 
       
 
Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):
       
 
   
 
       
 
Principal, applicable thereto, to be converted:      
    
  
       
Please confirm the following information:
       
 
Conversion Price:
   
  
       
 
Number of Common Shares to be issued:
     
  
       
Please issue Common Shares into which the Note is being converted in the following name and to the following address:
       
 
Issue to:
  
       
 
Facsimile Number:
   
       
 
E-mail Address:
   
       
 
Authorization:
    
  
       
   
By:
   
   
 
   
Title:
   
   
 
       
 
Dated:
      
   
 
       
 
DTC Participant Number and Name (if electronic book entry transfer):
   
 
Account Number (if electronic book entry transfer):
   

 
66

 
 
 
Exhibit B
 

ASSIGNMENT

(To be executed by the registered holder
desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached Senior Secured Convertible Note (the “Note”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $__________ from Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada, evidenced by the attached Note and does hereby irrevocably constitute and appoint __________ attorney to transfer the said Note on the books of the Company, with full power of substitution in the premises.

Dated:
   
Signature
     

Fill in for new registration of Note:

   
Name
 
   
   
Address
 
   
   
Please print name and address of assignee
 
(including zip code number)
 

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note in every particular, without alteration or enlargement or any change whatsoever.
 
 
67

 
 
Exhibit C

FORM OF OPINION

______, 20__

[___________]

Re:            Tribute Pharmaceuticals Canada Inc.

Dear Sir:

[___________] (“[__________]”) intends to transfer its Senior Secured Convertible Note in the principal amount of $_______ (the “Note”) of the Company to __________ (“________”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection herewith, we have examined such documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Note by _______ to ______ may be effected without registration under the Securities Act, provided, however, that the Note to be transferred to _______ contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Note is subject to a stop order.

The foregoing opinion is furnished only to ____________ and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,
 
 

 
68

 
 
Schedule 1

The Additional Share Coefficient” shall mean the number of additional Common Shares issuable per $1,000 of principal amount of the Note upon a Major Transaction and shall be the additional share number set forth on the chart with respect to the “Share Price Result” on the “y” axis and the corresponding “Remaining Note Life” on the “x” axis; provided, however, that to the extent the actual Share Price Result (as defined below) falls between two data points on the “y” axis and/or the actual date of the Major Transaction falls between two data points on the “x” axis, the “Additional Share Coefficient” shall be determined by calculating the arithmetic mean between (i) the result obtained for the Share Price Result based on the linear interpolation between the additional share numbers corresponding to the two Share Price Result data points and (ii) the result obtained for the Remaining Note Life based on the linear interpolation between the two additional share numbers corresponding to the two Remaining Note Life data points; and providedfurther, however, that in the event of any adjustment to the Conversion Price pursuant to Section 2 of this Note, the numbers of additional Common Shares issuable per $1,000 of principal amount of this Note as set forth in the chart below shall be deemed adjusted pro rata with any adjustment resulting from the adjustment to the Conversion Price that would be made to the number of Common Shares then convertible with respect to $1,000 of principal amount of this Note as calculated under Section 2 of this Note. For purposes of the chart below, the “Share Price Result” shall be the greater of: (i) the last sales price of Common Shares on NASDAQ, or, if that is not the principal trading market for Common Shares, such principal market on which Common Shares are traded or listed (the Closing Market Price”) immediately prior to the consummation of the Major Transaction or (ii) in the case of a Major Transaction in which holders of Common Shares receive solely cash consideration in connection with such major Transaction, the cash amount payable per share of Common Stock in such Major Transaction. If the actual Share Price Result is greater than $60 per share (subject to adjustment in the same manner as the Conversion Price as provided in Section 2 of this Note), or if the actual Shares Price Result is less than $5.00 per share (subject to adjustment in the same manner as the Conversion Price as provided in Section 2 of this Note), then the Additional Share Coefficient shall be equal to the amount applicable to $60 and $5, respectively.
 
 
 
69

 
 
Additional Shares per $1,000 Principal ($6.25 Pozen Purchase Price)

Remaining Note Life (Yrs)
 
       
            6       5       4       3       2       1       X  
      Y                                                          
Share Price Result ($)
                                                               
    5.00       54.206       47.964       40.827       32.537       22.693       10.685       0  
    10.00       52.732       48.104       42.735       36.361       28.489       17.944       0  
    15.00       29.625       26.126       22.127       17.493       12.024       5.490       0  
    20.00       19.423       16.679       13.606       10.158       6.321       2.329       0  
    25.00       13.916       11.699       9.267       6.625       3.848       1.295       0  
    30.00       10.570       8.735       6.762       4.681       2.605       0.877       0  
    35.00       8.367       6.820       5.185       3.509       1.910       0.672       0  
    40.00       6.832       5.506       4.129       2.752       1.487       0.555       0  
    45.00       5.715       4.564       3.387       2.235       1.211       0.478       0  
    50.00       4.874       3.864       2.845       1.868       1.021       0.423       0  
    55.00       4.223       3.328       2.437       1.596       0.884       0.381       0  
    60.00       3.707       2.908       2.121       1.390       0.781       0.347       0  
 
 
Additional Shares per $1,000 Principal ($7.20 Pozen Purchase Price)
 

Remaining Note Life (Yrs)
 
       
            6       5       4       3       2       1       X  
      Y                                                          
Share Price Result ($)
                                                               
    5.00       43.591       37.992       31.651       24.393       16.004       6.420       0  
    10.00       55.660       51.310       46.257       40.244       32.787       22.678       0  
    15.00       31.532       28.154       24.266       19.710       14.218       7.302       0  
    20.00       20.776       18.080       15.027       11.541       7.539       3.061       0  
    25.00       14.932       12.723       10.268       7.542       4.570       1.612       0  
    30.00       11.361       9.514       7.496       5.319       3.056       1.022       0  
    35.00       9.001       7.430       5.743       3.968       2.203       0.743       0  
    40.00       7.351       5.996       4.563       3.091       1.684       0.591       0  
    45.00       6.148       4.965       3.732       2.493       1.348       0.497       0  
    50.00       5.240       4.196       3.124       2.067       1.118       0.433       0  
    55.00       4.536       3.608       2.665       1.753       0.954       0.387       0  
    60.00       3.978       3.146       2.310       1.515       0.832       0.351       0  
 
[Schedules to be revised to reflect a Pozen Purchase Price between $6.25 and $7.20 in a manner consistent with the methodology applied in preparing the foregoing schedules]
 
 
70

 
 
Exhibit A-2

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4(1) AND A HALF” SALE.

THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF DECEMBER 7, 2015, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.


SENIOR SECURED CONVERTIBLE NOTE

Issuance Date: ________, 2016
Principal: U.S. $___________

FOR VALUE RECEIVED,  ARALEZ PHARMACEUTICALS INC., a corporation formed under the laws of the Province of British Columbia, Canada (the “Company”), hereby promises to pay to [ ], or its registered assigns (the “Holder”) the principal amount of _______________________($________) (the “Principal”) pursuant to, and in accordance with, the terms of that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, by and among the Company, the Lenders party thereto and the other parties thereto (together with all exhibits and schedules thereto and as may be amended, restated, modified and supplemented from time to time, the “Facility Agreement”). The Company hereby promises to pay accrued and unpaid Interest (as defined below) and premium, if any, on the Principal on the dates, at the rates and in the manner provided for in the Facility Agreement. This Senior Secured Convertible Note (including all Senior Secured Convertible Notes issued in exchange, transfer or replacement hereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, this “Note”) is one of the Senior Secured Convertible Notes issued pursuant to the Facility Agreement (collectively, including all Senior Secured Convertible Notes issued in exchange, transfer or replacement thereof, and as any of the foregoing may be amended, restated, supplemented or otherwise modified from time to time, the “Notes”). All capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Facility Agreement.
 
 
71

 
 
This Note is subject to mandatory prepayment on the terms specified in the Facility Agreement. Except as expressly provided in the Facility Agreement, the Company has no right, but under certain circumstances may have an obligation, to make payments of Principal prior to the sixth anniversary of the Issuance Date. At any time an Event of Default exists, the Principal of this Note, together with all accrued and unpaid Interest and any applicable premium due, if any, may be declared, or shall otherwise become, due and payable in the manner, at the price and with the effect provided in the Facility Agreement.

Notwithstanding anything herein to the contrary, from and after the closing of the transactions contemplated by the Arrangement Agreement, all references to the Company shall be deemed references to Aralez Pharmaceuticals Inc., a British Columbia corporation (the “Parent”), and that all references to “Common Shares” shall be deemed references to the common shares of the Parent.

1.            Definitions.

(a)            Certain Defined Terms. For purposes of this Note, the following terms shall have the following meanings:

(i)            “Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder will be deemed to be an Affiliate of such Holder. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii)            “Capital Stock” means, for any entity, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity, but for the avoidance of doubt, excluding any debt securities convertible into such stock.

(iii)            “Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote, in the election of directors of such person or (b) if such Person is not a corporation, to vote or otherwise participate in the election of the governing body, partners, managers or others that will control the management or policies of such person.
(iv)            “Common Shares” means the common shares of the Company.

 
(v)            “Conversion Amount” means the Principal to be converted, redeemed or otherwise with respect to which this determination is being made.
 
 
72

 

(vi)            “Conversion Price” means, as of any Conversion Date or other date of determination, $[____]2 per Share, subject to adjustment as provided herein and subject to appropriate adjustment to reflect any subdivision of outstanding Common Shares (by any stock split, share or stock dividend, recapitalization or otherwise) or combination of outstanding Common Shares (by consolidation, combination, reverse stock split or otherwise), repayment or reduction of capital or other event giving rise to an adjustment of the nominal amount of such Common Shares hereafter.

(vii)            “Dollars” or “$” means United States Dollars.

(viii)            “Eligible Market” means the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock Exchange, the NYSE Alternext, the Toronto Stock Exchange, or the Nasdaq Capital Market.

(ix)            “Exchange Act” means the Securities Exchange Act of 1934, as amended.

(x)            “Interest” means any interest (including any default interest) accrued on the Principal pursuant to the terms of this Note and the Facility Agreement.

(xi)            “Issuance Date” means _____, 2016, regardless of any exchange or replacement hereof.

(xii)            “Major Transaction” means any of the following events:

(A)            a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Shares immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold at least 50% of the Common Shares or (b) no longer have the ability to elect at least 50% of the members of the board of directors of the Company or (2) as a result of which Common Shares shall be converted into or re-designated as (or the Common Shares become entitled to receive) the same or a different number of shares of the same or another class or classes of stock or securities of the Company or another entity (other than to the extent the Common Shares are changed or exchanged solely to reflect a change in the Company’s jurisdiction of incorporation); or

(B)            the sale or transfer (other than to a wholly owned subsidiary of the Company) of (i) all or substantially all of the assets of the Company or (ii) assets of the Company for a purchase price equal to more than 50% of the Enterprise Value (as defined below) of the Company. For purposes of this clause (B), “Enterprise Value” shall mean (I) the product of (x) the number of issued and outstanding Common Shares on the date the Company delivers the Major Transaction Notice (as defined below in Section 3(b)) multiplied by (y) the per share closing price of the Common Shares on such date plus (II) the amount of the Company’s debt as shown on the latest financial statements filed with the SEC (the “Current
 

2 Conversion Price shall equal a 32.5% premium over the Pozen Purchase Price.  The “Pozen Purchase Price” shall be equal to the lesser of (i) $7.20, and (ii) a five percent (5%) discount off the five (5) day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, calculated over the five (5) trading days immediately preceding the date of Closing (as defined in the Merger Agreement), not to be less than $6.25. In the event any of Pozen, Tribute or Aralez announce a material event, whether by press release or filing of a Form 8-K (other than results of any shareholder meeting) during the ten (10) day period immediately preceding Closing, then clause (ii) above shall be revised to read: “(ii) a five percent (5%) discount off the two (2) day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, calculated over the two (2) trading days immediately preceding the date of Closing, not to be less than $6.25.”
 
 
73

 
 
Financial Statements”) less (III) the amount of cash and cash equivalents of the Company as shown on the Current Financial Statements; or
 
(C)            a “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than the Company, files a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect “beneficial owner” as defined in Rule 13d-3 under the Exchange Act of the Company’s Common Equity representing more than 50% of the voting power of the Company’s Common Equity;

provided, however, that a transaction or transactions described above shall not constitute a Major Transaction, if at least 90% of the consideration received or to be received by the holders of Common Shares, excluding cash payments for fractional shares, in connection with such transaction or transactions, consists of freely tradable, unrestricted common shares, ordinary shares or ADRs (“Equity Shares”) of a Qualified Issuer (as defined below) that are listed on an Eligible Market or will be so listed when issued or exchanged in connection with such transaction or transactions and if as a result of such transaction or transactions the obligations of the Company under the Notes and the Facility Agreement are assumed by such Qualified Issuer, and such notes thereafter become convertible at any time and from time to time, pursuant to the terms hereof, into such Equity Shares, including with such appropriate revisions to the Conversion Price and to Schedule I hereto to reflect the conversion ratio to be received by holders of Common Shares in such transaction as shall be reasonably satisfactory to the Holder. An issuer is a Qualified Issuer if, as of the 5th Trading Date prior to the announcement of the foregoing transaction (1) its Market Cap (as defined below) is at least $5 billion and (2) the rating assigned to its long term debt by S&P is at least “A” or its debt has an equivalent rating on Moody’s or a comparable rating agency. Market Cap shall mean the product of the number of outstanding Equity Securities and the Volume Weighted Average Price of such securities, both determined as of the foregoing 5th Trading Day.

(xiii)            “Major Transaction Company Shares” shall have the meaning set forth in Section 3(a) hereof.

(xiv)            “Major Transaction Conversion Period” means the period beginning upon receipt by the Holder of a Major Transaction Notice (as defined below) and ending (1) in the case of a Successor Major Transaction (as defined below), five (5) Trading Days prior to consummation of the Major Transaction and (2) in the case of a Company Share Major Transaction (as defined below), any time until the later of (x) the six (6) year anniversary of the Funding Date and (y) the one-year anniversary of the applicable Company Share Major Transaction.

(xv)           “Maturity Date” means the sixth anniversary of the Issuance Date, subject to the terms specified in the Facility Agreement.
 

(xvi)            “Person” means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a joint stock company, a trust, an unincorporated organization or a government or agency or a political subdivision thereof.
 
 
74

 
 
(xvii)            “Principal” means the outstanding principal amount of this Note as of any date of determination.

(xviii)            “Principal Market” means the Eligible Market on which the Common Shares are primarily listed on and quoted for trading, which as of the Issuance Date, shall be the NASDAQ Stock Market LLC.

(xix)            “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement registering Conversion Shares (as defined below), (B) the Company fails to use its best efforts to obtain effectiveness with the SEC, prior to the Registration Deadline (as defined in the Registration Rights Agreement), of any Registration Statements (as defined in the Registration Rights Agreement) that are required to be filed pursuant to Section 2(a) of the Registration Rights Agreement registering Conversion Shares, or fails to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statements required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement registering Conversion Shares on or before the Additional Filing Deadline or fails to use its best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline, (D) the Company fails to file any amendment to any Registration Statement registering Conversion Shares, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement registering Conversion Shares within twenty (20) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its best efforts to cause such amendment and/or new Registration Statement to become effective within forty-five (45) days of the applicable Registration Trigger Date, (E) any Registration Statement required to be filed under the Registration Rights Agreement registering Conversion Shares, after its initial effectiveness and during the Registration Period (as defined in the Registration Rights Agreement), lapses in effect or sales of any Conversion Shares constituting Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and to obtain effectiveness with the SEC of an additional Registration Statement registering Conversion Shares or amended Registration Statement required pursuant to Sections 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), and (F) the Company fails to provide a commercially reasonable written response to any comments to the foregoing Registration Statements submitted by the SEC within twenty (20) days of the date that such SEC comments are received by the Company.

(xx)            “Registration Rights Agreement” means that certain Registration Rights Agreement dated as of June 8, 2015, as amended and restated on October 29, 2015 and December 7, 2015, among the Company and the Lenders party to the Facility Agreement.
 
 
75

 

(xxi)            “Required Note Holders” means Holders of at least 50.1% of the aggregate principal amount of the Notes outstanding.

(xxii)            “SEC” means the Securities and Exchange Commission.

(xxiii)            “Securities Act” means the Securities Act of 1933, as amended.

(xxiv)            “Shares” means Common Shares.

(xxv)            “Successor Entity” means any Person purchasing the Company’s assets or Common Shares in a Major Transaction, or any successor entity resulting from such Major Transaction.

(xxvi)            “Trading Day” means any day on which the Common Shares are traded for any period on the Principal Market.

(xxvii)            “VolumeWeighted Average Price” for any security as of any date means the volume weighted average sale price of such security on the Principal Market as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Note Holders and the Company (“Bloomberg”) or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority, Inc. or on the “over the counter” Bulletin Board (or any successor) or in the “pink sheets” (or any successor) by the OTC Markets Group, Inc. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Company and the Holders of a majority in interest of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes.

2.            Conversion Rights. This Note may be converted into Shares on the terms and conditions set forth in this Section 2 and, where applicable, Section 3.

(a)            Conversion at Option of the Holder. On or after the date hereof, the Holder shall be entitled to convert all or any part of the Principal into, and the Company shall issue, fully paid Shares, ranking pari passu with the fully paid Shares then in issue (the “Conversion Shares”) in accordance with this Section 2 and, if applicable, Section 3, at the Conversion Rate (as defined in Section 2(b)); provided that the Company will not be required to issue Conversion Shares with respect to a Conversion Notice with respect to less than the lesser of (i) $1,000,000 principal amount of this Note and (ii) the principal amount outstanding under this Note. The Company shall not issue any fraction of a Share upon any conversion. If the issuance would result in the issuance of a fraction of a Share, then the Company shall round such
 
 
76

 
 
fraction of a Share up or down to the nearest whole share (with 0.5 rounded up). Notwithstanding anything herein to the contrary, the Company shall not issue to the Holder, and the Holder may not acquire, a number of Shares upon conversion of this Note or otherwise issue any Common Shares pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of Shares then beneficially owned by the Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Shares would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 9.985% of the total number of Common Shares then issued (excluding treasury shares) (the “9.985% Cap”); provided, however, that the 9.985% Cap shall only apply to the extent that Common Shares are deemed to constitute an “equity securities” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to the Holder the number of Shares then outstanding.
 
(b)            Conversion Rate. The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section 2 shall be determined according to the following formula (the “Conversion Rate”):

_______Conversion Amount_______
Conversion Price

The Conversion Rate shall be subject to adjustment in connection with a Major Transaction Conversion (as defined below) in accordance with and subject to the provisions of Section 3 hereof.

(c)            Mechanics of Conversion. The conversion of this Note shall be conducted in the following manner:

(i)            Holder’s Delivery Requirements. To convert a Conversion Amount into Conversion Shares on any date (the “Conversion Date”), the Holder shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A or, in the case of a Major Transaction Conversion for Major Transaction Company Shares (as defined below), a Major Transaction Conversion Notice (such applicable notice, the “Conversion Notice”) to the Company (Attention: [__________, __________________, Fax: (___) ___-____, Email: __________@________.com)], and (B) if required by Section 2(c)(vi), surrender to a common carrier for delivery to the Company, no later than three (3) Business Days after the Conversion Date, the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).
 
 
77

 

(ii)            Company’s Response. Upon receipt or deemed receipt by the Company of a copy of a Conversion Notice, the Company (I) shall immediately send, via facsimile or electronic mail, a confirmation of receipt of such Conversion Notice to the Holder and the Company’s designated transfer agent (the “Transfer Agent”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein and (II) on or before the second (2nd) Trading Day following the date of receipt or deemed receipt by the Company of such Conversion Notice or, in the case of Major Transaction Company Shares, within the period provided in Section 3(d) (the “Share Delivery Date”); (A) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program and provided that the Holder is eligible to receive Shares through DTC, credit such aggregate number of Conversion Shares to which the Holder shall be entitled to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (B) if the foregoing shall not apply, issue and deliver to the address as specified in the Conversion Notice, a share or stock certificate (as the case may be), registered in the name of the Holder or its designee, for the number of Conversion Shares to which the Holder shall be entitled. If this Note is submitted for conversion, and the Principal represented by this Note is greater than the Principal being converted, then the Company shall, as soon as practicable and in no event later than three (3) Trading Days after receipt of this Note (the “Note Delivery Date”) and at its own expense, issue and deliver to the Holder a new Note representing the Principal not converted and cancel this Note. This Note and the Conversion Shares will be free-trading, and freely transferable, and will not contain a legend restricting the resale or transferability of the Conversion Shares if the Unrestricted Conditions (as defined below) are met.

(iii)            Dispute Resolution. In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Company shall instruct the Transfer Agent to issue to the Holder the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Holder via facsimile or electronic mail within two (2) Business Days of receipt or deemed receipt of the Holder’s Conversion Notice or other date of determination. If the Holder and the Company are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Holder, then the Company shall promptly (and in any event within two (2) Business Days) submit via facsimile or electronic mail (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Company and the Required Note Holders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Company’s independent registered public accounting firm, as the case may be. The Company shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error. Notwithstanding anything herein to the contrary, any such final determination in respect of a dispute in connection with a Major Transaction in which the
 
 
78

 
 
Company is not the surviving parent entity, shall be made prior to consummation of such Major Transaction.

(iv)            Record Holder. The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such Shares upon delivery of the Conversion Notice via facsimile, electronic mail or otherwise in accordance with the terms hereof.
 
(v)            Company’s Failure to Timely Convert.

(A)            Cash Damages. If within three (3) Business Days after the Company’s receipt of the facsimile or electronic mail copy of a Conversion Notice or deemed receipt of a Conversion Notice the Company shall fail to issue and deliver a certificate to the Holder for, or credit the Holder’s or its designee’s balance account with DTC with, the number of Conversion Shares (free of any restrictive legend if the Unrestricted Conditions (as defined below) are met) to which the Holder is entitled upon the Holder’s conversion of any Conversion Amount, then in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement, the Company shall pay additional damages to the Holder for each 30-day period (prorated for any partial period) after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of, the product of (I) the number of Conversion Shares not issued to the Holder or its designee on or prior to the Share Delivery Date and to which the Holder is entitled and (II) the Volume Weighted Average Price of an Common Share on the Share Delivery Date (such product is referred to herein as the “Share Product Amount. Alternatively, subject to Section 2(c)(iii), at the election of the Holder made in the Holder’s sole discretion, the Company shall pay to the Holder, in lieu of the additional damages referred to in the preceding sentence (but in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement), 105% of the amount by which (A) the Holder’s total purchase price (including brokerage commissions, if any) for the Shares purchased to make delivery in satisfaction of a sale by the Holder of the Conversion Shares to which the Holder is entitled but has not received upon a conversion exceeds (B) the net proceeds received by the Holder from the sale of the Shares to which the Holder is entitled but has not received upon such conversion. If the Company fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Holder entitled to such payments shall have the right at any time, so long as the Company continues to fail to make such payments, to require the Company, upon written notice, to immediately issue, in lieu of such cash damages, the number of Shares equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price in effect on such Conversion Date as specified by the Holder in the Conversion Notice.

(B)            Void Conversion Notice. If for any reason the Holder has not received all of the Conversion Shares prior to the fifteenth (15th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “Conversion Failure”), then the Holder, upon written notice to the Company (a “Void Conversion Notice”), may void its Conversion Notice with respect to, and retain or have returned, as the case may be,
 
 
79

 
 
any portion of this Note that has not been converted pursuant to the Holder’s Conversion Notice; provided, that the voiding of the Holder’s Conversion Notice shall not affect the Company’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section 2(c)(v)(A) or otherwise.

(C)            Event of Default. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.
 
(vi)            Book-Entry. Notwithstanding anything to the contrary set forth herein, upon conversion or redemption of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Company unless all of the Principal is being converted or redeemed. The Holder and the Company shall maintain records showing the Principal converted or redeemed and the dates of such conversions or redemptions or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon any such partial conversion or redemption. Notwithstanding the foregoing, if this Note is converted or redeemed as aforesaid, the Holder may not transfer this Note unless the Holder first physically surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Note of like tenor, registered as the Holder may request, representing in the aggregate the remaining Principal represented by this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or redemption of any portion of this Note, the Principal of this Note may be less than the principal amount stated on the face hereof.

(d)            Taxes. The Company shall pay any and all Other Taxes that may be payable with respect to the issuance and delivery of Conversion Shares upon the conversion of this Note. For greater certainty, the provisions of Section 2.6 of the Facility Agreement shall apply with respect to any and all Taxes with respect to payments by the Company (or any other applicable Credit Party) hereunder, including with respect to the delivery of Conversion Shares upon the conversion of this Note.

(e)            Legends.

(i)            Restrictive Legend. The Holder understands that until such time as this Note or the Conversion Shares have been registered under the Securities Act and applicable state securities laws as contemplated by the Registration Rights Agreement or otherwise may be sold pursuant to Rule 144 under the Securities Act or an exemption from registration under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Note and the Conversion Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
 
 
80

 
 
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION, PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4(1) AND A HALF” SALE.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF DECEMBER 7, 2015, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii)            Removal of Restrictive Legends. This Note and the certificates evidencing the Conversion Shares (including any Major Transaction Company Shares), as applicable, shall not contain any United States legend restricting the transfer thereof (including the United States legend set forth above in subsection 2(e)(i)): (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of the Conversion Shares is effective under the Securities Act, or (B) following any sale of such Note and/or Conversion Shares pursuant to Rule 144, or (C) if such Note or Conversion Shares, as the case may be, are eligible for sale under Rule 144(b)(1), (D) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date (as defined below), or at such other time as any of the Unrestricted Conditions have been satisfied, if required by the Company’s transfer agent to effect the issuance of this Note or the Conversion Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of any of the Conversion Shares, then such Conversion Shares shall be issued free of all United States legends. The Company agrees that following the Effective Date or at such time as any of the Unrestricted Conditions are met or such United States legend is otherwise no longer required under this Section 2(e), it will, no later than five (5) Trading Days following the delivery (the “Unlegended Shares Delivery Deadline”) by the Holder to the Company or the Transfer Agent of this Note and a certificate representing Conversion Shares, as applicable, issued with a restrictive United States legend (such third Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to such Holder this Note and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other United States legends. For purposes hereof, “Effective Date” shall mean the date that the Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.
 
 
81

 

(iii)            Sale of Unlegended Shares. Holder agrees that the removal of the restrictive United States legend from this Note and any certificates representing securities as set forth in Section 2(e)(i) above is predicated upon the Company’s reliance that the Holder will sell this Note or any Conversion Shares, as applicable, pursuant to either the registration requirements of the Securities Act and applicable state securities laws, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f)            Dividend, Subdivision, Combination or Reclassification. If the Company shall, at any time or from time to time, (A) declare a dividend on the Common Shares, or capitalization of profits or reserves, payable in shares of its Capital Stock (including Common Shares), other than a dividend for which the Holder would be entitled to participate pursuant to Section 6, (B) subdivide the outstanding Common Shares into a larger number of Common Shares, (C) consolidate or combine the outstanding Common Shares into a smaller number of shares of its Common Shares or (D) issue any shares of its Capital Stock in a reclassification of the Common Shares (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), or (E) repay or reduce its capital or otherwise adjust the nominal value of its Shares, then in each such case, the Conversion Price in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination or reclassification shall be adjusted so that the Holder of this Note upon conversion after such date shall be entitled to receive the aggregate number and kind of shares of its Capital Stock which, if this Note had been converted immediately prior to such date, such holder would have owned upon such conversion and been entitled to receive by virtue of such dividend, subdivision, combination or reclassification. Any such adjustment shall become effective immediately after the record date of such dividend or the effective date of such subdivision, combination or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur. If a dividend on the Common Shares, or capitalization of profits or reserves, payable in shares of its Capital Stock (including Common Shares) is declared and such dividend is not paid, the Conversion Price shall again be adjusted to be the Conversion Price, in effect immediately prior to such record date (giving effect to all adjustments that otherwise would be required to be made pursuant to this Section 2 from and after such record date).

3.            Rights Upon Major Transaction. In the event that a Major Transaction occurs, then the Holder, at its option, may (i) require the Company to repay all or a portion of the principal amount outstanding on the Holder’s Notes plus all accrued and unpaid Interest thereon, in accordance with Section 5.3 of the Facility Agreement or (ii) convert all or a portion of the principal amount outstanding in accordance with the provisions of this Section 3 (a “Major Transaction Conversion”) and cause the Company to pay to the Holder all accrued and unpaid Interest under this Note. The Holder shall have the right to waive its rights under this Section 3 with respect to such Major Transaction.

(a)            Major Transaction Conversion. In the event that a Major Transaction occurs, then (1) in the case of a transaction covered by the provisions of clause (A) of the definition of “Major Transaction”, in which the Common Shares of the Company are
 
 
82

 
 
converted into the right to receive cash, securities of another entity and/or other assets (a “Successor Major Transaction”), the Holder, at its option, may convert, in whole or in part, the outstanding principal amount under this Note into the right to receive upon consummation of the Major Transaction, the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that the Holder would have received had such Holder converted the Major Transaction Conversion Amount (as defined below) into Base Conversion Shares and Additional Conversion Shares (as defined below and without regard to the 9.985% Cap) immediately prior to the consummation of such Major Transaction (the “Successor Consideration”) and (2) in the case of any other Major Transactions not covered under clause (1) above (a “Company Share Major Transaction”), the Holder shall have the right to convert, in whole or in part, and from time to time, the outstanding principal amount under this Note into Base Conversion Shares and Additional Conversion Shares (“Major Transaction Company Shares”).

(b)            Base Conversion Shares and Additional Conversion Shares. Notwithstanding anything herein to the contrary, with respect to any conversion or deemed conversion effected in connection with a Major Transaction pursuant to this Section 3, the aggregate total number of Major Transaction Company Shares into which all or any portion of the principal amount of this Note may be converted or, the aggregate number of conversion shares to be used for calculating the Successor Consideration, as applicable, shall be calculated to be the sum of (a) the number of Common Shares into which the principal amount of this Note then being converted would otherwise be converted as calculated under Section 2 hereof (such number of shares, the “Base Conversion Shares”), plus (b) the number of Common Shares equal to the product of (x) the Additional Share Coefficient (as such term is defined and determined for each $1,000 of principal amount of this Note on Schedule I attached hereto and made a part hereof) for such Major Transaction and (y) a fraction the numerator of which is the amount of the principal amount of this Note then being converted and the denominator of which is $1,000 (such number of Common Shares calculated in accordance with this clause (b), the Additional Conversion Shares”).
 
(c)            Notice; Major Transaction Conversion Election. At least thirty (30) days prior to the consummation of any Major Transaction (other than a transaction described in clause (C) of the definition of “Major Transaction”), but, in any event, within five (5) Business Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via (i) facsimile or electronic mail and (ii) overnight courier to the Holder (a “Major Transaction Notice”). At any time during the Major Transaction Conversion Period, the Holder may elect to effect a Major Transaction Conversion by delivering written notice thereof (“Major Transaction Conversion Notice”) to the Company, which Major Transaction Conversion Notice shall indicate the portion of the Note (the “Major Transaction Conversion Amount”), calculated with reference to the principal amount outstanding that the Holder is electing to treat as a Major Transaction Conversion. For the avoidance of doubt, the Holder shall be permitted to make successive conversions and send successive Major Transaction Conversion Notices in respect of a Company Share Major Transaction from time to time at any time during the Major
 
 
83

 
 
Transaction Conversion Period; provided that the Company will not be required to issue Conversion Shares with respect to a Major Transaction Conversion Notice with respect to less than the lesser of (i) $1,000,000 principal amount of this Note and (ii) the principal amount outstanding under the Note.

(d)            Settlement of Major Transaction Conversion. Following the receipt of a Major Transaction Conversion Notice from the Holder, the Company shall not effect a Successor Major Transaction that is being treated as a Major Transaction Conversion unless at the time of the execution of the definitive documentation relating to such Major Transaction it obtains the written agreement of the Successor Entity that payment or issuance of the Successor Consideration plus accrued and unpaid interest through the date of payment, shall be made to the Holder prior to consummation of such Major Transaction and such payment or issuance, as the case may be, shall be a condition precedent to consummation of such Major Transaction. Concurrently upon closing of such Successor Major Transaction, the Company shall pay or issue, as the case may be, or shall instruct any escrow agent for the transaction to pay or issue, and will cause the Successor Entity to issue and/or pay, the applicable Successor Consideration, plus accrued and unpaid interest through the date of payment. Any Major Transaction Company Shares issuable in respect of a Company Share Major Transaction shall be issued to the Holder within three (3) Trading Days following the date of each Major Transaction Conversion Notice.
 
(e)            Damages. Following the receipt of a Major Transaction Conversion Notice from the Holder, in the event that the Company attempts to consummate a Successor Major Transaction without obtaining the written agreement of the Successor Entity described in subsection (d) above, the Holder shall have the right to apply for an injunction in any state or federal courts sitting in the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Successor Consideration is satisfied to the Holder in full.

Notwithstanding anything to the contrary contained herein and without derogating any obligations or rights herein, until the Holder receives its appropriate payment or securities, plus any accrued and unpaid interest under this Note, in accordance with the provisions of this Section 3, this Note may be converted, in whole or in part, by the Holder into Shares, or in the event that such payments and/or shares have not been delivered prior to the consummation of the Successor Major Transaction in which the Company is not the surviving parent entity, Common Shares (or their equivalent) of the Successor Entity at an appropriate conversion price based upon the prevailing Conversion Rate (as adjusted hereunder) at the time of such Major Transaction and price per share or conversion ratio received by holders of Common Shares in the Major Transaction.

4.            Registration Failures. Upon any Registration Failure, in addition to all other available remedies that the Holder may pursue hereunder and under the Facility Agreement, the Registration Rights Agreement and this Note, the Company shall pay additional damages to the Holder for each 30-day period (prorated for any partial period) after the date of such Registration Failure in an amount in cash equal to one and one-half percent (1.5%) of such Holder’s original principal amount of this Note on the date of such Registration Failure. Such payments shall accrue until the earlier of (i) such time as the Registration Failure has been cured
 
 
84

 
 
and (ii) the date on which all of the Conversion Shares may be sold without restriction under Rule 144 (including, without limitation, volume restrictions and without the need for the availability of current public information under Rule 144). All such payments that accrue under this Section 4 shall be payable no later than five (5) business days following such date of accrual.

5.            Voting Rights. Except as required by law, the Holder shall have no voting rights with respect to any of the Conversion Shares until delivery of the Conversion Notice relating to the conversion of this Note upon which such Conversion Shares are issuable.

6.            Participation. The Holder, as the holder of this Note, shall be entitled to receive such dividends paid and distributions of any kind made to the holders of Common Shares to the same extent as if the Holder had converted this Note into Common Shares (without regard to any limitations on exercise herein or elsewhere and without regard to whether or not a sufficient number of shares are authorized and reserved to effect any such exercise and issuance) and had held such Common Shares on the record date for such dividends and distributions. Payments under the preceding sentence shall be made concurrently with the dividend or distribution to the holders of Common Shares.

7.           Certain Provisions Related to Common Shares Issued Hereunder.
 
(a)           Sufficient Common Shares.  The Company shall provide, free from preemptive rights, out of the Company’s authorized but unissued shares or shares held in treasury, sufficient Common Shares to provide for conversion of the Notes held by the Holder from time to time as such Notes are presented for conversion (assuming that at the time of computation of such number of Common Shares, all such Notes would be converted by the Holder into Conversion Shares (without regard to the 9.985% Cap)).
 
(b)           Fully-Paid.  The Company covenants that all Common Shares issued upon conversion of Notes held by the Holder will be fully paid by the Company and free from all taxes, liens and charges with respect to the issue thereof.
 
8.            Amendment; Waiver. The terms and provisions of this Note shall not be amended or waived except in a writing signed by the Company and the Required Note Holders.

9.            Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note, the Facility Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief). No remedy contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy, and nothing herein shall limit the Holder’s right to pursue actual damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any
 
 
85

 
 
breach, without the necessity of showing economic loss and without any bond or other security being required.

10.            Specific Shall Not Limit General; Construction. No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Company and all purchasers of Notes pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

11.            Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

12.            Notices. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.2 of the Facility Agreement.

13.            Restrictions on Transfer.

(a)            Registration or Exemption Required. This Note has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of the exemption provided by Section 3(a)(10) thereof. None of the Note or the Conversion Shares may be pledged, transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws including, without limitation, a so-called “4(1) and a half” transaction.

(b)            Assignment. Subject to Section 13(a), the Holder may sell, transfer, assign, pledge, hypothecate or otherwise dispose of this Note, in whole or in part. Holder shall deliver a written notice to Company, substantially in the form of the Assignment attached hereto as Exhibit B, indicating the Person or Persons to whom the Note shall be assigned and the respective principal amount of the Note to be assigned to each assignee. The Company shall effect the assignment within five (5) Trading Days (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Note or Notes of like tenor and terms for the appropriate principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Holder. The provisions of this Note are intended to be for the benefit of all Holders from time to time of this Note, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4(1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for the Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4(1) and half” transaction.
 
14.            Obligations of the Company. For so long as any conversion rights under this Note remain capable of being exercised, the Company will (a) keep available for issue
 
 
86

 
 
out of its authorized but unissued shares capital free from pre-emptive rights such number of Common Shares as would enable the Conversion Shares to be issued in full, and (b) will not, without the consent of the Holder, make any alteration to its articles of association which could have a material adverse effect on the rights attaching to the Common Shares or the rights of the Holder.

15.            Payment of Collection, Enforcement and Other Costs. If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Holder in any bankruptcy, reorganization, receivership of the Company or other proceedings affecting Company creditors’ rights and involving a claim under this Note, then the Company shall pay the costs incurred by the Holder for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements.

16.            Cancellation. After all Principal, Interest and other amounts at any time owed under, or on account of, this Note have been paid in full or converted into Shares in accordance with the terms hereof, this Note shall automatically be deemed cancelled, shall be surrendered to the Company for cancellation and shall not be reissued.

17.            Registered Note. In order to qualify as a “registered note” for purposes of the Code, transfer of this Note may be effected only by (i) surrender of this Note to the Company and the re-issuance of this Note to the transferee, or the Company’s issuance to the Holder of a new note in the same form as this Note but with the transferee denoted as the Holder, or (ii) the recording of the identity of the transferee by the Affiliate of the Holder that is maintaining a record ownership register of this Note as a non-fiduciary agent of, and on behalf of, the Company for the tax purposes set forth herein. Such Affiliate in its capacity as such agent shall notify the Company in writing immediately upon any change in such identity. Any attempted transfer in violation of the relevant provisions of this Note shall be void and of no force and effect. Until there has been a valid transfer of this Note and of all of the rights hereunder by the Holder in accordance with this Note, the Company shall deem and treat the Holder as the absolute beneficial owner and holder of this Note and of all of the rights hereunder for all purposes (including, without limitation, for the purpose of receiving all payments to be made under this Note).
 
18.            Waiver of Notice. To the extent permitted by law, the Company hereby waives demand, notice, presentment, protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Facility Agreement.

19.            Governing Law. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note and all disputes arising hereunder shall be governed by, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware and without prejudice to the applicability of the laws of the Province of British Columbia, Canada or Ontario, Canada, as the
 
 
87

 
 
case may be and, in either case, under the federal laws of Canada applicable thereunder, to the issuance of Shares pursuant to the Note. The Company (a) agrees that any legal action or proceeding with respect to this Note or any other agreement, document, or other instrument executed in connection herewith, shall be brought exclusively in any state or federal court located within Wilmington, Delaware, (b) irrevocably waives any objections which the Company may now or hereafter have to the venue of any suit, action or proceeding arising out of or relating to this Note, or any other agreement, document, or other instrument executed in connection herewith, brought in the aforementioned courts, (c) further irrevocably waives any claim that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum and (d) hereby consents that personal service of summons or other legal process may be made as set forth in Section 6.5 of the Facility Agreement. EACH OF THE COMPANY AND THE HOLDER (BY ACCEPTANCE HEREOF) IRREVOCABLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING BROUGHT TO ENFORCE ANY PROVISION OF THIS NOTE OR ANY OTHER TRANSACTION DOCUMENT.

20.            Interpretative Matters. Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a stock split, stock dividend, stock combination or other similar event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such event.

21.            Execution. A facsimile, telecopy, PDF or other reproduction of this Note may be delivered by the Company, and an executed copy of this Note may be delivered by the Company by facsimile, electronic mail or other similar electronic transmission device pursuant to which the signature of or on behalf of the Company can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. The Company hereby agrees that it shall not raise the execution of facsimile, PDF or other reproduction of this Note, or the fact that any signature was transmitted by facsimile, electronic mail or other similar electronic transmission device, as a defense to the Company’s execution of this Note. Notwithstanding the foregoing, the Company shall be required to deliver an originally executed Note to the Holder.
 
 [Signature page follows]
 
 
88

 

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the date first set forth above.

GIVEN UNDER THE COMMON SEAL OF ARALEZ PHARMACEUTICALS INC.

 
   
 
 
[Title]
 
     
     
 
   
 
 
[Title]
 
 
 
89

 
 
Exhibit A
 
CONVERSION NOTICE

Reference is made to the Senior Secured Convertible Note (the “Note”) of Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “Company”), in the original principal amount of $[__________]. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into Common Shares (the “Common Shares”), of the Company, as of the date specified below.
 
 
Date of Conversion:                                 
       
 
Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):
       
 
   
 
       
 
Principal, applicable thereto, to be converted:      
    
  
       
Please confirm the following information:
       
 
Conversion Price:
   
  
       
 
Number of Common Shares to be issued:
     
  
       
Please issue Common Shares into which the Note is being converted in the following name and to the following address:
       
 
Issue to:
  
       
 
Facsimile Number:
   
       
 
E-mail Address:
   
       
 
Authorization:
    
  
       
   
By:
   
   
 
   
Title:
   
   
 
       
 
Dated:
      
   
 
       
 
DTC Participant Number and Name (if electronic book entry transfer):
   
 
Account Number (if electronic book entry transfer):
   

 
 
90

 
 
Exhibit B
 
ASSIGNMENT

(To be executed by the registered holder
desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached Senior Secured Convertible Note (the “Note”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $__________ from Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada, evidenced by the attached Note and does hereby irrevocably constitute and appoint __________ attorney to transfer the said Note on the books of the Company, with full power of substitution in the premises.

Dated:
   
Signature
     

Fill in for new registration of Note:

   
Name
 
   
   
Address
 
   
   
Please print name and address of assignee
 
(including zip code number)
 

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note in every particular, without alteration or enlargement or any change whatsoever.
 
 
 
91

 
 
Exhibit C

FORM OF OPINION

______, 20__

[___________]

Re:            Aralez Pharmaceuticals Inc.

Dear Sir:

[___________] (“[__________]”) intends to transfer its Senior Secured Convertible Note in the principal amount of $_______ (the “Note”) of the Company to __________ (“________”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection herewith, we have examined such documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Note by _______ to ______ may be effected without registration under the Securities Act, provided, however, that the Note to be transferred to _______ contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Note is subject to a stop order.

The foregoing opinion is furnished only to ____________ and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,
 
 
 
 
92

 
 
Schedule 1

The Additional Share Coefficient” shall mean the number of additional Common Shares issuable per $1,000 of principal amount of the Note upon a Major Transaction and shall be the additional share number set forth on the chart with respect to the “Share Price Result” on the “y” axis and the corresponding “Remaining Note Life” on the “x” axis; provided, however, that to the extent the actual Share Price Result (as defined below) falls between two data points on the “y” axis and/or the actual date of the Major Transaction falls between two data points on the “x” axis, the “Additional Share Coefficient” shall be determined by calculating the arithmetic mean between (i) the result obtained for the Share Price Result based on the linear interpolation between the additional share numbers corresponding to the two Share Price Result data points and (ii) the result obtained for the Remaining Note Life based on the linear interpolation between the two additional share numbers corresponding to the two Remaining Note Life data points; and providedfurther, however, that in the event of any adjustment to the Conversion Price pursuant to Section 2 of this Note, the numbers of additional Common Shares issuable per $1,000 of principal amount of this Note as set forth in the chart below shall be deemed adjusted pro rata with any adjustment resulting from the adjustment to the Conversion Price that would be made to the number of Common Shares then convertible with respect to $1,000 of principal amount of this Note as calculated under Section 2 of this Note. For purposes of the chart below, the “Share Price Result” shall be the greater of: (i) the last sales price of Common Shares on NASDAQ, or, if that is not the principal trading market for Common Shares, such principal market on which Common Shares are traded or listed (the Closing Market Price”) immediately prior to the consummation of the Major Transaction or (ii) in the case of a Major Transaction in which holders of Common Shares receive solely cash consideration in connection with such major Transaction, the cash amount payable per share of Common Stock in such Major Transaction. If the actual Share Price Result is greater than $60 per share (subject to adjustment in the same manner as the Conversion Price as provided in Section 2 of this Note), or if the actual Shares Price Result is less than $5.00 per share (subject to adjustment in the same manner as the Conversion Price as provided in Section 2 of this Note), then the Additional Share Coefficient shall be equal to the amount applicable to $60 and $5, respectively.
 
 
 
93

 
 
Additional Shares per $1,000 Principal ($6.25 Pozen Purchase Price)

Remaining Note Life (Yrs)
 
       
            6       5       4       3       2       1       X  
      Y                                                          
Share Price Result ($)
                                                               
    5.00       54.206       47.964       40.827       32.537       22.693       10.685       0  
    10.00       52.732       48.104       42.735       36.361       28.489       17.944       0  
    15.00       29.625       26.126       22.127       17.493       12.024       5.490       0  
    20.00       19.423       16.679       13.606       10.158       6.321       2.329       0  
    25.00       13.916       11.699       9.267       6.625       3.848       1.295       0  
    30.00       10.570       8.735       6.762       4.681       2.605       0.877       0  
    35.00       8.367       6.820       5.185       3.509       1.910       0.672       0  
    40.00       6.832       5.506       4.129       2.752       1.487       0.555       0  
    45.00       5.715       4.564       3.387       2.235       1.211       0.478       0  
    50.00       4.874       3.864       2.845       1.868       1.021       0.423       0  
    55.00       4.223       3.328       2.437       1.596       0.884       0.381       0  
    60.00       3.707       2.908       2.121       1.390       0.781       0.347       0  
 
Additional Shares per $1,000 Principal ($7.20 Pozen Purchase Price)

Remaining Note Life (Yrs)
 
       
            6       5       4       3       2       1       X  
      Y                                                          
Share Price Result ($)
                                                               
    5.00       43.591       37.992       31.651       24.393       16.004       6.420       0  
    10.00       55.660       51.310       46.257       40.244       32.787       22.678       0  
    15.00       31.532       28.154       24.266       19.710       14.218       7.302       0  
    20.00       20.776       18.080       15.027       11.541       7.539       3.061       0  
    25.00       14.932       12.723       10.268       7.542       4.570       1.612       0  
    30.00       11.361       9.514       7.496       5.319       3.056       1.022       0  
    35.00       9.001       7.430       5.743       3.968       2.203       0.743       0  
    40.00       7.351       5.996       4.563       3.091       1.684       0.591       0  
    45.00       6.148       4.965       3.732       2.493       1.348       0.497       0  
    50.00       5.240       4.196       3.124       2.067       1.118       0.433       0  
    55.00       4.536       3.608       2.665       1.753       0.954       0.387       0  
    60.00       3.978       3.146       2.310       1.515       0.832       0.351       0  
 
[Schedules to be revised to reflect a Pozen Purchase Price between $6.25 and $7.20 in a manner consistent with the methodology applied in preparing the foregoing schedules]
 
 
94

 
 
Exhibit A-3
 
SECURED PROMISSORY NOTE
______, ____, 2015

FOR VALUE RECEIVED, Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “Maker”), by means of this Secured Promissory Note (this “Note”), hereby unconditionally promises to pay to _______________ (the “Payee”), a principal amount equal to the lesser of (a) Two Hundred Million Dollars ($200,000,000) and (b) the aggregate amount of Acquisition Loans allocated to the Payee pursuant to Section 2.3 of the Facility Agreement referenced below, in lawful money of the United States of America and in immediately available funds, on the dates provided in the Facility Agreement.

This Note is an “Acquisition Note” referred to in the Second Amended and Restated Facility Agreement dated as of December 7, 2015 between the Maker, the Payee and the other parties thereto (as modified and supplemented and in effect from time to time, the “Facility Agreement”), with respect to an Acquisition Loan made by the Payee thereunder and is secured by all Collateral pursuant to the Security Documents. Capitalized terms used herein and not expressly defined in this Note shall have the respective meanings assigned to them in the Facility Agreement.

This Note shall bear interest on the principal amount hereof pursuant to the provisions of the Facility Agreement.

The Maker shall make all payments to the Payee of interest and principal under this Note in the manner provided in and otherwise in accordance with the Facility Agreement.

If an Event of Default has occurred and is continuing, this Note may in accordance with the applicable provisions of the Facility Agreement, become immediately due and payable.

All payments of any kind due to the Payee from the Maker pursuant to this Note shall be made in the full face amount thereof. Subject to the terms of the Facility Agreement, all such payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Maker shall pay all and any costs (administrative or otherwise) imposed by the Maker’s banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Maker shall pay all costs of collection, including, without limitation, all reasonable, legal expenses and attorneys’ fees, paid or incurred by the Payee in collecting and enforcing this Note.

Other than those notices required to be provided by Payee to Maker under the terms of the Facility Agreement, the Maker and every endorser of this Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the
 
 
95

 
 
obligations under this Note and/or the Facility Agreement. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment of this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Maker or any endorser of this Note.
 
No delay or omission by the Payee in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Note may be waived or amended only in a writing signed by the Maker and the Payee. This Note may not be prepaid in whole or in part, except in accordance with the provisions of the Facility Agreement.

This Note, and any rights of the Payee arising out of or relating to this Note, may, at the option of the Payee, be enforced by the Payee in the courts of the United States of America located in the State of Delaware or in any other courts having jurisdiction. For the benefit of the Payee, the Maker hereby irrevocably agrees that any legal action, suit or other proceeding arising out of or relating to this Note may be brought in the courts of the State of Delaware or of the United States of America for the District of Delaware, and hereby consents that personal service of summons or other legal process may be made as set forth in Section 6.2 of the Facility Agreement, which service the Maker agrees shall be sufficient and valid. The Maker hereby waives any and all rights to demand a trial by jury in any action, suit or other proceeding arising out of or relating to this Note or the transactions contemplated by this Note.

This Note shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts made and to be performed in such State.

[Signature page follows]
 
 
96

 

IN WITNESS WHEREOF, an authorized representative of the Maker has executed this Note as of the date first written above.

 
ARALEZ PHARMACEUTICALS INC.
       
 
By:
    
 
   
Name:
 
   
Title:
 

 
 
97

EX-10.2 5 tbuff_ex102.htm SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT tbuff_ex102.htm
Exhibit 10.2
 
SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

This SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of  December 7, 2015, by and among Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “Company”), and those lenders set forth on Schedule 1 to the Amended Facility Agreement (as defined below) (each individually, a “Lender” and together, the “Lenders”).

WHEREAS:

A. The Lenders and certain other parties  previously executed and delivered that certain Registration Rights Agreement, dated as of June 8, 2015, as amended and restated on October 29, 2015 (the “Original Registration Rights Agreement”);

B. The Original Registration Rights Agreement was entered into in connection with a Facility Agreement, dated as of June 8, 2015, as amended and restated on October 29, 2015 (the “Original Facility Agreement”), which has now been further amended and restated as of December 7, 2015 (the “Amended Facility Agreement”);

C. The parties hereto desire to amend and restate the Original Registration Rights Agreement to provide for certain appropriate changes required as a result of the Amended Facility Agreement;

D. Pursuant to the Amended Facility Agreement, Tribute Pharmaceuticals Canada Inc. (“Tribute”), a corporation formed under the laws of the Province of Ontario, Canada, has agreed, upon the terms and subject to the conditions contained therein, to issue and sell to the Lenders convertible notes (the “Tribute Notes”) in the amount described in the Amended Facility Agreement, where each of the Tribute Notes may be convertible into common shares, no par value per share, of Tribute, upon the terms and conditions and subject to the limitations and conditions set forth in the Tribute Notes, all subject to the terms and conditions of the Amended Facility Agreement;

E.Upon consummation of the plan of arrangement under the Arrangement Agreement (as defined in the Facility Agreement), the Tribute Notes held by the Lenders will be sold, assigned and transferred to the Company in exchange for senior secured convertible notes of the Company (the “Convertible Notes”), where each of the Convertible Notes may be convertible into common shares of the Company (the “Common Shares”), upon the terms and conditions and subject to the limitations and conditions set forth in the Convertible Notes, all subject to the terms and conditions of the Amended Facility Agreement and the foregoing plan of arrangement; and

F. To induce the Lenders to execute and deliver the Amended Facility Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws,

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Lenders hereby agree as follows:

1. DEFINITIONS.

a. As used in this Agreement, the following terms shall have the following meanings:

(i) “Additional Filing Deadline” means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(ii), (a) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (b) if such additional Registration Statement is required for a reason other than as described in (a) above, the tenth (10th) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required.

(ii) “Additional Registration Deadline” means, with respect to any additional Registration Statement(s) that may be required to be filed pursuant to Section 2(a)(ii), the thirtieth (30th) day following (a) the first date or time that such
 
 
 

 
 
Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (b) if such additional Registration Statement is required for a reason other than as described in (a) above, the fortieth (40th) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement(s) is required.

(iii) “Buyer” means any Lender and any transferee or assignee who agrees to become bound by the provisions of this Agreement in accordance with Section 10 hereof.

(iv) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, and any successor statute.

(v) “Filing Deadline,” shall mean January 15, 2016 in the case of the Registration Statement required to be filed under Section 2(a)(i), and, in the case of Section 2(a)(ii) shall mean the Additional Filing Deadline.

(vi) “Person” means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

(vii) “Register,” “Registered,” and “Registration” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415 under the Securities Act or any successor rule providing for offering securities on a continuous basis, and the declaration or ordering of effectiveness of such Registration Statement by the United States Securities and Exchange Commission (the “SEC”).

(viii) “Registrable Securities,” for a given Registration, means (a) any Common Shares (the “Conversion Shares”) issued or issuable upon conversion of or otherwise pursuant to the Convertible Notes (without giving effect to any limitations on conversion set forth in the Convertible Notes), (b) any shares of capital stock issued or issuable as a dividend on or in exchange for or otherwise with respect to any of the foregoing, (c) any additional Common Shares issuable in connection with any anti-dilution provisions in the Convertible Notes and (d) any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing.

(ix) “Registration Deadline” shall mean (i) forty-five (45) days after the date of issuance of the Convertible Notes in the case of the Registration Statement required under Section 2(a)(i), and (ii) the Additional Registration Deadline in the case of a Registration Statement required under Section 2(a)(ii).

(x) “Registration Statement(s)” means a registration statement(s) of the Company under the Securities Act required to be filed hereunder.

2. REGISTRATION.

a. MANDATORY REGISTRATION.  (i) The Company shall prepare, and on or prior to the Filing Deadline (as defined above) file with the SEC a Registration Statement (the “Mandatory Registration Statement”) on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a registration of the Registrable Securities, subject to the consent of the Buyers, which consent will not be unreasonably withheld) covering the resale of the Registrable Securities which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration Statement also covers such indeterminate number of additional Common Shares as may become issuable upon conversion of or otherwise pursuant to the Convertible Notes to prevent dilution resulting from stock splits, stock dividends, stock issuances or similar transactions. The number of Common Shares initially included in such Registration Statement shall be no less than the aggregate number of Conversion Shares that are then issuable upon conversion of or otherwise pursuant to the Convertible Notes, without regard to any limitation on the Buyers’ ability to convert the Convertible Notes.  The Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and subject to the approval of) the Buyers and their counsel prior to its filing or other submission.
 
 
2

 

(ii) If for any reason the SEC does not permit all of the Registrable Securities to be included in the Registration Statement filed pursuant to Section 2(a)(i) above, or for any other reason any Registrable Securities are not then included in a Registration Statement filed under this Agreement, then the Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415.

b. PIGGY-BACK REGISTRATIONS. If at any time prior to the expiration of the Registration Period (as hereinafter defined) the Company shall determine to file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its securities (other than debt securities or securities being registered on Form S-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), the Company shall send to each Buyer written notice of such determination and, if within fifteen (15) days after the effective date of such notice, the Buyer shall so request in writing, the Company shall include in such Registration Statement all or any part of such Buyer’s Registrable Securities the  requests to be registered, except that if, in connection with any underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall impose a limitation on the number of Registrable Securities which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Buyer has requested inclusion hereunder as the underwriter shall permit;

PROVIDED, HOWEVER, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled by contract to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities; and

PROVIDED, FURTHER, HOWEVER, that, after giving effect to the immediately preceding proviso, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in the Registration Statement other than holders of securities entitled to inclusion of their securities in such Registration Statement by reason of demand registration rights. No right to registration of Registrable Securities under this Section 2(b) shall be construed to limit any registration required under Section 2(a) hereof. If an offering in connection with which a Buyer is entitled to registration under this Section 2(b) is an underwritten offering, then such Buyer shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other Common Shares included in such underwritten offering.  Notwithstanding anything to the contrary set forth herein, the registration rights of the Buyer pursuant to this Section 2(b) shall only be available in the event the Company fails to timely file, obtain effectiveness or maintain effectiveness of any Registration Statement to be filed pursuant to Section 2(a) in accordance with the terms of this Agreement.

3.  OBLIGATIONS OF THE COMPANY. In connection with the registration of the Registrable Securities, the Company shall have the following obligations:

a. The Company shall prepare promptly, and file with the SEC by the Filing Deadline, a Registration Statement with respect to the number of Registrable Securities provided in Section 2(a), and thereafter use its best efforts to cause each Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall cause each such Registration Statement relating to Registrable Securities to become effective no later than the Registration Deadline, and shall keep the Registration Statement current and effective pursuant to Rule 415 at all times until such date as is the earlier of (i) the date on which all of the Registrable Securities for such Registration Statement have been sold and (ii) the one-year anniversary of the date of issuance of the Convertible Notes (the “Registration Period”), which Registration Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided by a Buyer or any transferee of a Buyer pursuant to Section 4(a), shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading.
 
 
3

 

b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with each Registration Statement as may be necessary to keep each Registration Statement current and effective at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in each Registration Statement.  In the event that on any Trading Day (as defined below) (the “Registration Trigger Date”) the number of shares available under the Registration Statements filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities issued or issuable upon conversion of the Convertible Notes or otherwise pursuant to the Convertible Notes, including, without limitation, any additional Common Shares issued in connection with any anti-dilution provisions contained in the Convertible Notes, without giving effect to any limitations on the Buyers’ ability to convert the Convertible Notes, the Company shall amend the Registration Statements, or file a new Registration Statement (on the short form available therefore, if applicable), or both, so as to cover the total number of Registrable Securities so issued or issuable (without giving effect to any limitations on conversion contained in the Convertible Notes) as of the Registration Trigger Date as soon as practicable, but in any event within twenty (20) days after the Registration Trigger Date (based on the Conversion Price (as defined in the Convertible Notes) of the Convertible Notes, and other relevant factors on which the Company reasonably elects to rely). The Company shall use its best efforts to cause such amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event the Company shall cause such amendment and/or new Registration Statement to become effective within forty-five (45) days of the Registration Trigger Date or as promptly as practicable in the event the Company is required to increase its authorized shares.  “Trading Day” shall mean any day on which the Common Shares are traded for any period on the NASDAQ Global Market, or on the principal securities exchange or other securities market on which the Common Shares are then being traded.

c. The Company shall furnish to each Buyer and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto, and, in the case of a Registration Statement referred to in Section 2(a), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as a Buyer may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Buyer. The Company will immediately notify the Buyers by facsimile of the effectiveness of each Registration Statement or any post-effective amendment. The Company will promptly respond to any and all comments received from the SEC, with a view towards causing each Registration Statement or any amendment thereto to be declared effective by the SEC as soon as practicable and shall file an acceleration request as soon as practicable, but no later than three (3) business days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review.

d. The Company shall use its best efforts to (i) register and qualify, in any jurisdiction where registration and/or qualification is required, the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States as the Buyers shall reasonably request, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions.

e.  As promptly as practicable after becoming aware of such event, the Company shall notify each Buyer of the happening of any event, of which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and use its best efforts
 
 
4

 
 
promptly to prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and deliver such number of copies of such supplement or amendment to each Buyer as such Buyer may reasonably request.

f. The Company shall use its best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify each Buyer who holds Registrable Securities being sold (or, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof.

g. The Company shall permit a single firm of counsel designated by the Buyers to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof), at Buyers’ own cost, a reasonable period of time prior to their filing with the SEC (not less than five (5) business days but not more than eight (8) business days) and not file any documents in a form to which such counsel reasonably objects and will not request acceleration of such Registration Statement without prior notice to such counsel.

h. The Company shall hold in confidence and not make any disclosure of information concerning a Buyer provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning such Buyer is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Buyer prior to making such disclosure, and allow such Buyer, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

i. The Company shall use its best efforts to cause all the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, and, if listed on a national exchange, to arrange for at least two market makers to register with the Financial Industry Regulatory Authority, Inc. (“FINRA”) as such with respect to such Registrable Securities.

j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the initial Registration Statement.

k. The Company shall cooperate with each Buyer who holds Registrable Securities being offered and the managing underwriter or underwriters with respect to an applicable Registration Statement, if any, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to such Registration Statement and enable such certificates to be in such denominations or amounts, as the case may be, as the managing underwriter or underwriters, if any, or the Buyer may reasonably request and registered in such names as the managing underwriter or underwriters, if any, or the Buyer may request, and, within three (3) business days after a Registration Statement which includes Registrable Securities is ordered effective by the SEC, the Company shall deliver, and shall cause legal counsel selected by the Company to deliver, to the transfer agent for the Registrable Securities (with copies to each Buyer) an appropriate instruction and an opinion of such counsel in the form required by the transfer agent in order to issue the Registrable Securities free of restrictive legends.

l. At the request of a Buyer, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement.

m. The Company shall not, and shall not agree to, allow the holders of any securities of the Company to include any of their securities in any Registration Statement under Section 2(a) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of the Buyers.  In addition, the Company shall not offer any securities
 
 
5

 
 
for its own account or the account of others in any Registration Statement under Section 2(a) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of the Buyers.

n. The Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Buyers of Registrable Securities pursuant to a Registration Statement.

o. The Company shall comply with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules and regulations of governmental authorities in connection therewith (including, without limitation, the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC).

p.  If required by the Financial Industry Regulatory Authority, Inc. Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. The Company shall use commercially reasonable efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering contemplated by the Registration Statement.

4. OBLIGATIONS OF THE BUYER. In connection with the registration of the Registrable Securities, each Buyer shall have the following obligations:

a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of a Buyer that such Buyer shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least five (5) business days prior to the first anticipated filing date of a Registration Statement, the Company shall notify each Buyer of the information the Company requires from such Buyer.  Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading.

b. Each Buyer, by such Buyer’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Buyer has notified the Company in writing of the Buyer’s election to exclude all of the Buyer’s Registrable Securities from such Registration Statement.

c. In the event of an underwritten offering pursuant to Section 2(b) in which any Registrable Securities are to be included, the Buyer agrees to enter into and perform the Buyer’s obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the managing underwriter of such offering and take such other actions as are reasonably required in order to expedite or facilitate the disposition of the Registrable Securities, unless the Buyer has notified the Company in writing of the Buyer’s election to exclude all of the Buyer’s Registrable Securities from such Registration Statement.

d. Each Buyer agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(e) or 3(f), the Buyer will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until the Buyer’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 3(e) or 3(f) and, if so directed by the Company, the Buyer shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in the Buyer’s possession, of the prospectus covering such Registrable Securities current at the time of receipt of such notice.

5. REGISTRATION FAILURE.  In the event of a Registration Failure (as defined in the Convertible Notes), the Buyers shall be entitled to the payments provided in the Convertible Notes and such other rights as they may have under the Amended Facility Agreement, the Convertible Notes and hereunder.

6. EXPENSES OF REGISTRATION. All reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3,
 
 
6

 
 
including, without limitation, all registration, listing and qualification fees, printers and accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company.

7. INDEMNIFICATION. In the event any Registrable Securities are included in a Registration Statement under this Agreement:

a. The Company will indemnify, hold harmless and defend (i) each Buyer, (ii) the directors, officers, partners, managers, members, employees, agents and each Person who controls any Buyer within the meaning of the Securities Act or the Exchange Act, if any, (iii) any underwriter (as defined in the Securities Act) for each Buyer in connection with an underwritten offering pursuant to Section 2(b) hereof, and (iv) the directors, officers, partners, employees and each Person who controls any such underwriter within the meaning of the Securities Act or the Exchange Act, if any (each, an “Indemnified Person”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Claims”) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus if used prior to the effective date of such Registration Statement, or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The Company shall reimburse the Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.  Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 7(a) shall not apply to a Claim arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing to the Company by any Indemnified Person for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto.  Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Buyer pursuant to Section 10.

b. Promptly after receipt by an Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnified Person, as the case may be.

PROVIDED, HOWEVER, that an Indemnified Person shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the Company, if, in the reasonable opinion of counsel for the Buyer, the representation by such counsel of the Indemnified Person and the Company would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel for the Indemnified Persons, and such legal counsel shall be selected by Buyers. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 7, except to the extent that the Company is actually prejudiced in its ability to defend such action. The indemnification required by this Section 7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.

c.  Each Buyer will indemnify, hold harmless and defend (i) the Company, and (ii) the directors, officers, partners, managers, members, employees, or agents of the Company, if any (each, a “Company Indemnified Person”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings
 
 
7

 
 
or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Indemnity Claims”) to which any of them may become subject insofar as such Claims arise out of or are based upon any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities, which occurs due to the inclusion by the Company in a Registration Statement of false or misleading information about a Buyer, where such information was furnished in writing to the Company by such Buyer for the purpose of inclusion in such Registration Statement.  Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section 7(c) shall not apply to amounts paid in settlement of any Indemnity Claim if such settlement is effected without the prior written consent of the Buyers which consent shall not be unreasonably withheld or delayed; and provided, further, however, that a Buyer shall be liable under this Section 7(c) for only that amount of an Indemnity Claim as does not exceed the net amount of proceeds received by such Buyer as a result of the sale of Registrable Securities pursuant to such Registration Statement.

d.  Promptly after receipt by a Company Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Company Indemnified Person shall, if an Indemnity Claim in respect thereof is to be made against a Buyer under this Section 7, deliver to such Buyer a written notice of the commencement thereof, and such Buyer shall have the right to participate in, and, to the extent such Buyer so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Buyer and the Company Indemnified Person, as the case may be.
 
8.  CONTRIBUTION.  To the extent any indemnification by the Company is prohibited or limited by law, the Company agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 7 to the fullest extent permitted by law, based upon a comparative fault standard.
 
9.  REPORTS UNDER THE 1934 ACT.  With a view to making available to the Buyers the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Buyers to sell securities of the Company to the public without registration the Company agrees to:
 
a.  make and keep public information available, as those terms are understood and defined in Rule 144;
 
b.  file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and
 
c.  so long as the Buyers own Registrable Securities, promptly upon request, furnish to the Buyers (i) a written statement by the Company that it has complied with the reporting requirements of the Securities Act and the Exchange Act as required for applicable provisions of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested to permit the Buyers to sell such securities pursuant to Rule 144 without registration.
 
10.  ASSIGNMENT OF REGISTRATION RIGHTS.  The rights under this Agreement shall be automatically assignable by each Buyer to any transferee of all or any portion of the Registrable Securities if:  (i) the Buyer agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration rights are being transferred or assigned, and (iii) at or before the time the Company receives the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein.  In the event that a Buyer transfers all or any portion of its Registrable Securities pursuant to this Section, the Company shall have at least ten (10) days to file any amendments or supplements necessary to keep a Registration Statement current and effective pursuant to Rule 415, and the commencement date of any Event of Default (as defined in the Convertible Notes) under the Convertible Notes caused thereby will be extended by ten (10) days.
 
 
8

 
 
11.  AMENDMENT OF REGISTRATION RIGHTS.  Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the holders of a majority in interest of then-outstanding Registrable Securities.  Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each of the Buyers and the Company.
 
12.  MISCELLANEOUS.
 
a.  A Person is deemed to be a holder of Registrable Securities whenever such Person owns of record or beneficially through a “street name” holder such Registrable Securities.  If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities.
 
b.  Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile and shall be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed to a party.  The addresses for such communications shall be:
 
If to the Company:
 
Aralez Pharmaceuticals Inc.
c/o DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St. W
Toronto, Ontario
M5X 1E2
Canada
Fax:  (919) 490-5552
Attn: Andrew Koven


With copy (which shall not constitute notice) to:

DLA Piper LLP (US)
51 John F. Kennedy Parkway, Suite 120
Short Hills, New Jersey  07098-2704
Fax:  (973) 520-2573
Attn:  Andrew Gilbert, Esq.

If to a Buyer:
 
c/o Deerfield Mgmt, L.P.
780 Third Avenue, 37th Floor
New York, New York 10017
Fax:  (646) 536-5662
Attn:  David J. Clark
 
With a copy (which shall not constitute notice) to:
Katten Muchin Rosenman LLP
575 Madison Avenue
New York, New York 10022
Fax:  (212) 940-8776
Attn:  Mark I. Fisher, Esq.
           Elliot Press, Esq.
 
 
9

 
 
Each party shall provide notice to the other party of any change in address.
 
c.  Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.
 
d.  Governing Law.  All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.  Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.  The parties hereby waive all rights to a trial by jury.  If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
 
e.  This Agreement, the Convertible Notes and the Amended Facility Agreement (including all schedules and exhibits thereto) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof.  There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein.  This Agreement, the Convertible Notes and the Amended Facility Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.
 
f.  Subject to the requirements of Section 10 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable).
 
g.  The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
 
h.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement.  This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile or other electronic transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.
 
i.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
 
j.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyers by vitiating the intent and purpose of the transactions contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by the Company of any of the provisions hereunder, that the Buyers shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.
 
 
10

 
 
k.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
 
l.  In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.
 
m.  In the event a Buyer shall sell or otherwise transfer any of such holder’s Registrable Securities, each transferee shall be allocated a pro rata portion of the number of Registrable Securities included in a Registration Statement for such transferor.
 
n.  There shall be no oral modifications or amendments to this Agreement.  This Agreement may be modified or amended only in writing.
 
[Remainder of page left intentionally blank]
 
[Signature page follows]
 
 
11

 
 
IN WITNESS WHEREOF, the undersigned Buyers and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.
 
COMPANY:
 
ARALEZ PHARMACEUTICALS INC.
 
 
By:  /s/ Andrew Koven
Name:   Andrew Koven
Title:     President
BUYERS:
 
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By:  Deerfield Mgmt III, L.P., General Partner
By:  J.E. Flynn Capital III, LLC, General Partner
 
By:  /s/ David J. Clark
Name:     David J. Clark
Title:       Authorized Signatory
   
 
 
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By:  Deerfield Mgmt, L.P., General Partner
By:  J.E. Flynn Capital, LLC, General Partner
 
By:  /s/ David J. Clark
Name:     David J. Clark
Title:       Authorized Signatory
   
 
 
DEERFIELD PARTNERS, L.P.
By:  Deerfield Mgmt, L.P., General Partner
By:  J.E. Flynn Capital, LLC, General Partner
 
By:  /s/ David J. Clark
Name:     David J. Clark
Title:       Authorized Signatory
   
   

 
 
 
 
[Second Amended and Restated Registration Rights Agreement]

EX-10.3 6 tbuff_ex103.htm AMENDED AND RESTATED SHARE SUBSCRIPTION AGREEMENT tbuff_ex103.htm
Exhibit 10.3
 
 
AMENDED AND RESTATED
 
SHARE SUBSCRIPTION AGREEMENT
 
by and among
 
ARALEZ PHARMACEUTICALS INC.,
 
ARALEZ PHARMACEUTICALS PLC,
 
TRIBUTE PHARMACEUTICALS CANADA INC.,
 
POZEN INC.,
 
QLT INC.
 
and
 
THE OTHER CO-INVESTORS IDENTIFIED
 
ON SCHEDULE I HERETO
 
_______________
 
Dated as of December 7, 2015
 

 
 
 

 

TABLE OF CONTENTS
 
    Page
ARTICLE I DEFINITIONS
2
1.1
Certain Definitions.
2
1.2
Terms Defined Elsewhere in this Agreement.
4
1.3
Other Definitional and Interpretive Matters.
5
ARTICLE II SUBSCRIPTION FOR SHARES; SUBSCRIPTION PRICE; INVESTMENT CLOSING
6
2.1
Subscription for Shares.
6
2.2
Payment of Subscription Price; Allotment of Shares.
6
2.3
Investment Closing.
7
2.4
Tribute Deliveries.
7
2.5
Pozen Deliveries.
7
2.6
Co-Investor Deliveries.
7
2.7
Company Deliveries.
8
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY; TRIBUTE; POZEN
8
3.1
Representations and Warranties of the Company.
8
3.2
Representations and Warranties of Pozen.
10
3.3
Representations and Warranties of Tribute.
11
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE CO-INVESTORS
14
4.1
Representations and Warranties of the Co-Investors.
14
ARTICLE V COVENANTSAND AGREEMENTS
17
5.1
Furnishing Information.
17
5.2
Filings; Commercially Reasonable Efforts; Notification.
17
5.3
NASDAQ and TSX Listing.
18
5.4
Further Assurances.
18
 
 
 

 
 
TABLE OF CONTENTS
(continued)
 
    Page
5.5
Advice of Changes.
19
5.6
Governance Matters.
19
5.7
Cooperation.
20
5.8
Equal Treatment of Purchaser and the Investors.
20
5.9
Investors’ Registration Rights.
21
5.1
Purchaser’s Registration Rights.
21
ARTICLE VI CONDITIONS TO INVESTMENT CLOSING
21
6.1
Mutual Conditions.
21
6.2
Co-Investor’s Conditions.
22
6.3
Company’s Conditions.
23
ARTICLE VII TERMINATION
24
7.1
Termination.
24
7.2
Procedure Upon Termination.
25
7.3
Effects of Termination.
25
ARTICLE VIII MISCELLANEOUS
25
8.1
Survival.
25
8.2
Expenses.
25
8.3
Counterparts; Effectiveness.
25
8.4
Governing Law.
26
8.5
Jurisdiction; Specific Enforcement.
26
8.6
WAIVER OF JURY TRIAL.
26
8.7
Notices.
27
8.8
Assignment; Binding Effect.
29
8.9
Severability.
30
8.10
Independent Legal and Investment Advice.
30
 
 
II

 
 
TABLE OF CONTENTS
(continued)
 
    Page
8.11
Entire Agreement.
30
8.12
Amendments; Waivers.
30
8.13
Headings.
30
8.14
No Third-Party Beneficiaries.
30
8.15
Obligations of the Co-Investors and the Company.
31

SCHEDULE I                           Schedule of Co-Investors
ANNEX A                               Investors’ Registration Rights
ANNEX B                                Purchaser’s Registration Rights
 
 
III

 
 
AMENDED AND RESTATED SHARE SUBSCRIPTION AGREEMENT
 
This AMENDED AND RESTATED SHARE SUBSCRIPTION AGREEMENT, dated as of December 7, 2015 (the “Agreement”), is by and among QLT Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“Purchaser”), Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (“Tribute”), POZEN Inc., a corporation formed under the laws of the State of Delaware (“Pozen”), Aralez Pharmaceuticals plc, a public limited company formed under the laws of Ireland (formerly known as Aguono Limited, a private limited company formed under the laws of Ireland, and subsequently renamed Aralez Pharmaceuticals Limited prior to its re-registration as a public limited company named Aralez Pharmaceuticals plc) (the “Former Company”), Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “Company”) and, other than Purchaser, the Persons identified on Schedule I hereto (each an “Investor” and together, the “Investors”).
 
W I T N E S S E T H:
 
WHEREAS, on June 8, 2015, Purchaser, Tribute, Pozen, the Former Company (as “Aguono Limited”) and the Investors entered into the Share Subscription Agreement (the “Original Agreement”) whereby, following the Merger Effective Time and the Arrangement Effective Time, the parent company of Pozen and Tribute would be domiciled in Ireland;
 
WHEREAS, on October 29, 2015, Purchaser, Tribute, Pozen, the Former Company (as “Aralez Pharmaceuticals Limited”) and the Investors entered into that certain Amendment No. 1 to Share Subscription Agreement to provide for the revised filing deadline of a Canadian preliminary prospectus with the Canadian Commissions;
 
WHEREAS, Purchaser, Tribute, Pozen, the Former Company, the Company and the Investors desire to terminate the Original Agreement and amend and restate the Original Agreement in its entirety to add the Company as a party to this Agreement and to remove the Former Company as a party to this Agreement, whereby, following the Merger Effective Time and the Arrangement Effective Time, the parent company of Pozen and Tribute will be domiciled in British Columbia, Canada;
 
WHEREAS, Tribute and Pozen wish to enter into a business combination transaction (the “Mergers”), pursuant to the terms of the Merger Agreement described below;
 
WHEREAS, the Mergers will be effected in accordance with that certain Agreement and Plan of Merger and Arrangement, as amended (the “Merger Agreement”), by and among the Company, Tribute, Pozen, ARLZ CA Acquisition Corp., a corporation formed under the laws of the Province of Ontario, Canada (“Merger Sub One”) ARLZ US Acquisition II Corp., a corporation formed under the laws of the State of Delaware (“Merger Sub Two”), pursuant to which (i) Merger Sub One will amalgamate with Tribute (the “Tribute Merger”), with Tribute continuing as a wholly-owned direct subsidiary of the Company, and (ii) Merger Sub Two will merge with and into Pozen (the “Pozen Merger” and together with the Tribute Merger, the “Mergers”), with Pozen continuing as the surviving corporation of the Pozen Merger and as a wholly-owned indirect subsidiary of the Company;
 
 
 

 
 
WHEREAS, the parties desire to remove JW Opportunities Fund, LLC as a party to this Agreement and add JW Opportunities Master Fund, Ltd. as a party to this Agreement;
 
WHEREAS, Purchaser, together with the Investors (collectively, the “Co-Investors”), have agreed to provide capital to the Company in support of the Mergers;
 
WHEREAS, in furtherance of the foregoing, Tribute desires to allot and issue to the Co-Investors, and the Co-Investors desire to subscribe for, up to a maximum of 82,474,227 common shares of Tribute (the “Shares”) for the Subscription Price (as hereinafter defined) as set forth in, and in accordance with the other provisions of, this Agreement such that the Shares purchased by the Co-Investors are arranged in connection with the Tribute Merger pursuant to the Plan of Arrangement (as defined below) on the same basis as all other outstanding common shares of Tribute;
 
WHEREAS, following its subscription for its portion of the Shares, Purchaser may cause all or a portion of such securities to be distributed to its shareholders pursuant to a special election distribution effected by way of a reorganization of share capital of the Purchaser or a reduction in paid-up capital of their Purchaser Common Shares, and/or a plan of arrangement regarding the same (allowing Purchaser’s shareholders to receive such securities or cash, subject to possible proration) (the “Distribution”) and the Company has agreed to register such Distribution under the Securities Act of 1933 (the “Securities Act”) (all as defined below), with any portion of the Purchaser Shares not distributed to its shareholders to be sold and transferred on a private placement basis to certain of the Investors;
 
WHEREAS, the Company has agreed to grant the Investors and Purchaser the registration rights provided for herein; and
 
WHEREAS, certain terms used in this Agreement are defined in Section 1.1.
 
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements hereinafter contained, the parties hereby agree as follows:
 
ARTICLE I
 
DEFINITIONS
 
1.1 Certain Definitions.  Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Merger Agreement.
 
In addition, for purposes of this Agreement, the following terms shall have the meanings specified in this Section 1.1:
 
Canadian Securities Laws” means all applicable Canadian securities laws, rules, regulations, notices, instruments, blanket orders and policies in the Canadian Qualifying Provinces.
 
Commission” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.
 
Company Shares” means the common shares in the capital of the Company.
 
Governmental Authority” means any international, multinational, federal, provincial, territorial, state, regional, municipal, local or other government or governmental body and any ministry, department, division, bureau, agent, official, agency, commission, board or
 
 
 
2

 
 
authority of any government, governmental body, quasi-governmental or private body (including the TSXV, the TSX, the NASDAQ or any other applicable stock exchange), domestic or foreign, exercising any statutory, regulatory, expropriation or taxing authority under the authority of any of the foregoing and any domestic, foreign or international judicial, quasi-judicial or administrative court, tribunal, commission, board, panel, arbitrator or arbitral body acting under the authority of any of the foregoing.
 
Investor Shares” with respect to each Investor means a number of Shares equal to the quotient obtained by dividing the Subscription Price of such Investor by the Per Share Subscription Price.  For the avoidance of doubt, Investor Shares, in the aggregate, shall not include Purchaser Shares.
 
Law” any and all laws, statutes, codes, ordinances (including zoning), approvals, rules, regulations, instruments, by-laws, notices, policies, protocols, guidelines, guidance, manuals, treaties or other requirements of any Governmental Authority having the force of law and any legal requirements arising under the common law or principles of law or equity.
 
NASDAQ” means the NASDAQ Global Select Market.
 
Per Share Subscription Price” means the per Share price calculated by multiplying the Pozen Purchase Price by 0.1455.  The “Pozen Purchase Price” shall be equal to the lesser of (i) $7.20, and (ii) a five percent (5%) discount off the five (5) day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, calculated over the five (5) trading days immediately preceding the date of Closing; provided that in no event shall the Pozen Purchase Price be less than $6.25.  In the event any of Pozen, Tribute or Aralez announce a material event, whether by press release or filing of a Form 8-K (other than results of any shareholder meeting) during the ten (10) day period immediately preceding the Closing, then clause (ii) above shall be deemed amended and restated as follows: “(ii) a five percent (5%) discount off the two (2) day volume weighted average price as reported on Bloomberg Financial Markets (“VWAP”) per share of Pozen common stock, calculated over the two (2) trading days immediately preceding the date of Closing; provided that in no event shall the Pozen Purchase Price be less than $6.25.”
 
Plan of Arrangement” shall mean the Amended and Restated Plan of Arrangement attached to the Merger Agreement.
 
Purchaser Common Shares” means the common shares, without par value, of Purchaser.
 
Purchaser Meeting” means the meeting of the holders of the Purchaser Common Shares, and any postponement or adjournment thereof, at which the holders of the Purchaser Common Shares will be asked to vote, among other things, on the Distribution being effected by way of a reorganization of share capital of the Purchaser or a reduction in paid-up capital of their Purchaser Common Shares, and/or a plan of arrangement regarding the same.
 
Purchaser Proxy Statement” means the proxy statement of Purchaser to be furnished to the holders of the Purchaser Common Shares in connection with the Purchaser Meeting.
 
Purchaser Shares” means a number of Shares equal to the quotient obtained by dividing the Subscription Price of the Purchaser by the Per Share Subscription Price.  For the avoidance of doubt, Purchaser Shares shall not include Investor Shares.
 
Securities Act” means the Securities Act of 1933, as amended, or any successor Law thereto, and the rules and regulations issued pursuant to that statute or any successor Law.
 
TSX” means the Toronto Stock Exchange.
 
1.2 Terms Defined Elsewhere in this Agreement.  For purposes of this Agreement, the following terms have meanings set forth in the sections indicated:
 
 
3

 
 
Term
Section
Agreement
Preamble
Canadian Commissions
Annex B
Co-Investors
Recitals
Co-Investors’ Disclosure Schedule
ARTICLE IV
Company
Preamble
Confidentiality Agreements
5.1(b)
Consents
5.2(a)
Distribution
Recitals
Investment Closing
2.3
Investment Closing Date
2.3
Investors
Preamble
Investor Registration Expenses
Annex A
Investor Registration
Annex A
Investor Registration Statement
Annex A
Losses
1.2(f)
Mergers
Recitals
Merger Agreement
Recitals
Merger Closing Conditions
6.1(d)
Pozen
Preamble
Pozen Merger
Recitals
Pozen SEC Documents
3.2(c)
Prospectus
Annex B
Purchaser
Preamble
register, registered, registration
Annex A
Registrable Securities
Annex A
Registration
Annex B
Registration Expenses
Annex B
Registration Statement
Annex B
Securities Act
Preamble
Selling Expenses
Annex A
Share Price
2.1(b)
Shares
Recitals
Subscription Price
2.1(d)
Transfer Agent
2.2(b)
Tribute
Preamble
Tribute Merger
Recitals
Tribute SEC Documents
3.3(c)

1.3 Other Definitional and Interpretive Matters.
 
(a) Unless otherwise expressly provided, for purposes of this Agreement, the following rules of interpretation shall apply:
 
Calculation of Time Period.  When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement,
 
 
4

 
 
the date that is the reference date in calculating such period shall be excluded.  If the last day of such period is a non-Business Day, the period in question shall end on the next succeeding Business Day.
 
Dollars.  Any reference in this Agreement to $ shall mean U.S. dollars.
 
Schedules and Annexes.  The Schedules and Annexes to this Agreement are hereby incorporated and made a part hereof and are an integral part of this Agreement.  All Schedules and Annexes annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein.  Any capitalized terms used in any Schedule or Annex but not otherwise defined therein shall be defined as set forth in this Agreement.
 
Gender and Number.  Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only shall include the plural and vice versa.
 
Headings.  The provision of a Table of Contents, the division of this Agreement into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement.  All references in this Agreement to any “Section” are to the corresponding Section of this Agreement unless otherwise specified.
 
Herein.  The words such as “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires.
 
Including.  The word “including” or any variation thereof means “including, without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it.
 
(b) The parties hereto have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
 
ARTICLE II
 
SUBSCRIPTION FOR SHARES; SUBSCRIPTION PRICE; INVESTMENT CLOSING
 
2.1 Subscription for Shares.
 
(a) Subject to the terms and conditions hereof, at the Investment Closing, the Purchaser hereby agrees to subscribe for the Purchaser Shares.
 
(b) Subject to the terms and conditions hereof, at the Investment Closing, each Investor hereby agrees to subscribe for such Investor’s Investor Shares.
 
 
5

 
(c) Subject to the terms and conditions hereof, at the Investment Closing, Tribute will allot and issue to (i) the Purchaser, the Purchaser Shares and (ii) each Investor, such Investor’s Investor Shares.
 
(d) Subject to the terms and conditions hereof, at the Investment Closing, the Board of Tribute will approve the allotment and issue to (i) the Purchaser of the Purchaser Shares and (ii) each Investor of such Investor’s Investor Shares, procure that Tribute 's shareholder register reflects the allotment and issue share certificates to the Co-Investors.
 
(e) The aggregate amount that each Co-Investor will pay to Tribute for the Shares it subscribes for hereunder shall be set forth opposite such Co-Investor’s name under the heading “Subscription Price” on Schedule I hereto (with respect to each Co-Investor, the “Subscription Price”).
 
2.2 Payment of Subscription Price; Allotment of Shares.
 
(a) At the Investment Closing, each Co-Investor shall pay its respective Subscription Price to Tribute by wire transfer of immediately available funds into an account designated in writing by Tribute not less than three Business Days prior to the Investment Closing Date.
 
(b) At the Investment Closing, Tribute will instruct its transfer agent (the “Transfer Agent”) to deliver (i) the Purchaser Shares to the Purchaser and (ii) to each Investor, such Investor’s Investor Shares, in certificate form, in each case registered in the name of such Co-Investor.
 
2.3 Investment Closing.  Subject to the satisfaction or waiver of the conditions set forth in ARTICLE VI (other than conditions that by their nature are to be satisfied at the Investment Closing, but subject to the satisfaction or waiver of those conditions at such time), the consummation of the allotment and issue of the Shares provided for in Section 2.1 hereof (the “Investment Closing”) shall occur immediately prior to and at the same location as the Closing under the Merger Agreement.  The date the Investment Closing occurs is referred to as the “Investment Closing Date”.
 
2.4 Tribute Deliveries.  At the Investment Closing, subject to the terms and conditions hereof, Tribute shall deliver, or cause to be delivered, to each Co-Investor:
 
(a) copies of resolutions, certified by an officer of Tribute, as to the authorization by Tribute of this Agreement and all of the transactions contemplated hereby;
 
(b) a certificate in form and substance reasonably satisfactory to each Co-Investor, dated the Investment Closing Date and signed by the Chief Executive Officer of Tribute, stating that the conditions set forth in Sections 6.2(a) and 6.2(b) hereof (as they relate to Tribute) and the conditions set forth in Sections 8.1 (as they relate to Tribute) and 8.2 of the Merger Agreement have been satisfied and/or complied with by Tribute; and
 
(c) such other documents as Purchaser shall reasonably request.
 
2.5 Pozen Deliveries.  At the Investment Closing, subject to the terms and conditions hereof, Pozen will deliver, or cause to be delivered, to each Co-Investor:
 
 
6

 
 
(a) copies of resolutions, certified by the Secretary of Pozen, as to the authorization by Pozen of this Agreement and all of the transactions contemplated hereby; and
 
(b) a certificate in form and substance reasonably satisfactory to each Co-Investor, dated the Investment Closing Date and signed by the Chief Executive Officer of Pozen, stating that the conditions set forth in Sections 6.2(a) and 6.2(b) hereof (as they relate to Pozen) and the conditions set forth in Sections 8.1 (as they relate to Pozen) and 8.3 of the Merger Agreement have been satisfied and/or complied with by Pozen.
 
2.6 Co-Investor Deliveries.  At the Investment Closing, subject to the terms and conditions hereof, each Co-Investor will deliver, or cause to be delivered, to Tribute:
 
(a) payment to Tribute of such Co-Investor’s respective Subscription Price by wire transfer of immediately available funds to an account designated by Tribute in writing at least three Business Days prior to the Investment Closing Date;
 
(b) a cross-receipt executed by each Co-Investor and delivered to Tribute certifying that, as of the Investment Closing Date, it has received (i) in the case of the Purchaser, the Purchaser Shares and (ii) in the case of each Investor, such Investor’s Investor Shares;
 
(c) copies of resolutions, certified by an authorized signatory of such Co-Investor, as to the authorization by such Co-Investor of this Agreement and all of the transactions contemplated hereby; and
 
(d) a certificate in form and substance reasonably satisfactory to the Company, dated the Investment Closing Date and signed by an authorized signatory of such Co-Investor, stating that the conditions in Sections 6.3(a) and 6.3(b) hereof have been satisfied and/or complied with by each Co-Investor.
 
2.7 Tribute Additional Deliveries.  At the Investment Closing, subject to the terms and conditions hereof, Tribute shall deliver, or cause to be delivered, to each Co-Investor:
 
(a) the Shares as set forth in Section 2.2(b) hereof, in certificate form, in each case registered in the name of such Co-Investor, which Shares shall be free and clear of any Liens; and
 
(b) a cross-receipt, executed by Tribute and delivered to each Co-Investor certifying that it has received the Subscription Price from such Co-Investor as of the Investment Closing Date.
 
ARTICLE III
 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY; TRIBUTE; POZEN
 
3.1 Representations and Warranties of the Company.  In order to induce the Co-Investors to enter into this Agreement, except with respect to Section 3.1(f) below, to which the Company solely represents and warrants, the Company, Tribute and Pozen represent and warrant to each Co-Investor as follows:
 
 
7

 
 
(a) Corporate Existence; Authority.
 
(i) The Company is a corporation duly incorporated and validly existing under the Laws of British Columbia, Canada .  The Company has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.
 
(ii) The Company has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement, and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by the Board of the Company.  The Board of the Company has determined that this Agreement is advisable to and is in the best interests of the Company and its shareholders and no other corporate proceedings on the part of the Company are necessary to approve this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by the Company and (assuming the due authorization, execution and delivery by each of the Co-Investors, Pozen and Tribute) constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).
 
(b) Conflicts; Consents and Approvals.  Neither the execution and delivery of this Agreement by the Company nor the consummation of the transactions contemplated by this Agreement will:
 
(i) conflict with, or result in a breach of, any provision of the Articles of Incorporation, or By-Laws, of the Company;
 
(ii) violate, or conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with the giving of notice, the passage of time or otherwise, would constitute a default) under, or entitle any party (with the giving of notice, the passage of time or otherwise) to terminate, accelerate, adversely modify or call a default under, or result in the creation of any Liens upon any of the properties or assets of the Company or any of its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, contract, undertaking, agreement, lease or other instrument or obligation to which the Company or any of its Subsidiaries is a party;
 
(iii) violate any Laws applicable to the Company or any of its Subsidiaries or any of their respective properties or assets; or
 
(iv) require any action or consent or approval of, or review by, other than registrations or other actions required under federal and state securities Laws and the Canadian Securities Laws as are contemplated by this Agreement or any post-closing notice filings required under applicable United States federal or state securities laws.
 
 
8

 
 
(c) The Company has provided Purchaser and the Investors with true, correct and complete copies of the Merger Agreement and any annexes, exhibits, schedules (including disclosure schedules) thereto.
 
(d) Registration Statement and Investor Registration Statement.  None of the information supplied or to be supplied by the Company for inclusion or incorporation by reference in the Registration Statement or the Investor Registration Statement to be filed with the Commission by the Company under the Securities Act at the time the Registration Statement or Investor Registration Statement becomes effective will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (it being understood that no representation or warranty is made by the Company with respect to statements made or incorporated by reference therein based on written information supplied by Purchaser expressly for inclusion or incorporation by reference in the Registration Statement or the Investors expressly for inclusion or incorporation by reference in the Investor Registration Statement). Each of the Registration Statement, except for such portions thereof that relate only to Purchaser and its Subsidiaries, and the Investor Registration Statement, except for such portions thereof that relate only to Investors, will comply as to form in all material respects with the provisions of the Securities Act.
 
(e) Valid Issuance.  The Company Shares to be issued to the Purchaser and the Investors pursuant to the Plan of Arrangement will, when issued, allotted and delivered in accordance with the terms of the Plan of Arrangement, be duly and validly issued, will be exempt from the prospectus requirements of applicable Canadian Securities Laws and all such Company Shares will be fully paid and free of preemptive rights, with no personal liability attaching to the ownership thereof, and will be free and clear of all Liens.  The first trade in Company Shares will be exempt from the prospectus requirements of applicable Canadian Securities Laws subject to compliance with applicable Canadian Securities Laws at the time of such resale.
 
(f) The Company Shares to be issued to the Purchaser and the Investors upon consummation of the Plan of Arrangement will have been duly and validly issued pursuant to an exemption from the registration requirement of the Securities Act as provided by Section 3(a)(10) thereof.
 
3.2 Representations and Warranties of Pozen.  In order to induce the Co-Investors to enter into this Agreement, Pozen represents and warrants to each Co-Investor as follows:
 
(a) Corporate Existence; Authority.
 
(i) Pozen is a corporation validly existing and in good standing under the Laws of the State of Delaware.  Pozen has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.
 
(ii) Pozen has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement, and to consummate
 
 
9

 
 
the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by the Board of Pozen and no other corporate proceedings on the part of Pozen are necessary to approve this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by Pozen and (assuming the due authorization, execution and delivery by each of the Co-Investors and Tribute) constitutes the valid and binding obligation of Pozen, enforceable against Pozen in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).
 
(b) Conflicts; Consents and Approvals.  Neither the execution and delivery of this Agreement by Pozen nor the consummation of the transactions contemplated by this Agreement will:
 
(i) conflict with, or result in a breach of, any provision of the Certificate of Incorporation, as amended, and the Bylaws, as amended, of Pozen;
 
(ii) violate, or conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with the giving of notice, the passage of time or otherwise, would constitute a default) under, or entitle any party (with the giving of notice, the passage of time or otherwise) to terminate, accelerate, adversely modify or call a default under, or result in the creation of any Liens upon any of the properties or assets of Pozen or any of its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, contract, undertaking, agreement, lease or other instrument or obligation to which Pozen or any of its Subsidiaries is a party;
 
(iii) violate any Laws applicable to Pozen or any of its Subsidiaries or any of their respective properties or assets; or
 
(iv) require any action or consent or approval of, or review by, or registration or filing by Pozen or any of its Affiliates with, any third party or any Governmental Authority, other than registrations or other actions required under federal and state securities Laws as are contemplated by this Agreement.
 
(c) SEC Filings.  Pozen has timely filed or received the appropriate extension of time within which to file with the Commission all forms, reports, schedules, statements and other documents required to be filed by it since January 1, 2014 under the Exchange Act or the Securities Act (such documents, as supplemented and amended since the time of filing, collectively, the “Pozen SEC Documents”).  The Pozen SEC Documents, including any financial statements or schedules included therein, at the time filed (and, in the case of registration statements and proxy statements, on the dates of effectiveness and the dates of mailing, respectively) (i) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (ii) complied in all material respects with the applicable requirements of the Exchange Act and the Securities Act, as the case may be.  The financial statements of Pozen included in the Pozen SEC Documents at the
 
 
10

 
 
time filed complied as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto, were prepared in accordance with GAAP during the periods involved (except as may be indicated in the notes thereto, auditor’s report thereon or, in the case of unaudited statements, as permitted by Form 10-Q of the Commission), and fairly present in all material respects (subject in the case of unaudited statements to normal audit adjustments and subject to restatements filed with the Commission prior to the date of this Agreement) the consolidated financial position of Pozen and its consolidated Subsidiaries as at the dates thereof and the consolidated results of their operations and cash flows for the periods then ended.  No Subsidiary of Pozen is subject to the periodic reporting requirements of the Exchange Act other than as part of Pozen’s consolidated group or required to file any form, report or other document with the Commission, NASDAQ, any other stock exchange or comparable Governmental Authority.
 
(d) Private Placement.  Neither Pozen nor, to Pozen’s knowledge, any person acting on behalf of Pozen has offered or sold any of the Shares by any form of “general solicitation” or “general advertising”, as such terms are used in Rule 502(c) of Regulation D under the Securities Act.
 
3.3 Representations and Warranties of Tribute.  In order to induce the Co-Investors to enter into this Agreement, Tribute represents and warrants to each Co-Investor as follows:
 
(a) Corporate Existence; Authority.
 
(i) Tribute is a corporation validly existing and in good standing under the Laws of the jurisdiction of its organization.  Tribute has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.
 
(ii) Tribute has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement, and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by the Board of Tribute and no other corporate proceedings on the part of Tribute are necessary to approve this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by Tribute and (assuming the due authorization, execution and delivery by each of the Co-Investors and Pozen) constitutes the valid and binding obligation of Tribute, enforceable against Tribute in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).
 
(b) Valid Issuance.  The Shares to be issued pursuant to this Agreement will, when issued, allotted and delivered in accordance with the terms of this Agreement for the consideration expressed herein, be duly and validly issued, will be exempt from the prospectus requirements of applicable Canadian Securities Laws and, at the Investment Closing, all such
 
 
11

 
 
Shares will be fully paid and free of preemptive rights, with no personal liability attaching to the ownership thereof, and will be free and clear of all Liens.
 
(c) Conflicts; Consents and Approvals.  Neither the execution and delivery of this Agreement by Tribute nor the consummation of the transactions contemplated by this Agreement will:
 
(i) conflict with, or result in a breach of, any provision of the Organizational Documents of Tribute;
 
(ii) violate, or conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with the giving of notice, the passage of time or otherwise, would constitute a default) under, or entitle any party (with the giving of notice, the passage of time or otherwise) to terminate, accelerate, adversely modify or call a default under, or result in the creation of any Liens upon any of the properties or assets of Tribute or any of its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, contract, undertaking, agreement, lease or other instrument or obligation to which Tribute or any of its Subsidiaries is a party;
 
(iii) violate any Laws applicable to Tribute or any of its Subsidiaries or any of their respective properties or assets; or
 
(iv) require any action or consent or approval of, or review by, or registration or filing by Tribute or any of its Affiliates with, any third party or any Governmental Authority, other than registrations or other actions required under federal and state securities Laws as are contemplated by this Agreement.
 
(d) Tribute Reporting Issuer.  Tribute has been  a "reporting issuer" (as such term is defined in Canadian Securities Laws) in a jurisdiction of Canada for the four months preceding the date of this Agreement and will be a reporting issuer not in default immediately preceding the Investment Closing and until the Plan of Arrangement is effected.
 
(e) SEC Filings.  Tribute has timely filed or received the appropriate extension of time within which to file with the Commission all forms, reports, schedules, statements and other documents required to be filed by it since January 1, 2014 under the Exchange Act or the Securities Act (such documents, as supplemented and amended since the time of filing, collectively, the “Tribute SEC Documents”).  The Tribute SEC Documents, including any financial statements or schedules included therein, at the time filed (and, in the case of registration statements and proxy statements, on the dates of effectiveness and the dates of mailing, respectively) (i) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (ii) complied in all material respects with the applicable requirements of the Exchange Act and the Securities Act, as the case may be.  The financial statements of Tribute included in the Tribute SEC Documents at the time filed complied as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto, were prepared in accordance with GAAP during the periods involved (except as
 
 
12

 
 
may be indicated in the notes thereto, auditor’s report thereon or, in the case of unaudited statements, as permitted by Form 10-Q of the Commission), and fairly present in all material respects (subject in the case of unaudited statements to normal audit adjustments and subject to restatements filed with the Commission prior to the date of this Agreement) the consolidated financial position of Tribute and its consolidated Subsidiaries as at the dates thereof and the consolidated results of their operations and cash flows for the periods then ended.  No Subsidiary of Tribute is subject to the periodic reporting requirements of the Exchange Act other than as part of Tribute’s consolidated group or required to file any form, report or other document with the Commission, NASDAQ, the TSX, any other stock exchange or comparable Governmental Authority.
 
(f) Private Placement.  Assuming that the representations of each Co-Investor set forth in Section 4.1(c) are true and correct and assuming that the representation of Pozen set forth in Section 3.2(d) and is true and correct, the initial allotment and issuance of the Shares in conformity with the terms of this Agreement are exempt from both (i) the registration requirements of Section 5 of the Securities Act and (ii) the prospectus requirements of the Canadian Securities Laws, and neither Tribute nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions.  Neither Tribute nor, to Tribute’s knowledge, any person acting on behalf of Tribute has offered or sold any of the Shares by any form of “general solicitation” or “general advertising”, as such terms are used in Rule 502(c) of Regulation D under the Securities Act.
 
(g) Registration Statement and Investor Registration Statement.  None of the information supplied or to be supplied by Tribute for inclusion or incorporation by reference in the Registration Statement or the Investor Registration Statement to be filed with the Commission by the Company under the Securities Act at the time the Registration Statement or Investor Registration Statement becomes effective will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (it being understood that no representation or warranty is made by Tribute with respect to statements made or incorporated by reference therein based on written information supplied by Purchaser expressly for inclusion or incorporation by reference in the Registration Statement or the Investors expressly for inclusion or incorporation by reference in the Investor Registration Statement). Each of the Registration Statement, except for such portions thereof that relate only to Purchaser and its Subsidiaries, and the Investor Registration Statement, except for such portions thereof that relate only to Investors, will comply as to form in all material respects with the provisions of the Securities Act.
 
ARTICLE IV
 
REPRESENTATIONS AND WARRANTIES OF THE CO-INVESTORS
 
4.1 Representations and Warranties of the Co-Investors.  In order to induce the Company, Tribute and Pozen to enter into this Agreement, each Co-Investor severally for itself and not jointly with any one or more of the other Co-Investors represents and warrants to each of the Company, Tribute and Pozen as follows:
 
 
13

 
 
(a) Corporate Existence; Authority; No Violation.
 
(i) Co-Investor is a legal entity validly existing under the Laws of the jurisdiction of its organization.  Co-Investor has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.
 
(ii) Co-Investor has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by all necessary corporate action on the part of Co-Investor.  No other corporate proceedings on the part of Co-Investor are necessary to approve this Agreement and to consummate the subscription for (A) in the case of the Purchaser, the Purchaser Shares and (B) in the case of each Investor, such Investor’s Investor Shares.  This Agreement has been duly and validly executed and delivered by Co-Investor and (assuming the due authorization, execution and delivery by the Company, Tribute, Pozen and the other Co-Investors) constitutes the valid and binding obligation of Co-Investor, enforceable against Co-Investor in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).
 
(b) Conflicts; Consents and Approvals.  Neither the execution and delivery of this Agreement by Co-Investor nor the consummation of the subscription for (A) in the case of the Purchaser, the Purchaser Shares and (B) in the case of each Investor, such Investor’s Investor Shares, will:
 
(i) conflict with, or result in a breach of, any provision of the organizational documents of Co-Investor;
 
(ii) violate any Laws applicable to Co-Investor or any of its Subsidiaries or any of their respective properties or assets; or
 
(iii) require any action or consent or approval of, or review by, or registration or filing by Co-Investor or any of its Affiliates with, any third party or any Governmental Authority, other than registrations, beneficial ownership filings or other actions required under federal and state securities Laws as are contemplated by this Agreement.
 
(c) Certain Securities Law Matters.
 
(i) Co-Investor is acquiring its Shares as principal for its own account and, in the case of Purchaser, other than for the Distribution, not with a view to the distribution thereof within the meaning of the Securities Act and Canadian Securities Law.
 
(ii) Each Co-Investor is resident in the jurisdiction stated in Schedule I applicable thereto.
 
(iii) Co-Investor understands that the Shares issued to it and the Company Shares to be issued in exchange for the Shares in connection with the Plan of  Arrangement will not be transferable except (a) pursuant to an effective registration statement under the Securities Act and compliance with Canadian Securities Laws as applicable (b) pursuant to an
 
 
14

 
 
available exemption from, or in a transaction not subject to, the Securities Act or applicable Canadian Securities Laws as evidenced by receipt by the Company of a written opinion of counsel for Co-Investor reasonably satisfactory to the Company to the effect that the proposed transfer is exempt from the registration requirements of the Securities Act and relevant state securities laws and exempt from the prospectus requirements of applicable Canadian Securities Laws, as applicable, or (c) pursuant to Rule 144 under the Securities Act (“Rule 144”) and after expiry of all “hold periods” or “seasoning periods” in Canada.  Applicable U.S. and Canadian restrictive legends shall be placed on certificates representing the Shares to be delivered to Co-Investor at the Investment Closing and the applicable U.S. restrictive legends shall be placed on any certificates representing the Company Shares to be issued in exchange for the Shares in connection with the Plan of Arrangement, substantially as follows:
 
“NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE RULES AND REGULATIONS IN EFFECT THEREUNDER AND ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS, (B) PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE SECURITIES ACT AS EVIDENCED BY THE CORPORATION BEING FURNISHED WITH AN OPINION OF COUNSEL FOR THE HOLDER, WHICH OPINION AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT, OR (C) PURSUANT TO RULE 144 UNDER THE SECURITIES ACT.”
 
At the time of the Investment Closing, the Shares to be issued to the Co-Investors will carry the following Canadian restrictive legend:
 
“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [__, 2016] [INSERT THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE INVESTMENT CLOSING DATE].  WITHOUT PRIOR WRITTEN APPROVAL OF TSX VENTURE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL [INSERT DATE].”
 
The Company Shares issued to the Co-Investors in exchange for the Shares pursuant to the Plan of Arrangement in accordance with the Plan of Arrangement will not carry any Canadian restrictive legend.
 
 
15

 
 
(a) Co-Investor Status.
 
(i) At the time Co-Investor was offered the Shares, it was, and at the date hereof it is, either (a) “qualified institutional buyer”, as defined in Rule 144A under the Securities Act, or (b) an “accredited investor” as defined in Rule 501(a) of Regulation D.
 
(ii) Co-Investor is an “accredited investor” as defined in National Instrument 45-106 - Prospectus Exemptions promulgated under applicable Canadian Securities Laws.
 
(b) Sufficiency of Funds.
 
(i) The Investor has sufficient cash on hand or other sources of immediately available funds to enable it to make payment of the Subscription Price and consummate the transactions contemplated by this Agreement.
 
(ii) The Purchaser has, and at all times during this Agreement (prior to and including the Investment Closing) shall have, sufficient cash on hand or other sources of immediately available funds to enable it to make payment of the Subscription Price and consummate the transactions contemplated by this Agreement.
 
(c) No Bad Actor.  No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act is applicable to the Co-Investor.
 
(d) No General Solicitation.  Neither the Co-Investor, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer, sale or contemplated distribution of the Shares.
 
(e) Exculpation Among Co-Investors.  Each Co-Investor represents that it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment in Tribute (and indirectly in the Company) pursuant to this Agreement and is able to bear the economic risk of loss of its investment in Tribute (and indirectly in the Company) pursuant to this Agreement.  Each Co-Investor acknowledges that it is not relying upon any Person, other than Tribute and Pozen and their officers and directors, in making its investment or decision to invest in Tribute (and indirectly the Company) pursuant to this Agreement.  Each Co-Investor agrees that none of the Co-Investors or their respective controlling Persons, officers, directors, partners, agents, or employees shall be liable to any other Co-Investor for any action taken or omitted to be taken by any of them in connection with entering into, or complying with its respective obligations under, this Agreement, including without limitation purchasing the Shares.
 
 
16

 
 
ARTICLE V
 
COVENANTS AND AGREEMENTS
 
5.1 Furnishing Information.
 
(a) For purposes of furthering the transactions contemplated hereby, each of the Company, Tribute and Pozen shall promptly provide Purchaser with any report, schedule or other document filed or received by it pursuant to the requirements of the federal securities laws of the United States or the Canadian Securities Laws relating to the Shares covered by this Agreement (other than reports or documents that Tribute or Pozen, as applicable, is not permitted to disclose under applicable Law).  
 
(b) The parties hereto hereby agree that all information received by them or their respective officers, directors, employees or representatives in connection with this Agreement and the consummation of the transactions contemplated hereby shall be governed in accordance with the respective confidentiality agreement entered into by such receiving party and any of the other parties hereto (collectively, the “Confidentiality Agreements”), each of which shall continue in full force and effect in accordance with its terms.
 
5.2 Filings; Commercially Reasonable Efforts; Notification.
 
(a) Upon the terms and subject to the conditions of this Agreement, each of the parties shall use its respective commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, as soon as practicable (and in any event prior to the End Date), the transactions contemplated by this Agreement, including (i) obtaining and maintaining all necessary actions or nonactions, waivers, consents, licenses, permits, authorizations, orders and approvals (collectively, “Consents”) from applicable Governmental Authorities and the making of all other necessary registrations and filings, (ii) obtaining all Consents from third parties that are reasonably necessary in connection with the transactions contemplated by this Agreement, and (iii) the execution and delivery of any additional instruments reasonably necessary to consummate any of the transactions contemplated by, and to fully carry out the purposes of, this Agreement.
 
(b) Each of the Company, Tribute and Pozen shall (i) use commercially reasonable efforts to make or cause to be made such filings with applicable Governmental Authorities as are required or, in Purchaser’s reasonable view, advisable in connection with the transactions contemplated by this Agreement as soon as reasonably practicable after the date of this Agreement and (ii) cooperate in good faith with the other party in obtaining any Consents from Governmental Authorities and in connection with resolving any investigation or other inquiry of any Governmental Authority with respect to such filings.
 
(c) Each of the Company, Pozen and Tribute shall use commercially reasonable efforts to ensure that none of the information supplied or to be supplied by for inclusion or incorporation by reference in the Registration Statement or the Investor Registration Statement to be filed with the Commission by the Company under the Securities Act at the time
 
 
17

 
 
the Registration Statement or Investor Registration Statement becomes effective will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (it being understood that no representation or warranty is made by the Company, Pozen, Tribute or the Co-Investors with respect to statements made or incorporated by reference therein based on written information supplied by the other parties hereto expressly for inclusion or incorporation by reference in the Registration Statement or the Investors expressly for inclusion or incorporation by reference in the Investor Registration Statement).
 
(d) Tribute shall prepare and file a business acquisition report with respect to the acquisition by Tribute of certain pharmaceutical products from Novartis AG announced in the press release of Tribute dated October 2, 2014.
 
5.3 NASDAQ and TSX Listing.  The Company, Tribute and Pozen shall use commercially reasonable efforts to cause the Company Shares to be approved for listing on NASDAQ and conditionally approved for listing on the TSX prior to the Investment Closing, as mutually agreed by the parties, subject to official notice of issuance in respect of NASDAQ and subject to compliance with all of the customary requirements of the TSX, including receipt of all documentation required by the TSX.
 
5.4 Reporting Issuer Status.  Tribute shall have the status of a reporting issuer not in default immediately preceding the Investment Closing and until the time the Plan of Arrangement is effected.
 
5.5 Further Assurances.  Subject to, and not in limitation of, Section 5.2, each of Tribute and Pozen shall use its respective commercially reasonable efforts to (i) take, or cause to be taken, all actions necessary or appropriate to consummate the transactions contemplated by this Agreement and (ii) cause the fulfillment at the earliest practicable date of all of the conditions to their respective obligations to consummate the transactions contemplated by this Agreement.
 
5.6 Advice of Changes.
 
(a) Tribute and/or Pozen, as applicable, shall promptly advise the Co-Investors of any fact, change, event or circumstance that has had a Material Adverse Effect on Tribute and/or Pozen which Tribute and/or Pozen believes would or would be reasonably likely to give rise to a failure of the condition precedent set forth in Sections 6.1(d) or 6.1(e) hereof; provided that any failure to give notice in accordance with the foregoing shall not be deemed to constitute a violation of this Section 5.6 or the failure of the condition set forth in Section 6.1(d) hereof to be satisfied, or otherwise constitute a breach of this Agreement by Tribute and/or Pozen, in each case unless the underlying breach would independently result in a failure of the condition set forth in any of Sections 6.1(d) or 6.1(e) hereof to be satisfied; provided further, that that the delivery of any notice pursuant to this Section 5.6 shall not limit or otherwise affect the remedies of the Co-Investors available hereunder and no information delivered pursuant to this Section 5.6 shall affect the representations or warranties of the parties hereunder.
 
(b) Tribute and/or Pozen shall promptly advise the Co-Investors of (i) any written notice or other written communication from any person alleging that the consent of such person is or may be required in connection with the transactions contemplated by this Agreement to the extent that either Tribute or Pozen believes there is a reasonable likelihood that the failure to obtain such consent would have a material impact on the timing of the consummation of the transactions contemplated by this Agreement or (ii) upon receiving any written communication
 
 
18

 
 
from any Governmental Authority or third party whose consent or approval is required for the satisfaction of the condition to the Investment Closing set forth in Sections 6.1(d) or 6.1(e) hereof that causes Tribute or Pozen to believe that there is a reasonable likelihood that any such consent or approval will not be obtained or that the receipt of any such consent or approval will be materially delayed.
 
(c) Tribute and/or Pozen, as applicable, shall promptly notify the Co-Investors of any notice, written threat, announcement or commencement of a material investigation by any Governmental Authority with respect to Tribute or any of its Subsidiaries or Pozen or any of its Subsidiaries.
 
(d) Each of Tribute and Pozen covenants and agrees to promptly provide Purchaser with notice and copies of any amendments to the Merger Agreement or any of the annexes, exhibits or schedules (including disclosure schedules) thereto within two (2) Business Days of any such amendment.  The provisions of this Section 5.6(d) shall not in any way affect each Co-Investor’s rights to insist upon the satisfaction of the condition to closing set forth in Section 6.1(c).
 
5.7 Governance Matters.  The Company shall take all actions as may be necessary to elect, or cause to be elected, to the Board of the Company, effective as soon as is practicable after the Investment Closing and the consummation of the subscription for the Purchaser Shares and the Investor Shares, the individual designated by Purchaser, in writing, at least five (5) Business Days prior to the Investment Closing Date.
 
5.8 Cooperation.
 
(a) The Company, Tribute and Pozen each acknowledge and the Purchaser hereby agrees that the Purchaser shall not effect the Distribution until such time as the Purchaser has complied with all applicable Laws, including without limitation that the Registration Statement shall be on file with the SEC and declared effective.  In connection therewith, Purchaser may call the Purchaser Meeting and may in connection therewith be filing the Purchaser Proxy Statement with the Commission and the Canadian Commissions (as defined in Annex B) and will be furnishing such document to the holders of the Purchaser Common Shares in connection with the votes to be taken at the Purchaser Meeting.  The Company, Tribute and Pozen each hereby agrees to furnish such information as Purchaser may reasonably request for inclusion, by way of incorporation by reference or otherwise, in the Purchaser Proxy Statement.  Each of the Company, Tribute and Pozen hereby agrees that such information pertaining to it provided for such inclusion will be true and accurate in all material respects and will not omit any material information as at the time it is given.  Purchaser hereby agrees to provide the Company, Tribute and Pozen with copies of all proposed disclosure in the Purchaser Proxy Statement relating to the Company, Tribute, Pozen, this Agreement and the transactions contemplated hereby, prior to its filing.  Purchaser further agrees to provide each of the Company, Tribute and Pozen with a reasonable opportunity (at least two (2) Business Days) to review and comment upon such proposed disclosure and Purchaser shall consider such comments in good faith and make any changes thereto reasonably requested by the Company, Tribute or Pozen.
 
 
19

 
 
(b) The Company, Tribute and Pozen each hereby agrees and acknowledges that Purchaser may be required to file reports under the Exchange Act from and after the Closing of the transactions contemplated by this Agreement, which reports may require information (including financial information) concerning the Company, Tribute and Pozen.  Each of the Company, Tribute and Pozen hereby agrees to furnish such information as Purchaser may reasonably request for inclusion in such reports.  Each of the Company, Tribute and Pozen hereby agrees that such information pertaining to it provided for such inclusion will be true and accurate in all material respects and will not omit any material information.  Purchaser hereby agrees to provide the Company, Tribute and Pozen with copies of all proposed disclosure in the Purchaser Proxy Statement relating to the Company, Tribute, Pozen, this Agreement and the transactions contemplated hereby, prior to filing.  Purchaser further agrees to provide each of the Company, Tribute and Pozen with a reasonable opportunity (at least two (2) Business Days) to review and comment upon such proposed disclosure and Purchaser shall consider such comments in good faith and make any changes thereto reasonably requested by the Company, Tribute or Pozen.
 
5.9 Equal Treatment of Purchaser and the Investors.  No consideration shall be offered or paid to Purchaser or any Investor to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties hereto.  For clarification purposes, this provision constitutes a separate right granted to each of Purchaser and the Investors in their own respective right by Tribute and Pozen and negotiated separately by each of them in their own respective right, and is intended for Tribute and Pozen to treat Purchaser and the Investors as a class and shall not in any way be construed as such persons acting jointly or in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.  Each Co-Investor represents that it does not have as of the date of this Agreement, and shall not have as of the Investment Closing, any verbal or written agreement, arrangement, commitment or understanding regarding voting rights attached to the Shares or the Company Shares.
 
5.10 Investors’ Registration Rights.  The Investors shall have the registration rights set forth on Annex A hereto.  The Investor Registration Statement (as defined in such Annex A) shall be separate and distinct from the Registration Statement (as defined in Annex B).  The Company shall use commercially reasonable efforts to convert the Investor Registration Statement from Form S-1 to Form S-3 as soon as practicable following the time the applicable rules and regulations allow for such conversion.
 
5.11 Purchaser’s Registration Rights.  Purchaser shall have the registration rights set forth on Annex B hereto.  The Registration Statement shall be separate and distinct from the Investor Registration Statement.
 
5.12 Co-Investor Agreement.  Each of the Co-Investors agrees that, for a period from the date hereof and ending on the earlier of (i) Closing, (ii) termination of the Merger Agreement, and (iii) April 30, 2016, it shall not short the securities of Pozen or Tribute.   In addition, each Co-Investor further agrees that during the ten (10) days immediately preceding the Closing it shall not trade in the securities of either Pozen or Tribute.
 
 
 
20

 
 
ARTICLE VI
 
CONDITIONS TO INVESTMENT CLOSING
 
6.1 Mutual Conditions.  The respective obligations of each Co-Investor and the Company to consummate the subscription and issuance of the Shares shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following conditions (any or all of which may be waived by a party on behalf of itself in writing, in whole or in part, to the extent permitted by applicable Law):
 
(a) No Law shall have been enacted or promulgated, and no action shall have been taken, by any Governmental Authority of competent jurisdiction that temporarily, preliminarily or permanently restrains, precludes, enjoins or otherwise prohibits the consummation of the transactions contemplated hereby or makes the transactions contemplated hereby illegal;
 
(b) No outstanding judgment, injunction, order or decree of a competent Governmental Authority shall have been entered and shall continue to be in effect, and no Law shall have been adopted or be effective, in each case that prohibits, enjoins or makes illegal the consummation of the transactions contemplated by this Agreement;
 
(c) No material amendment, modification or waiver of a material right under the Merger Agreement has occurred;
 
(d) The Merger Agreement in the form as executed by the Parties thereto as of the date of this Agreement and the Plan of Arrangement in the form attached as Schedule II to the Merger Agreement in the form as executed by the Parties thereto as of the date of this Agreement shall not have been materially amended; and
 
 
21

 
 
(e) The conditions set forth in Article VIII of the Merger Agreement (the (“Merger Closing Conditions”) shall have been satisfied or (except for Sections 8.1(j), 8.1(k), 8.1(l), 8.2(c) and 8.3(c)) waived, and the Parties to the Merger Agreement shall have irrevocably committed, subject to no further conditions, to effect the Closing under the Merger Agreement.
 
6.2 Co-Investor’s Conditions.  The obligations of each Co-Investor to consummate the subscription of such Co-Investor’s Investor Shares, in the case of an Investor, and the Purchaser Shares, in the case of the Purchaser shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following additional conditions (any or all of which may be waived by such Co-Investor on behalf of itself in writing, in whole or in part, to the extent permitted by applicable Law):
 
(a) The respective representations and warranties of the Company, Tribute and Pozen set forth in Sections 3.1, 3.2, and 3.3, respectively, qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, in each case, as of the date of this Agreement and as of the Investment Closing as though made at and as of the Investment Closing, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties qualified as to materially shall be true and correct, and those not so qualified shall be true and correct in all material respects, on and as of such earlier date);
 
(b) each of the Company, Tribute and Pozen shall have performed and complied in all material respects with its respective obligations and agreements required in this Agreement to be performed or complied with by it on or prior to the Investment Closing Date;
 
(c) the Company Shares shall have been approved for listing on NASDAQ and the TSX, subject to official notice of issuances in respect of NASDAQ and subject to compliance with all of the customary conditions of the TSX, including receipt of all documentation required by the TSX;
 
(d) Tribute shall have delivered, or caused to be delivered, to such Co-Investor at the Investment Closing, Tribute’s closing deliverables described in Section 2.4;
 
(e) Tribute shall have been a reporting issuer in a jurisdiction of Canada for the four (4) months immediately preceding the Investment Closing and shall be a reporting issuer not in default as at the time of the Investment Closing;
 
(f) The conditions set forth in Article 4.1 of the Second Amended and Restated Facility Agreement, dated as of the date hereof, by and among the Company, Pozen, Tribute and the lenders party thereto (the “Lenders”) shall have been fulfilled, or shall have been waived by the Lenders;
 
(g) there shall not be pending any suit, action or proceeding by any Person seeking to restrain, preclude, enjoin or prohibit the transactions contemplated by this Agreement, which suit, action or proceeding is reasonably likely to have a material adverse effect on such Co-Investor;
 
(h) Pozen shall have delivered, or caused to be delivered, to such Co-Investor at the Investment Closing, Pozen’s closing deliverables described in Section 2.5;
 
 
22

 
 
(i) the Company shall have delivered, or caused to be delivered, to such Co-Investor at the Investment Closing, the Company’s closing deliverables described in Section 2.7; and
 
(j) Purchaser, on the one hand, and the Company, Tribute and Pozen, on the other hand, shall not have terminated the Agreement pursuant to Section 7.1(a).
 
6.3 Tribute’s Conditions.  The obligation of Tribute to consummate the allotment and issuance of the Shares to each Co-Investor shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following conditions with respect to such Co-Investor (any or all of which may be waived by Tribute in writing, in whole or in part, to the extent permitted by applicable Law):
 
(a) the representations and warranties of such Co-Investor set forth in this Agreement qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, in each case, as of the date of this Agreement and as of the Investment Closing as though made at and as of the Investment Closing, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, on and as of such earlier date);
 
(b) such Co-Investor shall have performed and complied in all material respects with all obligations and agreements required by this Agreement to be performed or complied with by such Co-Investor on or prior to the Investment Closing Date; and
 
(c) there shall not be pending any suit, action or proceeding by any Person seeking to restrain, preclude, enjoin or prohibit the transactions contmplated by this Agreement, which suit, action or proceeding is reasonably likely to have a material adverse effect on the Company; and
 
(d) such Co-Investor shall have delivered, or caused to be delivered, to the Company at the Investment Closing such Co-Investor’s closing deliverables described in Section 2.6.
 
ARTICLE VII
 
TERMINATION
 
7.1 Termination.  Notwithstanding anything in this Agreement to the contrary, this Agreement may be terminated and abandoned at any time prior to the Investment Closing with respect to the applicable parties as follows:
 
(a) by mutual written consent of the Company, Tribute and Pozen, on the one hand, and one or more Co-Investors, on the other hand, which termination shall be effective as between or among the Company, Tribute and Pozen and such Co-Investor(s);
 
(b) by any of the Company, Tribute, Pozen, Purchaser or any of the Investors (but only with respect to such terminating Investor’s rights and obligations hereunder) if there
 
 
23

 
 
shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited, or if any judgment, injunction, order or decree of a competent Governmental Authority enjoining the Company, Tribute, Pozen, Purchaser or such Investor from consummating the transactions contemplated by this Agreement shall have been entered and such judgment, injunction, order or decree shall have become final and nonappealable; provided that the party seeking to terminate this Agreement pursuant to this Section 7.1(b) shall have used its commercially reasonable efforts to render inapplicable such Law or regulation or remove such judgment, injunction, order or decree as required by Section 5.2;
 
(c) by any of the Company, Tribute, Pozen, Purchaser or any Investor (by only with respect to such terminating Investor’s rights and obligations hereunder) if the Investment Closing shall not have occurred on or prior to April 30, 2016 (the “End Date”); provided, however, that the right to terminate this Agreement under this Section 7.1(c) shall not be available to any party whose material breach of any covenant or obligation under this Agreement has been the cause of or resulted in the failure of the Investment Closing to occur on or before the End Date;
 
(d) by any of the Company, Tribute, Pozen, Purchaser or any of the Investors (but only with respect to such terminating Investor’s rights and obligations hereunder) if the Merger Agreement shall have been terminated;
 
(e) by Purchaser or any of the Investors (but only with respect to such terminating Investor’s rights and obligations hereunder) if there shall have been a breach by the Company, Tribute or Pozen of any of their respective representations, warranties, covenants or agreements contained in this Agreement, which breach would result in the failure of one or more of the conditions set forth in Sections 6.2(a) or 6.2(b) to be satisfied on or prior to the End Date, and such breach shall not be capable of being cured or shall not have been cured by the earlier of (i) the End Date and (ii) twenty (20) Business Days after detailed written notice thereof shall have been received by the party alleged to be in breach; or
 
(f) by the Company, Tribute or Pozen, with respect to any Co-Investor, if there shall have been a breach by such Co-Investor of any of its representations, warranties, covenants or agreements contained in this Agreement, which breach would result in the failure of one or more of the conditions set forth in Sections 6.3(a) or 6.3(b) to be satisfied on or prior to the End Date, and such breach shall not be capable of being cured or shall not have been cured by the earlier of (i) the End Date and (ii) twenty (20) Business Days after detailed written notice thereof shall have been received by the party alleged to be in breach.
 
7.2 Procedure Upon Termination.  In the event of termination and abandonment by the Company, Tribute, Pozen, Purchaser or any Investor pursuant to Section 7.1, written notice thereof specifying the provision of this Agreement pursuant to which such termination is effected, shall forthwith be given to the other parties hereto, and, solely with respect to a termination by Tribute or Pozen or all of the Co-Investors, this Agreement shall terminate, and the subscription for the Shares hereunder shall be abandoned.  For the avoidance of doubt, a termination by any Co-Investor shall only terminate the rights and obligations of such Co-Investor hereunder and shall not affect the rights and obligations of the other parties hereto.  The parties acknowledge that the failure by any one Co-Investor to consummate the subscription for such Co-Investor’s Investor Shares or Purchaser Shares, as the case may be, shall not affect or modify the obligations of the Company or the other Co-Investors to consummate the transactions contemplated hereby.
 
 
24

 
 
7.3 Effects of Termination.  In the event of any termination of this Agreement as provided in Section 7.1 by the Company, Tribute or Pozen, or all of the Co-Investors, this Agreement, except for the provisions of Section 5.1(b), this Section 7.3 and ARTICLE VIII, shall terminate and become void and have no effect, without any liability on the part of any party or its directors, officers or stockholders with respect thereto.  Notwithstanding the foregoing, nothing in this Section 7.3 shall relieve any party to this Agreement of liability for fraud or any material breach of any covenant or agreement set forth in this Agreement.  No termination of this Agreement shall affect the obligations of the parties contained in any of the Confidentiality Agreements, all of which obligations shall survive termination of this Agreement in accordance with its terms.
 
ARTICLE VIII
 
MISCELLANEOUS
 
8.1 Survival.  Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company, Tribute, Pozen or the Co-Investors herein shall survive the execution of this Agreement, the delivery to the Co-Investors of the Shares and the payment therefor.
 
8.2 Expenses.  Except as otherwise provided in this Agreement, whether or not the transactions contemplated by this Agreement are consummated, all costs and expenses incurred in connection with the negotiation and execution of this Agreement and the transactions contemplated hereby shall be paid by the party incurring or required to incur such expenses, including the Registration Expenses and Investor Registration Expenses (which shall be from the account of the Company).
 
8.3 Counterparts; Effectiveness.  This Agreement may be executed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by telecopy, electronic delivery or otherwise) to the other parties.  Signatures to this Agreement transmitted by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.
 
8.4 Governing Law. This Agreement, and all claims or causes of action (whether at Law, in contract or in tort or otherwise) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other
 
 
25

 
 
jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.
 
8.5 Jurisdiction; Specific Enforcement Each of the parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other party hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware).  Each of the parties hereto hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than the aforesaid courts.  Each of the parties hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above named courts, (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by applicable Law, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.  To the fullest extent permitted by applicable Law, each of the parties hereto hereby consents to the service of process in accordance with Section 8.7; provided, however, that nothing herein shall affect the right of any party to serve legal process in any other manner permitted by Law.
 
8.6 WAIVER OF JURY TRIAL.  EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
 
8.7 Notices.  All notices and other communications hereunder shall be in writing and shall be deemed given (a) upon personal delivery to the party to be notified; (b) when received when sent by email or facsimile by the party to be notified, provided, however, that notice given by email or facsimile shall not be effective unless either (i) a duplicate copy of such email or fax notice is promptly given by one of the other methods described in this Section 8.7 or (ii) the receiving party delivers a written confirmation of receipt for such notice either by email or fax or any other method described in this Section 8.7; or (c) when delivered by a courier (with confirmation of delivery); in each case to the party to be notified at the following address:
 
If to Purchaser, to:
 
QLT Inc.
 
 
26

 
 
887 Great Northern Way, Suite 250
Vancouver, BC V5T 4T5
Canada
 
Facsimile:
(604) 707-7001
 
Attention:
Geoffrey Cox, Interim Chief Executive Officer
 
Dori Assaly, Vice President, Legal Affairs
 
Email:
gfcox@qltinc.com
 
dassaly@qltinc.com
 
with copies (which shall not constitute notice) to:
 
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, New York 10153
 
Facsimile:
(212) 310-8007
 
Attention:
Raymond O. Gietz
 
Email:
raymond.gietz@weil.com
 
If to the Company, to:
 
 
Aralez Pharmaceuticals Inc.
c/o DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St. W
Toronto, Ontario
M5X 1E2
 
Canada
 
Facsimile:           (919) 490-5552
Attention:          Andrew Koven, President
 
E-mail:
akoven@pozen.com
 
with copies (which shall not constitute notice) to:
 
 
DLA Piper LLP (US)
 
51 John F. Kennedy Parkway, Suite 120
 
Short Hills, New Jersey 07078-2704
 
Facsimile:
(973) 520-2573
 
Attention:
Andrew Gilbert, Esq.
Email:                 andrew.gilbert@dlapiper.com
 
If to the Former Company, to:
 
 
Aralez Pharmaceuticals plc
c/o DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St. W
Toronto, Ontario
M5X 1E2
 
 
27

 
 
 
Canada
 
Facsimile:          (919) 490-5552
Attention:         Andrew Koven, President
 
E-mail:
akoven@pozen.com
 
with copies (which shall not constitute notice) to:
 
 
DLA Piper LLP (US)
 
51 John F. Kennedy Parkway, Suite 120
 
Short Hills, New Jersey 07078-2704
 
Facsimile:
(973) 520-2573
 
Attention:
Andrew Gilbert, Esq.
 
Email:
andrew.gilbert@dlapiper.com
 
If to Pozen, to:
 
 
POZEN Inc.
 
1414 Raleigh Road, Suite 400
 
Chapel Hill, North Carolina 27517
 
Facsimile:
(919) 490-5552
 
Attention:
Adrian Adams, Chief Executive Officer
 
Email:
aadams@pozen.com
 
with copies (which shall not constitute notice) to:

 
DLA Piper LLP (US)
 
51 John F. Kennedy Parkway, Suite 120
 
Short Hills, New Jersey 07078-2704
 
Facsimile:
(973) 520-2573
 
Attention:
Andrew Gilbert, Esq.
 
Email:
andrew.gilbert@dlapiper.com

If to Tribute, to:

 
Tribute Pharmaceuticals Canada Inc.
 
151 Steeles Avenue East
 
Milton, Ontario, Canada  L9T 1Y1
 
Facsimile:
(519) 434-4382
 
Attention:
Robert Harris, President and Chief Executive Officer
 
E-mail:
rob.harris@tributepharma.com

 
with copies (which shall not constitute notice) to:

 
Fogler, Rubinoff LLP
 
77 King Street West, Suite 3000
 
Toronto, Ontario  M5K 1G8
 
Facsimile:
+1-416-941-8852
 
 
28

 
 
 
Attention:
Eric R. Roblin
 
E-mail:
eroblin@foglers.com
 
 
If to an Investor, at its address set forth under its name on Schedule I hereto,
 
or to such other address as any party shall specify by written notice so given, and such notice shall be deemed to have been delivered as of the date so telecommunicated or personally delivered.  Any party to this Agreement may notify any other party of any changes to the address or any of the other details specified in this Section 8.7; provided, however, that such notification shall only be effective on the date specified in such notice or five (5) Business Days after the notice is given, whichever is later.  Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.
 
8.8 Assignment; Binding Effect.  Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated by any of the parties hereto without the prior written consent of the other parties; provided, however, that (i) any Co-Investor may assign any of its rights hereunder to any of its Affiliates without the prior written consent of the Company, Tribute or Pozen, but no such assignment shall relieve such Co-Investor of any of its obligations hereunder, (ii) at any time prior to the filing of the Investor Registration Statement or the Registration Statement, as applicable, any Co-Investor may reallocate, in whole or in part, the number of Shares allocated to such Co-Investor hereunder and assign its rights and obligations hereunder with respect to such reallocated Shares, to any other Co-Investor (and Schedule I will be updated accordingly), and (iii) Purchaser may assign any of its rights hereunder in connection with a merger or amalgamation of Purchaser, or the sale of all or substantially all of the assets of Purchaser and its Subsidiaries.  In addition to the foregoing, the Company hereby acknowledges and agrees that, following the Arrangement Effective Time and pursuant to the Plan of Arrangement, the Company shall assume the obligations of Tribute with respect to the Purchaser Shares and the Investor Shares.  Subject to the first sentence of this Section 8.8, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.  Any purported assignment not permitted under this Section 8.8 shall be null and void.  In addition, if Purchaser were to sell in a private transaction any of its Shares to (i) another Co-Investor or (ii) one or more persons identified on Schedule II hereto, then such purchaser shall have the rights set forth in Annex A hereto with respect to such purchased Shares.
 
8.9 Severability.  Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement in any other jurisdiction.  If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.
 
8.10 Independent Legal and Investment Advice.  Each party acknowledges that Weil, Gotshal & Manges LLP, McCullough O’Connor Irwin LLP and Greenhill & Co., LLC are advisors to the Purchaser and not any other party to this Agreement.  In addition, each party to this Agreement acknowledges having had the opportunity to obtain independent legal advice and
 
 
29

 
 
independent investment advice in connection with the execution of this Agreement and the transactions contemplated hereby, prior to the execution of this Agreement, and further, each party to this Agreement represents to the other parties that it has either sought independent legal advice and independent investment advice or has waived its right to seek such advice.
 
8.11 Entire Agreement.  This Agreement together with the annexes, schedules and exhibits hereto and each of the Confidentiality Agreements constitute the entire agreement, and supersede all other prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof and thereof, and this Agreement is not intended to grant standing to any person other than the parties hereto.  For greater certainty the Original Agreement is terminated hereby.
 
8.12 Amendments; Waivers.  At any time prior to the Effective Time, any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Company, Tribute, Pozen, Purchaser and each of the Investors; provided, however, that any amendment or waiver of any of the provisions of Annex A shall require only the signature of the Company and the affected Investor, and any amendment or waiver of Annex B shall only require the signature of the Company and Purchaser.  Notwithstanding the foregoing, no failure or delay by any party hereto in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder.
 
8.13 Headings.  Headings of the Articles and Sections of this Agreement are for convenience of the parties only and shall be given no substantive or interpretive effect whatsoever.  The table of contents to this Agreement is for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.
 
8.14 No Third-Party Beneficiaries.  Each of the Co-Investors, Pozen, Tribute and the Company agrees that (a) their respective representations, warranties, covenants and agreements set forth herein are solely for the benefit of the other party hereto, in accordance with and subject to the terms of this Agreement, and (b) this Agreement is not intended to, and does not, confer upon any person other than the parties hereto any rights or remedies hereunder, including the right to rely upon the representations and warranties set forth herein, with the exception of the rights and remedies of the Indemnified Parties pursuant to Annex B.
 
8.15 Obligations of the Co-Investors and the Company.  The obligations of the Co-Investors are several and not joint and the breach by any Co-Investor of its obligations hereunder shall not result in any liability being incurred by any one or more of the other Co-Investors as a result of such breach.  Each of the Company, Tribute and Pozen acknowledges and agrees that should one or more Co-Investors not be ready, willing and able to subscribe for its respective Shares hereunder, any of the other Co-Investors may subscribe for such Shares in lieu of the non-performing Co-Investor.
 
 
** REMAINDER OF PAGE INTENTIONALLY LEFT BLANK**
 
 
 
 
 
30

 
 
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first written above.
 
  TRIBUTE PHARMACEUTICALS CANADA INC.  
       
 
By:
/s/ Scott Langille  
    Name: Scott Langille  
    Title: Chief Financial Officer  
       
       
  POZEN INC.  
       
  By: /s/ Adrian Adams  
    Name: Adrian Adams  
    Title: Chief Executive Officer  
       
       
  ARALEZ PHARMACEUTICALS PLC  
       
  By: /s/ William L. Hodges  
    Name: William L. Hodges  
    Title: Director  
       
       
  ARALEZ PHARMACEUTICALS INC.  
       
  By: /s/ Andrew Koven  
    Name: Andrew Koven  
    Title: President  
 
 
 
31

 
 
  QLT INC.  
       
 
By:
/s/ Geoffrey Cox  
    Name: Geoffrey Cox  
    Title: Interim Chief Executive Officer  
       
 
 
32

 
 
  DEERFIELD PRIVATE DESIGN FUND III, L.P.  
       
 
By:
Deerfield Mgmt III, L.P., General Partner  
  By: J.E. Flynn Capital III, LLC, General Partner  
       
  By: /s/ David J. Clark  
    Name: David J. Clark  
    Title: Authorized Signatory  
       
       
  DEERFIELD INTERNATIONAL MASTER FUND, L.P.  
       
  By: Deerfield Mgmt, L.P., General Partner  
  By: J.E. Flynn Capital, LLC, General Partner  
       
  By: /s/ David J. Clark  
    Name: David J. Clark  
    Title: Authorized Signatory  
       
       
  DEERFIELD PARTNERS, L.P.  
       
  By: Deerfield Mgmt, L.P., General Partner  
  By: J.E. Flynn Capital, LLC, General Partner  
       
  By: /s/ David J. Clark  
    Name: David J. Clark  
    Title: Authorized Signatory  
 
 
33

 
 
  BROADFIN HEALTHCARE MASTER FUND, LTD  
       
 
By:
/s/ Jason Abrams  
    Name: Jason Abrams  
    Title: Authorized Signatory  
       
 
 
34

 
 
  JW PARTNERS, LP  
       
 
By:
JW GP, LLC, its General Partner  
       
  By: /s/ Jason Wild  
    Name: Jason Wild  
    Title: Authorized Signatory  
       
       
  JW OPPORTUNITIES FUND, LLC  
       
  By: JW GP, LLC, its Manager  
       
  By: /s/ Jason Wild  
    Name: Jason Wild  
    Title: Authorized Signatory  
       
       
 
JW OPPORTUNITIES MASTER FUND, LTD.
 
       
  By:
JW GP, LLC, its Manager
 
       
  By: /s/ Jason Wild  
   
Name: Jason Wild
 
   
Title:   Authorized Signatory
 
 
 
 
 
 
 
 
 
 
 
35

 
 
SCHEDULE I
 
SCHEDULE OF CO-INVESTORS
 
Co-Investor – Name (Jurisdiction) and Address
Subscription Price
QLT Inc. (British Columbia)
250 – 887 Great Northern Way
Vancouver, B.C., Canada
Attn: Geoffrey Cox
Fax: (604) 707-7001
Email: gfcox@qltinc.com
$45,000,000
Deerfield Private Design Fund III, L.P. (Delaware)
        Deerfield International Master Fund, L.P. (British Virgin Islands)
Deerfield Partners, L.P. (Delaware)
780 Third Avenue, 37th Floor
New York , New York  100017
Attn: David J. Clark
Fax: (212) 599-3075
Email: dclark@deerfield.com
$5,000,000
$2,800,000
$2,200,000
Broadfin Healthcare Master Fund, LTD (Cayman Islands)
300 Park Avenue, 25th Floor,
New York, NY 10005
Attn: Jason Abrams
Fax: (212) 808-2464
Email: Jason@broadfincapital.com
$12,500,000
JW Partners, LP (Delaware)
JW Opportunities Master Fund, Ltd. (Cayman Islands)
515 Madison Ave, 14B
New York, NY 10022
Attn: Jason Wild
Fax: (212) 207-4674
Email: jwild@jwfunds.com
$5,850,000
$1,650,000
Total:
$75,000,000

 
 
36

 
 
SCHEDULE II

SCHEDULE OF POTENTIAL PURCHASER TRANSFEREES

1.  
NONE.
 
 
 
37

 
 
ANNEX A
 
INVESTORS’ REGISTRATION RIGHTS
 
1.1 Certain Definitions.
 
(a)  
Investor Prospectus” shall mean the prospectus (including any preliminary, final or summary prospectus) included in the Investor Registration Statement, all amendments and supplements to such prospectus and all other material incorporated by reference in such prospectus.
 
(b)  
Investor Registration Expenses” shall mean any and all expenses incurred by the Company and its Subsidiaries in effecting the Investor Registration pursuant to this Agreement, including, all (a) Investor Registration and filing fees, and all other fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (b) fees and expenses of compliance with any securities or “Blue Sky” Laws (including reasonable fees and disbursements of counsel in connection with “Blue Sky” qualifications of the Investor Shares), (c) expenses in connection with the preparation, printing, mailing and delivery of the Investor Registration Statement, Investor Prospectus and other documents in connection therewith and any amendments or supplements thereto, (d) printing expenses, (e) internal expenses of the Company (including, all salaries and expenses of its officers and employees performing legal or accounting duties), (f) fees and disbursements of counsel for the Company and fees and expenses for independent certified public accountants retained by the Company and (g) fees and expenses of any special experts retained by the Company in connection with such Investor Registration.  Investor Registration Expenses shall not include, and the Company shall not have any obligation to pay, any out-of-pocket expenses of any Investor, including the attorneys’ fees of any such Investor.
 
(c)  
Investor Registration” shall mean the registration effected by preparing and filing (a) the Investor Registration Statement in compliance with the Securities Act (and any post-effective amendments filed or required to be filed) and the declaration or ordering of effectiveness of such Investor Registration Statement, or (b) an Investor Prospectus and/or Investor Prospectus supplement in respect of the effective Investor Registration Statement.
 
(d)  
The terms “register,” “registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.
 
(e)  
Registrable Securities” shall mean:  (i) the Investor Shares, the Company Shares issuable to each Investor upon consummation of the Plan of Arrangement, and any Company Shares issued or issuable to each Investor (A) upon any distribution with respect to, any exchange for or any replacement of such Company Shares, or (B) upon any conversion, exercise or exchange of any securities issued in connection with any such distribution, exchange or replacement; (ii) securities issued or issuable upon any stock
 
 
A- 1

 
 
split, stock dividend, recapitalization or similar event with respect to the foregoing; and (iii) any other security issued as a dividend or other distribution with respect to, in exchange for or in replacement of the securities referred to in the preceding clauses, except that any such shares or other securities shall cease to be Registrable Securities when (A) they have been sold to the public or (B) they may be sold by such Investor without restriction pursuant to Rule 144.
 
(f)  
Selling Expenses” shall mean all selling commissions and transfer taxes applicable to the sale, transfer, issuance or allotment of Registrable Securities and all fees and disbursements of counsel for Investors.
 
1.2 Registration Requirements.  The Company shall use its commercially reasonable efforts to effect the registration of the resale of the Registrable Securities (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable Blue Sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act) as would permit or facilitate the resale of all the Registrable Securities in the manner (including manner of sale) and in all states reasonably requested by the Investors, provided that in no event shall the Company be required to register the resale of the Registrable Securities in an underwritten offering.  Such commercially reasonable efforts by the Company shall include, without limitation, the following:
 
(a)  
The Company shall use commercially reasonable efforts to, as expeditiously as possible:
 
(i)  
prepare and promptly following the filing of Registration Statement on Form S-4 by the Company (in no event later than January 15, 2016), file a registration statement with the Commission pursuant to Rule 415 under the Securities Act covering resales by the Investors as selling stockholders (not underwriters) of the Registrable Securities (the “Investor Registration Statement”).  The Company shall use its commercially reasonable efforts to cause such Investor Registration Statement and other filings to be declared effective as soon as possible following its filing.
 
(ii)  
respond to all Commission comments, inquiries and requests, and shall request acceleration of effectiveness of the Investor Registration Statement at the earliest possible date.  The Company shall provide the Investors reasonable opportunity to review the portions of any such Investor Registration Statement or amendment or supplement thereto containing disclosure regarding the Investors prior to filing.
 
(iii)  
prepare and file with the Commission such amendments and supplements to such Investor Registration Statement and the Investor Prospectus used in connection with such Investor Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Investor Registration Statement and notify the Investors of the filing and effectiveness of such Investor Registration Statement and any amendments or supplements.
 
 
A- 2

 
 
(iv)  
furnish or otherwise make available to each Investor copies of a current prospectus included in the Investor Registration Statement conforming with the requirements of the Securities Act, copies of the Investor Registration Statement, any amendment or supplement thereto and any documents incorporated by reference therein and such other documents as such Investor may reasonably require in order to facilitate the disposition of Registrable Securities owned by such Investor.
 
(v)  
register and qualify the securities covered by the Investor Registration Statement under the securities or “Blue Sky” Laws of all domestic jurisdictions, to the extent required; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.
 
(vi)  
notify each Co-Investor of the happening of any event (but not the substance or details of any such events) as a result of which the Investor Prospectus (including any supplements thereto or thereof) included in such Investor Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and use its commercially reasonable efforts to promptly update and/or correct such prospectus.
 
(vii)  
notify each Investor of the issuance by the Commission or any state securities commission or agency of any stop order suspending the effectiveness of the Investor Registration Statement or the threat or initiation of any proceedings for that purpose.  The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order and, if any stop order is issued, to obtain the lifting thereof at the earliest possible time.
 
(viii)  
if required by the NASDAQ or the principal securities exchange and/or market on which the Company’s common shares are then listed, qualify the Registrable Securities covered by such Investor Registration Statement for listing on the NASDAQ or the principal securities exchange and/or market on which the Company’s common shares are then listed, including the preparation and filing of any required filings with such principal market or exchange.
 
(b)  
The Company may suspend the use of any Investor Prospectus used in connection with the Investor Registration Statement only in the event, and for such period of time as, (i) such a suspension is required by the rules and regulations of the Commission or any self-regulatory organization, or (ii) it is determined in good faith by the Board of the Company that because of valid business reasons (not including the avoidance of the Company’s obligations hereunder), it is in the best interests of the Company to suspend such use, and prior to suspending such use in accordance with this clause (b) the Company provides the Investors with written notice of such suspension, which notice need not specify the nature of the event giving rise to such suspension.  The Company will use commercially reasonable efforts to cause such suspension to terminate at the
 
 
A- 3

 
 
earliest possible date. Notwithstanding the foregoing, the use of any Investor Prospectus may be suspended by reason of clause (ii) of this subsection (b) for a period of time not to exceed (A) sixty consecutive days for any one such suspension or (B) an aggregate of ninety days during the Investor Registration Period.
 
(c)  
The Company shall prepare and file with the Commission such amendments (including post-effective amendments) and supplements to the Investor Registration Statement and the Investor Prospectus used in connection with the Investor Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep the Investor Registration Statement effective at all times during the Investor Registration Period (as defined below), and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by the Investor Registration Statement.  In the case of amendments and supplements to the Investor Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 1.2(c)) by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into the Investor Registration Statement, if applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company to amend or supplement the Investor Registration Statement.
 
(d)  
Each Investor agrees by its acquisition of the Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Sections 1.2(a)(vi) or 1.2(a)(vii), and upon notice of any suspension under Section 1.2(b), such Investor will forthwith discontinue disposition of such Registrable Securities under the Investor Registration Statement until such Investor’s receipt of the copies of the supplemented prospectus and/or amendment to the Investor Registration Statement contemplated by this Section 1.2, or until it is advised in writing by the Company that the use of the applicable prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such prospectus or the Investor Registration Statement.  The Company may provide appropriate stop orders to enforce the provisions of this paragraph.
 
(e)  
If requested by an Investor, the Company shall (i) as soon as practicable incorporate in a prospectus supplement or post-effective amendment such information as an Investor reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the Subscription Price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering, (ii) as soon as practicable make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment, and (iii) as soon as practicable, supplement or make amendments to the Investor Registration Statement if reasonably requested by an Investor holding any Registrable Securities.
 
 
A- 4

 
 
1.3 Expenses of Investor Registration.  All Investor Registration Expenses in connection with any registration, qualification or compliance with registration pursuant to this Agreement shall be borne by the Company, and all Selling Expenses of an Investor shall be borne by such Investor.
 
1.4 Investor Registration Period.  In the case of the Investor Registration, the Company shall keep such registration effective from the date on which the Investor Registration Statement initially became effective until the earlier of: (i) the date on which all the Investors have completed the sales or distribution described in the Investor Registration Statement relating to the Registrable Securities registered for resale thereunder; (ii) until such Registrable Securities may be sold by the Investors without restriction pursuant to Rule 144 (or any successor thereto); or (iii) one year from the effective date of the Investor Registration Statement (the “Investor Registration Period”).  Thereafter, the Company shall be entitled to withdraw such Investor Registration Statement and the Investors shall have no further right to offer or sell any of the Registrable Securities registered for resale thereon pursuant to the Investor Registration Statement (or any prospectus relating thereto).
 
1.5 Indemnification.
 
(a)  
Indemnification by the Company.  The Company agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) each Investor and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each Investor’s Affiliates’ officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls (within the meaning of the Securities Act, the Exchange Act) such Persons, against any and all claims, losses, damages, penalties, judgments, suits, costs, liabilities and expenses (or actions in respect thereof) (collectively, the “Losses”) arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact contained in the Investor Registration Statement (including any Investor Prospectus) or any other document incorporated by reference therein, (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not false or misleading (in the case of any Investor Prospectus, in light of the circumstances under which they were made), or (C) any violation by the Company of the Securities Act, the Exchange Act, the Canadian Securities Laws or any state securities or “Blue Sky” Laws applicable to the Company, and will reimburse each of the Persons listed above, for any reasonable and documented out-of-pocket legal and any other expenses reasonably incurred in connection with investigating and defending any such Losses; provided, that the Company will not be liable in any such case to the extent that any such Losses arise out of or are based on any untrue statement or omission based upon written information furnished to the Company by such Person and stated to be specifically for use in such Investor Registration Statement or Investor Prospectus.
 
(b)  
Indemnification by Investors.  Each Investor agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) the Company and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each of the Company’s Affiliates’ officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls the Company (within the meaning of the Securities Act, the
 
 
A- 5

 
 
Exchange Act or the Canadian Securities Laws), against any and all Losses arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact made by such Investor contained in the Investor Registration Statement (including any Investor Prospectus) or any other document incorporated by reference therein or (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements by such Investor therein not false or misleading (in the case of any Investor Prospectus, in light of the circumstances under which they were made), and will reimburse the Persons listed above for any reasonable and documented legal or any other expenses reasonably incurred in connection with investigating or defending any such Losses, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use in such Investor Registration Statement or Investor Prospectus, provided, however, that the obligations of each Investor hereunder shall be limited to such Investor’s respective Subscription Price.
 
(c)  
Conduct of the Indemnification Proceedings.  Each Person entitled to indemnification under this Section 1.5 (the “Indemnified Party”) shall give notice to the Person required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at such Indemnified Party’s expense (unless the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the Indemnifying Party); and provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.5 unless the Indemnifying Party is actually and materially prejudiced thereby.  It is understood and agreed that the Indemnifying Party shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate legal counsel for all Indemnified Parties; provided, however, that where the failure to be provided separate legal counsel would be reasonably likely to result in a conflict of interest on the part of such legal counsel for all Indemnified Party, separate counsel shall be appointed for the Indemnified Parties to the extent needed to alleviate such potential conflict of interest.  No Indemnifying Party, in the defense of any such claim or litigation shall, except with the prior written consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation.  Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnified Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom.
 
 
A- 6

 
 
(d)  
Contribution.  If the indemnification provided for in this Section 1.5 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any Losses, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and the Indemnified Party, on the other, in connection with the statements or omissions (or alleged statements or omissions) which resulted in such Losses, as well as any other relevant equitable considerations.  The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission (or alleged omission) to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and such parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that the obligations of each Investor shall be limited to an amount equal to the such Investor’s respective Subscription Price; and provided, further, that no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) or gross negligence shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation or gross negligence.
 
(e)  
Exclusivity.  Subject to the limitations on each Investor’s liability set forth in Section 1.5(b) and Section 1.5(d), the remedies provided for in this Section 1.5 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Party at Law or equity.  The remedies shall remain in full force and effect regardless of any investigation made by or on behalf of an Investor or any Indemnified Party and survive the transfer of the Investor Shares by an Investor.
 
1.6 Survival.  The indemnity and contribution agreements contained in Section 1.5 shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Indemnified Party or by or on behalf of the Company, and (iii) the consummation of the sale or successive resales of the Registrable Securities.
 
1.7 Information by Investors.  Each Investor shall promptly furnish to the Company such information regarding such Investor and the distribution and/or sale proposed by such Investor as the Company may from time to time reasonably request in writing in connection with any Investor Registration, qualification or compliance referred to in this Agreement, and the Company may exclude from such Investor Registration the Registrable Securities of any Investor who unreasonably fails to furnish such information within a reasonable time after receiving such request.  The intended method or methods of disposition and/or sale of such securities as so provided by such purchaser shall be included without alteration in the Investor Registration Statement covering the Registrable Securities and shall not be changed without written consent of such Investor.  Each Investor agrees that, other than ordinary course brokerage arrangements, in the event it enters into any arrangement with a broker dealer for the sale of any Registrable Securities through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, such Investor shall promptly deliver to the Company in writing all applicable information required in order for the Company to be able to timely file a
 
 
A- 7

 
 
supplement to the Investor Prospectus pursuant to Rule 424(b), or take any other action, under the Securities Act, to the extent that such supplement or other action is legally required.  Such information shall include a description of (i) the name of such Investor and of the participating broker dealer(s), (ii) the number of Registrable Securities involved, (iii) the price at which such Registrable Securities were or are to be sold, and (iv) the commissions paid or to be paid or discounts or concessions allowed or to be allowed to such broker dealer(s), where applicable
 
 
A- 8

 
 
ANNEX B
 
PURCHASER’S REGISTRATION RIGHTS
 
1.1. Certain Definitions.
 
(a)  
Prospectus” means the prospectus (including any preliminary, final or summary prospectus) included in the Registration Statement, all amendments and supplements to such prospectus and all other material incorporated by reference in such prospectus.
 
(b)  
Registration” means the registration effected by preparing and filing (a) the Registration Statement in compliance with the Securities Act (and any post-effective amendments filed or required to be filed) and the declaration or ordering of effectiveness of such Registration Statement, or (b) a Prospectus and/or Prospectus supplement in respect of the effective Registration Statement.
 
(c)  
Registration Expenses” means any and all expenses incurred by the Company and its Subsidiaries in effecting the Registration pursuant to this Agreement, including, all (a) Registration and filing fees, and all other fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (b) fees and expenses of compliance with any securities or “Blue Sky” Laws (including reasonable fees and disbursements of counsel in connection with “Blue Sky” qualifications of the Purchaser Shares), (c) expenses in connection with the preparation, printing, mailing and delivery of the Registration Statement, Prospectus and other documents in connection therewith and any amendments or supplements thereto, (d) printing expenses, (e) internal expenses of the Company (including, all salaries and expenses of its officers and employees performing legal or accounting duties), (f) fees and disbursements of counsel for the Company and fees and expenses for independent certified public accountants retained by the Company and (g) fees and expenses of any special experts retained by the Company in connection with such Registration.  Registration Expenses shall not include, and the Company shall not have any obligation to pay, any out-of-pocket expenses of Purchaser or any transfer taxes (x) applicable to the sale, transfer, issuance or allotment of the Purchaser Shares; or (y) arising in connection with the Distribution, both of which shall be borne by Purchaser.
 
(d)  
Registration Statement” means the registration statement of the Company that covers the Distribution of the Purchaser Shares to the holders of the Purchaser Common Shares pursuant to the provisions of this Agreement filed with, or to be filed with, the Commission under the rules and regulations promulgated under the Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits, financial information and all other material incorporated by reference in such registration statement.
 
 
B- 1

 
 
1.2. Registration Requirements.
 
(a)  
As promptly as practicable following the filing of a Registration Statement on Form S-4 by the Company, the Company shall (i) prepare and cause to be filed with the Commission (no later than January 15, 2016) the Registration Statement on an eligible form and the Company shall use its commercially reasonable efforts to have the Registration Statement declared effective under the Securities Act as promptly as practicable after such filing.  The Company shall use its commercially reasonable efforts to keep the Registration Statement current and effective until the time the Distribution is completed.  In addition, until the completion of the Distribution, the Company shall take all reasonably necessary steps and proceedings as may be required from time to time under the Canadian Securities Laws to maintain its status as a reporting issuer under applicable Canadian Securities Laws, and cure any default outstanding as of the date hereof.  Each of Purchaser and Pozen shall furnish the Company all information concerning such person and its Affiliates, and provide such other assistance, as may be reasonably requested in connection with the preparation and filing of the Registration Statement.  The Registration Statement shall include all information reasonably requested by the Purchaser to be included therein.  The Company shall promptly notify the other upon the receipt of any comments from the Commission or any request from the Commission for amendments or supplements to the Registration Statement, and shall provide Purchaser with copies of all correspondence between it and its representatives, on one hand, and the Commission or the Canadian Commissions, on the other hand.  The Company shall use its commercially reasonable efforts to respond as promptly as practicable to any comments from the Commission with respect to the Registration Statement.  Notwithstanding the foregoing, prior to filing (i) the Registration Statement (or any amendment or supplement thereto) or responding to any comments of the Commission with respect thereto, the Company shall provide Purchaser an opportunity to review and comment on such document or response (including the proposed final version of such document or response).  The Company shall advise Purchaser, promptly after receipt of notice thereof, of the time of effectiveness of the Registration Statement, the issuance of any stop order relating thereto, and the Company shall use its commercially reasonable efforts to have any such stop order or suspension lifted, reversed or otherwise terminated.  The Company shall also take any other action (other than qualifying to do business in any jurisdiction in which it is not now so qualified) required to be taken under the Securities Act, the Exchange Act, the Canadian Securities Laws, any applicable foreign or state securities or “Blue Sky” Laws and the rules and regulations thereunder in connection with the transactions associated with this Agreement.
 
(b)  
If, prior to the completion of the Distribution, any event occurs with respect to the Company or Pozen or any of their respective Subsidiaries, or any change occurs with respect to other information supplied by the Company or Pozen for inclusion in the Registration Statement which is required to be described in an amendment of, or a supplement to, the Registration Statement, the Company shall promptly notify Purchaser of such event or Pozen shall promptly notify the Company and Purchaser of such event, as applicable, and the Company shall use commercially reasonable efforts to promptly file with (i) the Commission any necessary amendment or supplement to the Registration Statement, and, as required by Law and disseminate the information contained in such amendment or supplement.  Nothing in this Section 1.2(b) shall limit the obligations of any party under Section 1.2(a).
 
 
B- 2

 
 
(c)  
If prior to the completion of the Distribution, any event occurs with respect to Purchaser or any of its Subsidiaries, or any change occurs with respect to other information supplied by Purchaser for inclusion in the Registration Statement, which is required to be described in an amendment of, or a supplement to, the Registration Statement, Purchaser shall promptly notify the Company of such event, and the Company shall use commercially reasonable efforts to promptly file with the Commission any necessary amendment or supplement to the Registration Statement as required by Law, disseminate the information contained in such amendment or supplement.  Nothing in this Section 1.2(c) shall limit the obligations of any party under Section 1.2(a).
 
(d)  
The Company shall deliver to Purchaser, without charge, as many copies of the Prospectus and any amendment or supplement thereto as Purchaser may reasonably request in the context of the Distribution (it being understood that the Company consents to the use of the Prospectus and any amendment or supplement thereto in connection with the Distribution) and such other documents as Purchaser may reasonably request in order to facilitate the Distribution.
 
(e)  
The Company shall reasonably cooperate with Purchaser to facilitate the timely preparation and delivery of certificates, with requisite CUSIP numbers, representing the Purchaser Shares to be distributed to the holders of the Purchaser Common Shares pursuant to the Distribution and not bearing any restrictive legends.
 
(f)  
The Company will use its commercially reasonable efforts to procure the cooperation of the Company’s transfer agent in settling the distribution of the Purchaser Shares to the holders of the Purchaser Common Shares pursuant to the Distribution, including with respect to the transfer of physical security instruments into book-entry form in accordance with any procedures reasonably requested by Purchaser.
 
1.3. Indemnification.
 
(a)  
Indemnification by the Company.  The Company agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) Purchaser and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each of Purchaser’s Affiliates’ officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls (with the meaning of the Securities Act, the Exchange Act or the Canadian Securities Laws) such Persons, against any and all claims, losses, damages, penalties, judgments, suits, costs, liabilities and expenses (or actions in respect thereof) (collectively, the “Losses”) arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact contained in the Registration Statement (including any Prospectus) or any other document incorporated by reference therein, (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not false or misleading (in the case of any Prospectus, in light of the circumstances under which they were made), or (C) any violation by the Company of the Securities Act, the Exchange Act, the Canadian Securities Laws or any state securities or
 
 
B- 3

 
 
“Blue Sky” Laws applicable to the Company, and will reimburse each of the Persons listed above, for any reasonable and documented out-of-pocket legal and any other expenses reasonably incurred in connection with investigating and defending any such Losses; provided, that the Company will not be liable in any such case to the extent that any such Losses arise out of or are based on any untrue statement or omission based upon written information furnished to the Company by Purchaser and stated to be specifically for use in such Registration Statement or the Prospectus.
 
(b)  
Indemnification by Purchaser.  Purchaser agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) the Company and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each of the Company’s Affiliates’ officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls the Company (within the meaning of the Securities Act, the Exchange Act or the Canadian Securities Laws), against any and all Losses arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact made by Purchaser contained in any Registration Statement (including any Prospectus) or any other document incorporated by reference therein or (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements by Purchaser therein not false or misleading (in the case of any Prospectus, in light of the circumstances under which they were made), and will reimburse the Persons listed above for any reasonable and documented legal or any other expenses reasonably incurred in connection with investigating or defending any such Losses, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in reliance upon and in conformity with written information furnished to the Company by Purchaser and stated to be specifically for use in such Registration Statement or Prospectus, provided, however, that the obligations of Purchaser hereunder shall be limited to the Subscription Price.
 
(c)  
Conduct of the Indemnification Proceedings.  Each Person entitled to indemnification under this Section 1.3 (the “Indemnified Party”) shall give notice to the Person required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at such Indemnified Party’s expense (unless the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the Indemnifying Party); and provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.3 unless the Indemnifying Party is actually and materially prejudiced thereby.  It is understood and agreed that the Indemnifying Party shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate legal counsel for all Indemnified Parties; provided, however, that where the failure to be provided separate legal counsel would be reasonably
 
 
B- 4

 
 
 
likely to result in a conflict of interest on the part of such legal counsel for all Indemnified Party, separate counsel shall be appointed for the Indemnified Parties to the extent needed to alleviate such potential conflict of interest. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the prior written consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnified Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom.
 
(d)  
Contribution.  If the indemnification provided for in this Section 1.3 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any Losses, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and the Indemnified Party, on the other, in connection with the statements or omissions (or alleged statements or omissions) which resulted in such Losses, as well as any other relevant equitable considerations.  The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission (or alleged omission) to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and such parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that the obligations of Purchaser shall be limited to an amount equal to the Subscription Price; and provided, further, that no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) or gross negligence shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation or gross negligence.
 
(e)  
Exclusivity.  Subject to the limitations on Purchaser’s liability set forth in Section 1.3(b) and Section 1.3(d), the remedies provided for in this Section 1.3 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Party at Law or equity.  The remedies shall remain in full force and effect regardless of any investigation made by or on behalf of Purchaser or any Indemnified Party and survive the transfer of the Shares by Purchaser.
 

 
 

B-5

EX-99.1 7 tbuff_ex991.htm PRESS RELEASE tbuff_ex991.htm
Exhibit 99.1
 
 
   
 
 
POZEN AND TRIBUTE ANNOUNCE PLAN TO PROCEED WITH
MERGER TO FORM ARALEZ PHARMACEUTICALS

-US$350 Million Capital Commitment from Deerfield-Led Syndicate-
-Canada Domicile Provides Similar Competitive Structure and Benefits to Ireland-
-Previously Scheduled Shareholder Meetings of POZEN and Tribute to be Rescheduled-


CHAPEL HILL, NC and MILTON, Ontario – December 7, 2015 POZEN Inc. (“POZEN”) (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. (“Tribute”) (TSX VENTURE:TRX) (OTCQX International:TBUFF) today confirmed their merger plans and announced that they have entered into an amended agreement and plan of merger, which among other things, moves the domicile for their proposed parent company, Aralez Pharmaceuticals Inc. (“Aralez”), from Ireland to Canada. This alternative transaction structure, the parties believe, is in the best interest of their respective securityholders. The companies previously announced in June 2015 that POZEN would acquire Tribute and the combined company would be renamed Aralez Pharmaceuticals. With planned business operations in Ireland, Canada and the United States, the Canadian domicile offers a substantially similar corporate and tax structure to the previous Irish domicile, and will benefit from Tribute’s business foundation and strong presence in Canada where Tribute is incorporated and from where it has always operated.

POZEN’s proxy statement relating to the proposed transaction dated November 6, 2015 and Tribute’s Management Proxy Circular dated November 6, 2015, mailed by the parties to their respective securityholders, will be withdrawn and new filings will be made with the requisite regulatory authorities to reflect changes and updates to the transaction structure. As a result, the meetings of the securityholders of Tribute and POZEN scheduled for December 9 and 10, respectively, have been canceled and new meeting dates will be set and communicated in subsequent proxy materials. The transaction is expected to close in the first quarter of 2016. It is a condition of closing that the common shares of Aralez be approved for listing on the NASDAQ and conditionally approved on the TSX.

Capital Investment

In connection with the acquisition, a syndicate of leading healthcare investors, led by Deerfield and including QLT Inc., Broadfin Capital LLC and JW Asset Management, LLC has confirmed their commitment of up to US$350 million in growth capital for the combined company, intended to support the anticipated commercial launches of YOSPRALA™ and Fibricor® as well as future potential product and company acquisitions. Such financing is expected to close immediately prior to closing of the transaction with POZEN and Tribute. The proposed investment in Aralez includes:

●  
US$75 million of equity in Tribute immediately prior to closing of the transaction at a price per share equal to (a) the lesser of (i) US$7.20, and (ii) a five percent (5%) discount off the five day volume weighted average price (“VWAP”) per share of POZEN common stock, calculated over the five trading days immediately preceding the date of closing, not to be less than US$6.25, multiplied by (b) .1455 (the conversion ratio). In the event any of POZEN, Tribute or Aralez announce a material event (other than results of any shareholder meeting) during the ten day period immediately preceding closing, the VWAP lookback period will be reduced from five days to two days.
●  
US$75 million in 2.5% convertible senior secured notes due six years from issuance with a conversion price equal to a 32.5% premium to the aforementioned equity price.
●  
Up to US$200 million committed secured debt facility to fund future acquisitions.

 
 

 
 
“The change in domicile for Aralez remains consistent with our overall vision and strategy for the company and is expected to deliver similar competitive advantages to an Irish domicile,” said Adrian Adams, Chief Executive Officer of POZEN Inc. “We continue to maintain a presence in Ireland through an operating company that holds intellectual property, including YOSPRALA, and from which Aralez plans to execute its acquisition strategy. We are pleased that the Deerfield-led syndicate continues to be supportive of our growth strategy.”

“We are pleased with the alternative transaction structure and the plan to proceed with a Canadian domicile,” said Rob Harris, President and Chief Executive Officer of Tribute. “We believe that the new structure will benefit from Tribute’s business foundation in Canada and provide a platform for continued growth.”
 
Compelling Strategic Rationale of the Acquisition

●  
World-Class Management. Adrian Adams (Chief Executive Officer) and Andrew Koven (President and Chief Business Officer) formerly led companies including Auxilium, Inspire, Sepracor and Kos.

●  
Broad and Diversified Product Portfolio. Multiple United States and Canadian cardiovascular and pain products, in addition to products with specialist indications including dermatology, orthopedics, urology and acute care.

●  
Strong Financial Profile. Well-capitalized, competitive structure company with ample liquidity to commercialize existing portfolio products, including YOSPRALA and Fibricor, and to explore additional acquisition opportunities.

●  
Platform for Growth. Team, corporate structure, financial profile and Irish presence set the stage for sustained long-term growth, both organically and through acquisitions.

Transaction Terms and Structure

The parties have formed a new company, Aralez Pharmaceuticals Inc. (“Aralez”), organized under the laws of British Columbia, Canada. A Canadian subsidiary of Aralez will merge with Tribute, through a three-cornered amalgamation in a plan of arrangement, with Tribute surviving as a wholly-owned subsidiary of Aralez. Similarly, an indirect U.S. subsidiary of Aralez will merge with POZEN, with POZEN surviving as a wholly-owned subsidiary of Aralez.  At closing, each share of POZEN common stock will be converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) will be exchanged for 0.1455 of an Aralez common share.  This exchange ratio remains unchanged from the ratio announced when the parties initially entered into the agreement and plan of merger.  As a result of the proposed transaction and before giving effect to the contemplated financing, stockholders of POZEN will own approximately 64 percent of Aralez and shareholders of Tribute will own approximately 36 percent of Aralez, in each case prior to giving effect to any exercise of any outstanding options or warrants or vesting and delivery of any restricted stock units of either company after the date hereof. As of December 7, 2015, POZEN has 33.2 million common shares outstanding and 39.3 million fully diluted shares and Tribute has 126.2 million common shares outstanding and 163.4 million fully diluted shares. The transaction will be taxable to the POZEN stockholders.  It is a condition of closing that the common shares of Aralez be approved for listing on the NASDAQ and conditionally approved on the TSX.

 
 

 
 
Additional Information and Where to Find It

In connection with the proposed transaction, Aralez, POZEN and Tribute will be filing documents with the SEC, including a Registration Statement on Form S-4 by Aralez and POZEN that will include the proxy statement/prospectus relating to the proposed amended transaction involving POZEN and Aralez, and an information circular by Tribute relating to the proposed amended transaction involving Tribute. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to POZEN stockholders in connection with the proposed transaction. Upon receipt of an interim court order in respect of the plan of arrangement, Tribute will be mailing a revised information circular to its shareholders in connection with the proposed transaction. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS AS WELL AS THE INFORMATION CIRCULAR WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARALEZ, POZEN, TRIBUTE AND THE PROPOSED TRANSACTION. Investors and securityholders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov.  Investors and securityholders will be able to obtain free copies of the Information Circular and other documents filed by Tribute on the System for Electronic Document Analysis and Retrieval (“SEDAR”) website maintained by the Canadian Securities Administrators at www.sedar.com. Investors and securityholders may obtain free copies of the documents filed by POZEN and Aralez with the SEC on POZEN's website at www.POZEN.com under the heading “Investors” and then under the heading “SEC Filings” and free copies of the documents filed by Tribute with the SEC on Tribute's website at www.tributepharma.com under the heading “Investors” and then under the heading “SEC Filings”.

POZEN, Tribute and Aralez and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of POZEN and shareholders of Tribute and Aralez in connection with the proposed transaction. Information regarding the special interests, if any, of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus and Information Circular described above. Additional information regarding the directors and executive officers of POZEN and Tribute is contained in their respective Annual Reports on Form 10-K for the year ended December 31, 2014 filed with the SEC.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

All dollar amounts included herein are stated in United States dollars.

For full prescribing information refer to the individual product websites.

About POZEN

POZEN is a specialty pharmaceutical company that has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

On June 2, 2015, POZEN announced the formation of Pozen Limited, a wholly-owned Irish subsidiary, to expand its geographic footprint and increase its global presence, including potential international sales, manufacturing and product development.
 
POZEN’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

 
 

 
 
About Tribute

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.
 
Tribute's common shares are traded on the TSX Venture Exchange under the symbol “TRX” and on the OTCQX International under the symbol “TBUFF”. For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.

Cautionary Language Concerning Forward-Looking Statements

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof; the combined company's strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, competitive position, anticipated product portfolio, development programs and management structure; the Canadian domicile offering substantially similar financial and competitive advantages to an Irish domicile; the transaction structure being in the best interest of securityholders; the proposed listing on the NASDAQ and TSX and other statements that are not historical facts.  These forward-looking statements are based on POZEN's and Tribute’s current assumptions and expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the parties' ability to complete the combination and anticipated equity and debt financings on the proposed terms and schedule; the combined company meeting the listing requirements on the NASDAQ and Toronto Stock Exchange; risk that Aralez may be taxed as a U.S. resident corporation;  risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company's shares could decline, as well as other risks related to POZEN's and Tribute’s business, including  POZEN's inability to build, acquire or contract with a sales force of sufficient scale for the commercialization of YOSPRALA™ in a timely and cost-effective manner, the parties’ failure to successfully commercialize product candidates; costs and delays in the development and/or FDA approval of the parties’ product candidates (including YOSPRALA), including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of POZEN’s or Tribute’s product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of its product candidates; the inability to maintain or enter into, and the risks resulting from POZEN’s dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including its dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®; POZEN’s dependence on Patheon for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; the ability of POZEN and Tribute to protect their intellectual property and defend their patents; regulatory obligations and oversight; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in POZEN's SEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent Quarterly Reports on Form 10-Q, and in Tribute’s SEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent Quarterly Reports on Form 10-Q. The parties undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in their expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 
 

 
 
Contacts:

POZEN Inc.
Bill Hodges, Chief Financial Officer
919-913-1030

Nichol Ochsner
Executive Director, Investor Relations
& Corporate Communications
919-913-1030

Tribute Pharmaceuticals Canada Inc.
Scott Langille, Chief Financial Officer
905-876-3166





 
GRAPHIC 8 pozen.jpg begin 644 pozen.jpg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tribute.jpg begin 644 tribute.jpg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end